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ABSTRACT 
 
In addition to its essential roles in the maintenance, replication and transcription of the EBV 
genome, EBNA1 has more recently been shown to influence the transcription of cellular genes 
and to modulate the activity of key cellular signalling pathways. EBNA1 has previously been 
shown to abrogate TGFβ signalling in carcinoma cell lines, although the exact mechanism 
remains to be elucidated. This study has endeavoured to further dissect this observation, whilst 
revealing a novel function for EBNA1 in the activation of the closely-related BMP signalling 
pathway. The observed abrogation of canonical TGFβ signalling is now proposed to be the result 
of an EBNA1-mediated induction of negative regulators, while a concomitant increase in secreted 
TGFβ, in combination with a shift towards linker region phosphorylation of the R-Smad proteins 
in EBNA1-expressing cells conceivably constitutes a method of promoting pro-tumourigenic 
TGFβ-mediated effects, such as cellular migration. In addition, results demonstrating the 
activation of BMP signalling upon the expression of EBNA1, and in EBV-positive cell lines, are 
also indicative of a role in the promotion of migration, and potentially metastasis. In this way, 
EBNA1 may mediate effects that contribute to the development of EBV-associated tumours. 
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 1 
CHAPTER 1 
 
Introduction 
 
1.1 The biology of cancer 
Despite significant progress in the field of cancer research, cancer still remains a substantial 
health burden worldwide. Indeed an assessment of global cancer burden estimated that an 
overall 12.7 million new cancer cases and 7.6 million cancer deaths occurred in 2008 (Ferlay 
et al., 2010, Thun et al., 2010), which, by extrapolation, is projected to rise to almost 21.4 
million new cases diagnosed annually and over 13.2 million cancer deaths in 2030. 
 
An accumulating body of evidence defines cancer as a complex multistep process, 
predominantly reflecting genetic and epigenetic alterations that evolve to drive progressive 
cellular transformation. It has estimated that six major acquired capabilities collectively 
dictate the cancer phenotype; namely, self-sufficiency in growth signals, insensitivity to 
growth-inhibitory signals, evasion of apoptosis, limitless replicative potential, sustained 
angiogenesis, and tissue invasion and metastasis (Hanahan and Weinberg, 2000). Each 
constitutes a fundamental rate-limiting step during malignant development and their 
cooperative influence is required for complete malignant conversion. 
  
1.2 Viruses and cancer 
Globally, it is estimated that between 15-20% of all human cancers are aetiologically linked to 
viral infections (zur Hausen, 2001, Damania, 2006, Parkin, 2006, McLaughlin-Drubin and 
Munger, 2008, Kalland et al., 2009). The discovery of the first human tumour virus, Epstein-
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Barr virus (EBV), in the 1960s laid the foundations for the identification of a number of 
viruses with oncogenic potential in humans (de Oliveira, 2007, Javier and Butel, 2008). The 
consistency of associations of a given virus with a specific cancer is found to range from 
approximately 15% to essentially 100% (Pagano et al., 2004, McLaughlin-Drubin and 
Munger, 2008). While several viruses have been unequivocally linked to the aetiology of 
certain human malignancies, for others only potential roles have been suggested, as is 
summarised in Table 1.1, adapted from (McLaughlin-Drubin and Munger, 2008) 
 
Table 1.1:  Human tumour viruses and viruses implicated in human cancers 
Virus Viral taxonomy Genome Human Cancers 
HUMAN ONCOGENIC VIRUSES 
Human T-cell leukaemia 
virus (HTLV-1) 
Retroviridae dsRNA Adult T-cell leukaemia 
Hepatitis C virus (HCV) Flaviviridae dsRNA Hepatocellular carcinoma 
Human papillomavirus 
(HPV) (high-risk types) 
Papillomaviridae dsDNA Cervical, head and neck, and other 
anogenital cancers 
Hepatitis B virus (HBV) Hepadnaviridae Partially 
dsDNA 
Hepatocellular carcinoma 
Epstein-Barr virus (EBV) Herpesviridae dsDNA Burkitt’s lymphoma, nasopharyngeal 
carcinoma, HL, PTL, GC, NK/T-cell 
lymphoma 
Kaposi’s sarcoma 
herpesvirus (KSHV) 
Herpesviridae dsDNA Kaposi’s sarcoma, primary effusion 
lymphoma, Castleman’s disease 
VIRUSES IMPLICATED IN HUMAN CANCERS 
Simian virus 40 (SV40) Polyomaviridae dsDNA Mesothelioma, osteosarcoma, non-
Hodgkin lymphoma, brain? 
JC virus (JCV) Polyomaviridae dsDNA Brain? 
BK virus (BKV) Polyomaviridae dsDNA Prostate? 
Human endogenous 
retroviruses (HERVs) 
Retroviridae dsRNA/DNA? Germ cell tumours, breast, 
lymphoproliferative disease, ovarian, 
melanoma, prostate? 
Human mammary tumour 
virus (HMTV) 
Retroviridae dsRNA/DNA? Breast? 
Xenotropic murine leukaemia 
virus-related virus (XMRV) 
Retroviridae ssRNA Prostate? 
Torque teno virus (TTV) Circoviridae ssDNA Gastrointestinal, lung, breast, myeloma? 
 
Although many oncogenic viruses are ubiquitous within the human population (zur Hausen, 
2001), others display more localised distributions. As obligate intracellular parasites, 
oncogenic viruses have evolved strategies to exploit existing host cellular mechanisms to 
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establish infection and persist within the infected host. The frequency with which infected 
individuals progress to develop cancer is reasonably low (Butel, 2000, zur Hausen, 2001, 
Kalland et al., 2009), and there is usually a long latency period between primary infection and 
tumour development. Further criteria to establish such a link between viral infection and 
cancer include serological evidence of prior infection, and persistence of the virus in all 
tumour cells, epidemiological plausibility of the association, virus-induced target cell 
transformation in vitro, and virus-induced tumours in a suitable experimental host (zur 
Hausen, 2001, Pagano et al., 2004). It is now widely accepted that viruses act as tumour-
promoting factors rather than the sole initiators of cancer development (Butel, 2000, Javier 
and Butel, 2008). In consequence, carcinogenesis is defined by the cooperative influence of 
multiple events, with viruses constituting one link in the chain. 
 
1.3 Epstein-Barr Virus 
In 1958, Denis Burkitt described the occurrence of multifocal jaw tumours afflicting children 
in equatorial Africa, that were subsequently named Burkitt’s lymphomas (BL) (Burkitt, 
1958). The climatic and geographical distribution, coincident with the prevalence of 
holoendemic malaria, led to the suggestion that an infectious agent transmitted by an 
arthropod vector might be the aetiological agent responsible for BL (Burkitt, 1962). 
Following this, Epstein, Achong and Barr succeeded in culturing lymphoma cells from a 
primary BL tumour biopsy, in which they identified actively replicating herpesvirus-like 
particles by electron microscopy (Epstein et al., 1964) The virus was subsequently shown to 
be antigenically and biologically distinct from previously characterised herpesviruses, and 
was thus named Epstein-Barr virus (EBV). Using serology-based techniques, Henle and co-
workers then established a causal association between primary EBV infection and infectious 
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mononucleosis (Henle et al., 1968) and later, again using serology-based assays, identified a 
link between EBV and the epithelial malignancy, nasopharyngeal carcinoma (NPC) (zur 
Hausen et al., 1970). These founding observations led to the classification of EBV as the first 
candidate human tumour virus. 
 
EBV has been classified as a lymphocryptovirus (γ-1 herpesvirus), and its ubiquitous nature 
has been demonstrated by seroepidemiological studies revealing infection of over 90% of the 
world population (Rickinson and Kieff, 2007). As a member of the Gammaherpesvirinae 
subfamily, it displays a narrow host range for efficient EBV infection, which is restricted to 
primary B lymphocytes and oral epithelial cells (Roizman and Baines, 1991, Kieff and 
Rickinson, 2007, Pellett and Roizman, 2007). Like other human herpesviruses, EBV has the 
ability to persist for the lifetime of the infected host (Roizman and Baines, 1991, Rickinson 
and Kieff, 2007). Indeed, in the early stages of research, EBV was proposed to possess a 
“passenger” role in infected cells (Epstein et al., 1964), replicating in synchrony with the host 
cells of infected carriers. In this way, EBV has demonstrated remarkable success in 
persistence in the human population and efficient spread to naïve individuals. 
 
The γ-herpesviruses are distinguished from other herpesvirus families by their unique ability 
to transform resting B lymphocytes into continuously proliferating lymphoblastoid cell lines 
(LCLs) in vitro (Decker et al., 1996, Young and Rickinson, 2004). This observation has 
proven crucially important in confirming the oncogenic potential of EBV and its ability to 
induce neoplastic disease in the natural or experimental host (Damania, 2004, Kieff and 
Rickinson, 2007). 
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1.3.1 EBV genome 
The EBV genome is a linear, double-stranded 172kbp DNA, depicted in Figure 1.1A, coding 
for around 90 ORFs (Kieff and Rickinson, 2007), which circularises on release from the EBV 
capsid into the host nucleus (Pellett and Roizman, 2007) via fusion of terminal repeat 
sequences to form a covalently closed episome, the preferred conformation for persistence 
(Adams and Lindahl, 1975, Kintner and Sugden, 1979, Raab-Traub and Flynn, 1986). The 
linear form of EBV DNA has variable numbers of these direct tandem 0.5kbp repeats at each 
terminus, as well as 3kbp internal repeat sequences which in combination serve to effectively 
divide the genome into unique long and short regions (Hayward et al., 1980). The prototype 
EBV strain B95-8 was the first human herpesvirus genome to be fully cloned and sequenced 
(Baer et al., 1984), and regions of the EBV genome were thus designated by their position on 
a BamHI restriction endonuclease map (Murray and Young, 2001) (Figure 1.1B). 
 
1.3.2 EBV evolution in the human host 
Variation between natural EBV isolates has been identified, resulting in classification of EBV 
strains into two main sub-types, type 1 (EBV1) (prototype B95-8) and type 2 (EBV2) 
(prototype AG876), principally governed by the identity of the EBNA2 protein, but 
additionally by observed divergence in linked polymorphisms at EBNA3A, 3B and 3C gene 
loci (Young et al., 1987, Rowe et al., 1989, Sample et al., 1990, Chang et al., 2009). Type 1 
isolates demonstrate a more competent in vitro B-cell transformation ability, thought to be 
primarily mediated by the antigenically distinct EBNA2 proteins (82-87kDa and 75kDa for 
types 1 and 2, respectively) (Rickinson et al., 1987, Cohen et al., 1989), and postulated to be 
attributed to the differing abilities of the EBNA2 proteins to induce LMP1, as well as 
differential induction of a small set of cellular genes (Lucchesi et al., 2008). 
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(FIGURE 1.1) 
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Virus isolation and seroepidemiological studies suggest that, while EBV1 is the more 
prevalent type detected in China and in Western countries, both types are relatively common 
in equatorial Africa and New Guinea (Rickinson et al., 1987, Young et al., 1987, Sixbey et al., 
1989, Young et al., 2000). This more competitive survival of type 2 isolates could potentially 
be attributed to the depressed T-cell function and intense polyclonal B-cell stimulation that 
characterises patients in malaria-endemic areas (Sixbey et al., 1989). In this regard, increased 
rates of type 2 infection have been observed in immunodeficient hosts, and a positive 
correlation has been drawn with HIV seropositivity (Sixbey et al., 1989, van Baarle et al., 
2000). Furthermore, studies have reported the high prevalence of co-infection of multiple 
distinct EBV strains in healthy viral carriers (Srivastava et al., 2000), as well as in a variety of 
EBV-associated diseases (Tierney et al., 2006, Chang et al., 2009, Santón et al., 2011), yet the 
number initially acquired during primary infection is undetermined. 
 
1.4 EBV biology 
1.4.1 EBV infection in vitro and in vivo 
The lymphotropic nature of EBV is dictated by the restricted expression of the major EBV 
receptor, CD21/complement receptor 2 (CR2), which binds the viral envelope glycoprotein 
gp350 (Nemerow et al., 1987). Following this interaction, gp42, as an integral part of a 
trimolecular complex with gp85 and gp25 fusion proteins, acts as a ligand to bind human 
leukocyte antigen (HLA) class II molecules as co-receptors to initiate virus-cell fusion and 
permit viral entry (Borza and Hutt-Fletcher, 2002, Chesnokova et al., 2009).  
 
EBV displays dual tropism, being capable of infecting epithelial cells in addition to B 
lymphocytes. While EBV is rarely detected in oropharyngeal epithelial cells in healthy 
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individuals (Borza and Hutt-Fletcher, 2002), the occurrence of epithelial cell infection in vivo 
is indisputable, as evidenced by its presence in the epithelial lesions of oral hairy leukoplakia, 
and in the EBV-associated epithelial tumour, NPC. However, the mechanism by which EBV 
gains access to epithelial cells remains somewhat elusive. To date, epithelial cells have proven 
largely resistant to infection with cell-free virus in vitro, likely due to the absence of 
CD21/CR2 on cultured epithelial cells. Previously, moderate success was achieved in 
epithelial cells by transient transfection of the CR2 receptor and co-culturing with the virus-
producing Akata B-cell line (Li et al., 1992, Imai et al., 1998). However recent studies have 
demonstrated the more efficient delivery of virus to epithelial cells in vitro using EBV-coated 
resting B cells as transfer vehicles (Shannon-Lowe et al., 2006, Shannon-Lowe et al., 2009), 
indicating that epithelial cell infection in vivo may potentially occur as a result of being in 
close proximity with infected B cells. 
 
1.4.2 EBV primary infection 
Primary infection with EBV usually occurs during childhood and is generally asymptomatic; 
however, if infection is delayed until adolescence or later, as is more common in the Western 
world, it may provoke a self-limiting proliferative disease, infectious mononucleosis (IM) 
(Rickinson and Kieff, 2007). IM is initially characterised by B-cell activation, with a subset a 
virus-carrying cells found to express the latency III growth programme (Tierney et al., 1994, 
Niedobitek et al., 1997, Al Tabaa et al., 2011). However, a significant feature is the massive 
expansion of CD8+ T cell numbers in the blood (Rickinson and Kieff, 2007), thought to be an 
antigen-induced response that subsequently controls the unlimited growth potential of EBV-
infected B lymphocytes (Klein et al., 1981, Robinson, 1982). Acute IM is therefore typified 
by significant lymphocytosis (Young and Rickinson, 2004). Regular high-titre virus shedding 
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into saliva is also consistently observed, believed to derive from differentiating plasma cells 
(Niedobitek et al., 1997). 
 
1.4.3 EBV persistence 
The frequency of EBV-infected B cells in the peripheral blood of healthy persistently infected 
carriers ranges from 1-50 per 10
6
 B cells and remains relatively stable for each individual over 
long periods of time (Miyashita et al., 1995, Khan et al., 1996, Küppers, 2003). EBV 
establishment of persistent infection in B cells has been more clearly defined, owing to the 
ease of establishment of LCLs as a suitable in vitro model, and has been reviewed in 
(Thorley-Lawson and Gross, 2004). 
 
Upon initial infection, the virus infects naïve B lymphocytes, which undergo transient 
activation and proliferation, so as to rapidly expand the pool of EBV-infected cells. This 
expansion is stimulated through induction of the EBV “growth programme”, or latency III 
pattern of gene expression, where EBV-infected cells express the complete complement of 
latent viral proteins and RNAs (Masucci and Ernberg, 1994, Miyashita et al., 1997, Thorley-
Lawson et al., 1996). Similarly, in vitro, LCLs mimic the growth-transformed cells known to 
arise during the initial stages of EBV infection in vivo, and constitutively express the full 
complement of latent genes.  
 
After the initial replication phase, the primary objective of the virus is to gain access to a 
suitable niche in which to establish latency. According to the most current model, EBV is 
believed to persist within the resting memory B cell compartment in healthy individuals 
(Thorley-Lawson et al., 1996, Miyashita et al., 1997). The exact means by which this is 
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accomplished in vivo remains one of the major unanswered questions to date; however, it is 
believed to revolve around the ability of EBV to exploit the innate B-cell differentiation 
programme to first and foremost establish infection, then to advance the progression into the 
memory compartment, from which it can persist and replicate (reviewed in (Thorley-Lawson, 
2001)). 
 
The virus is able to selectively express its different latency programmes in accordance with B-
cell differentiation status in order to transit through the B-cell system (Babcock et al., 2000). 
The initial activation of B cells by the growth programme is necessary to induce 
differentiation (Babcock et al., 2000); however, immunodominant proteins must then be 
silenced for successful evasion of EBV-specific cytotoxic T-lymphocytes (CTLs). Viral latent 
gene expression is therefore progressively down-regulated. This is believed to be specifically 
driven by the actual process of B-cell differentiation, as direct infection of germinal centre 
and tonsillar memory B cells also gives rise to the classical growth programme of gene 
expression (Babcock et al., 2000). Latently infected B cells detected within the germinal 
centre express the default latency programme (see section 1.4.4) as an intermediary step in 
transit towards the memory compartment (Roughan and Thorley-Lawson, 2009), switching 
off EBNA2 to allow differentiation to a germinal centre B-cell phenotype, and retaining 
expression of LMP1 and LMP2 to provide constitutive, ligand-independent surrogate CD40 
and BCR signals, respectively, for B-cell proliferation and survival (Thorley-Lawson, 2001). 
 
On reaching the memory compartment, the virus adopts the most stringently restricted gene 
expression programme, termed Latency 0, advantageous for latent persistence. EBV-infected 
peripheral memory B cells are largely silent in terms of latent gene expression (Babcock et al., 
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2000), and are therefore not subject to elimination through immunosurveillance. A possible 
exception is the occasional detection of LMP2A, perhaps to protect against lytic reactivation, 
while periodic expression of EBNA1 in dividing cells is thought to be required as a 
homeostatic mechanism in periods of proliferation to replenish the infected cell pool and 
maintain a constant frequency (Khan et al., 1996). From this memory cell reservoir, cells are 
periodically subject to reactivation, allowing virus shedding into saliva for transmission to 
new hosts. 
 
1.4.4 EBV latency programmes 
In common with other members of the herpesvirus family, EBV displays a biphasic life cycle 
in vivo with both latent and lytic elements. As a general rule, it establishes long-term latency 
in the B-lymphocyte compartment, whilst it is capable of replicating in both B lymphocytes 
and epithelial cells (Kieff and Rickinson, 2007). However, the establishment of latent 
infection in epithelial cells has also been described in EBV-associated epithelial malignancies. 
Extensive analysis of EBV-associated malignancies and a number of EBV-infected cell lines, 
has led to the characterisation of different forms of EBV latency, each one defined by a 
distinct subset of viral gene expression. 
 
Latency 0 is proposed to occur in peripheral resting memory B cells so as to permit viral 
persistence. As such, while the viral genome is retained, only EBER and BART RNAs are 
detected, with a characteristic absence of viral proteins, except perhaps LMP2A and 
occasionally EBNA1. The latency state described in Burkitt’s lymphoma is termed latency I, 
limited to the EBER and BART RNAs, and selective expression of EBNA1 from the Qp 
promoter. Latency II, also referred to as the default programme, was initially identified in 
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nasopharyngeal carcinoma (Brooks et al., 1992), and has also been described in Hodgkin’s 
disease and certain EBV-positive T cell lymphomas. It is characterised by expression of Qp-
driven EBNA1, LMP1, LMP2, and the EBER and BART RNAs. The latency III, or growth 
programme, as exemplified in vitro by LCLs, can also be observed in post-transplant 
lymphoproliferative disorders. This includes expression of the full spectrum of EBNAs and 
LMPs, as well as the EBER and BART RNAs. 
 
Due to the dynamic nature of latent gene expression throughout the life cycle of the virus, it is 
not uncommon to observe deviations from these classifications. For example, established BL 
tumour cell lines have been reported to drift to a latency III pattern upon serial passage in 
vitro, with concomitant development to a LCL-like cell surface phenotype (Rowe et al., 1992, 
Young et al., 2000). Furthermore, an atypical “Wp-restricted” form of latency has been 
described in a subset of BL tumours, in which most EBNAs are additionally expressed with 
the exception of EBNA2 due to gene deletion (Kelly et al., 2002). 
 
1.4.5 Lytic cycle 
Latently infected B lymphocytes in the peripheral blood of healthy carriers are susceptible to 
local periodic reactivation when recirculating through oropharyngeal sites. This produces new 
infectious virus progeny, which are shed into saliva, in order to facilitate efficient propagation 
via oral transmission to naïve individuals (Kieff and Rickinson, 2007). In the viral productive 
cycle, the EBV genome is amplified more than 100-fold (Tsurumi et al., 2005), and the 
epithelium is proposed to serve as an important site for virus amplification prior to shedding 
(Hadinoto et al., 2009). 
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Lytic cycle is orchestrated by the simultaneous expression of two immediate-early (α) genes, 
BZLF1 and BRLF1, which encode the transcription factors, Zta and Rta respectively 
(Feederle et al., 2000). These act as essential transactivators of viral DNA replication, which 
trigger a cascade of events involving the temporal expression of early (β) genes, with 
important roles in viral DNA replication and nucleotide metabolism, followed by late (γ) 
genes, which support viral DNA amplification and encode viral structural components, and 
whose expression is either augmented by, or totally dependent on, the onset of viral DNA 
synthesis (Pellett and Roizman, 2007). 
 
The exact trigger for lytic replication is not fully understood; however, it is believed to be 
linked to a differentiation-dependent phenomenon. Indeed in B lymphocytes it can be initiated 
in vivo by the differentiation of memory cells into plasma cells (Laichalk and Thorley-
Lawson, 2005), while lytic cycle activity in vitro in a human keratinocyte line, SCC12F, was 
found to be substantially increased upon induction of epithelial terminal differentiation 
(Karimi et al., 1995). 
 
Full virus replication can be observed in vivo in oral hairy leukoplakia (OHL), a benign 
hyperproliferative lesion found principally on the lateral borders of the tongue, characterised 
by high-level EBV replication. It is associated with immunosuppression, and observed in 
AIDS patients, or occasionally in post-renal transplant patients (Friedman-Kien, 1986, 
Greenspan et al., 1984, Lopes et al., 2003). In accordance with observations in vitro, in situ 
hybridisation (ISH) for EBV DNA indicates replication is restricted to the upper, more 
differentiated epithelial layers of the tongue (Niedobitek et al., 1991) and a differentiation-
associated pattern of BZLF1 expression is observed (Young et al., 1991). 
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1.5 EBV latent proteins 
1.5.1 EBNA1 
1.5.1.1 Structure of the EBNA1 protein 
The prototypical B95-8 EBV nuclear antigen 1 (EBNA1) protein is a 641 amino acid nuclear 
phosphoprotein (Hearing and Levine, 1985) (Figure 1.2A). Its N-terminal region is inclusive 
of a glycine-alanine repeat sequence between residues 90 and 325, seen to be somewhat 
heterogeneous between different EBV isolates (Fischer et al., 1997). This glycine-alanine 
repeat domain is considered to be dispensable for the maintenance of a stable latent infection 
and, by default, the replication, transactivation and segregation functions of EBNA1 (Yates et 
al., 1985, Lee et al., 1999, Ceccarelli and Frappier, 2000). For a long time, EBNA1 was 
believed to utilise this domain to bestow reduced immunogenicity, as a unique means of 
evading recognition by CD8+ T lymphocytes through inhibition of endogenous processing 
and presentation through the MHC class I pathway (Levitskaya et al., 1997, Blake et al., 
1997). More recently, its effects have been attributed to its capacity to retard its own mRNA 
translation (Yin et al., 2003, Tellam et al., 2008, Apcher et al., 2009, Apcher et al., 2010), as a 
means of reducing the frequency of production of EBNA1-derived defective ribosomal 
products (DriPs) (Lee et al., 2004), considered the major source of T-cell epitopes for CD8+ 
T-cell recognition (Voo et al., 2004). 
 
Ambinder and colleagues identified a nuclear localisation signal (NLS), Leu-Lys-Arg-Pro-
Arg-Ser-Pro-Ser-Ser, located between amino acids 379 and 386 (Ambinder et al., 1990), and 
of paramount importance in directing EBNA1 to the nucleus. Additionally, yeast two-hybrid 
screening identified an in vitro interaction of EBNA1 with the nuclear transporter, importin  
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(FIGURE 1.2) 
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α/Rch1 (Fischer et al., 1997, Kim et al., 1997, Ito et al., 2000), which is also likely to be 
important. 
 
The EBNA1 protein lacks intrinsic enzymatic activity (Frappier and O'Donnell, 1991) and so 
exerts its key functions as a site-specific DNA binding protein, displaying an active dimeric 
conformation (Ambinder et al., 1991). In order to effectively accomplish this demand, the C-
terminal region of the protein encompasses a DNA binding and dimerisation domain located 
within the C-terminal between amino acids 459 and 607, responsible for binding to target 
recognition sequences (Ceccarelli and Frappier, 2000). The ability of EBNA1 to bind to RNA 
through arg-gly-gly (RGG) motifs has also been characterised (Snudden et al., 1994, Lu et al., 
2004), highlighting a potential involvement in the formation of ribonucleoprotein complexes 
in vivo. 
 
1.5.1.2 Transcription of EBNA1 
EBNA1 transcription in EBV-infected cells is driven from three different viral promoters, 
termed Cp/Wp, Qp and Fp, located in the BamHI-C, BamHI-Q, and BamHI-F regions of the 
viral genome respectively (Kieff and Rickinson, 2007). Alternative promoter usage is 
important in the establishment of different latency programmes and lytic cycle in EBV-
infected lymphocytes (Chen et al., 1999). 
 
Upon initial infection of B cells, the constitutively active Wp promoter drives EBNA 
expression. This function is then assumed by the Cp promoter (Schlager et al., 1996), which is 
subsequently used as the promoter of choice to drive EBNA transcription as part of the 
latency III programme, as is typified in infectious mononucleosis and in LCLs (Schlager et 
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al., 1996, Chen et al., 1999). In this setting, EBNA1 is transcribed as part of a polycistronic 
unit coding for all six EBNAs (Schlager et al., 1996, Chen et al., 1999, Zetterberg et al., 
1999), and is the product of differential splicing. The constitutively active Qp promoter is not 
subject to methylation control but instead is silenced by autoregulatory binding of EBNA1 to 
two low affinity EBNA1-binding sites immediately downstream of the transcription initiation 
site (Schaefer et al., 1997b, Tao et al., 1998, Davenport and Pagano, 1999, Yoshioka et al., 
2008). 
 
In contrast, in situations where the virus adopts either latency I or II patterns of gene 
expression, as exemplified in BL and C666-1 NPC cell lines, EBNA1 transcripts are initiated 
from the Qp promoter (Bakos et al., 2007). This switch to the EBNA1-specific Qp promoter 
in order for the more restricted exclusive expression of EBNA1 to prevail, is necessitated by 
host-mediated silencing of Cp (Chen et al., 1999), which in turn alleviates host-mediated 
repression of Qp. Qp-driven EBNA1 expression is also subject to further regulation via 
putative E2F binding sites (Nonkwelo et al., 1997, Ruf and Sample, 1999), as well as by the 
JAK/STAT pathway and cell cycle factors (Schaefer et al., 1997a, Chen et al., 1999, Chen et 
al., 2001, Davenport and Pagano, 1999). The Fp promoter, located around 200bp upstream of 
Qp, was found to be utilised to drive EBNA1 transcription upon entry into lytic cycle 
(Zetterberg et al., 1999). 
 
1.5.1.3 Modulation of viral replication, episome segregation and transcription 
EBNA1 is the most consistently expressed latent protein in all forms of viral latency on 
account of its absolute requirement in maintaining and efficiently replicating the EBV 
genome, and therefore intimate role in maintenance of latent EBV infection. In addition, its 
 18 
ability to act as a transcriptional transactivator is key to the activation and regulation of viral 
Cp and LMP1 promoters (Sugden and Warren, 1989, Gahn and Sugden, 1995). EBNA1 is 
implicitly dependent upon its DNA-binding and dimerisation domain in order to fulfil its vital 
functions in the replication, segregation and transcriptional activation of the viral genome 
(Polvino-Bodnar and Schaffer, 1992). Further regions located upstream are responsible for 
subsequent full orchestration of these functions (Figure 1.2B). 
 
Maintenance and replication of the viral episome is accomplished through the interaction of 
the trans-acting EBNA1 protein with cis-acting sequences within the viral origin of latent 
DNA replication, OriP, a 1.7kb region of the EBV episome containing two functional 
elements, the dyad symmetry (DS) and family-of-repeats (FR) (Reisman and Sugden, 1986, 
Ambinder et al., 1990, Ambinder et al., 1991, Bashaw and Yates, 2001). The approximately 
120bp DS element of OriP has been identified as the main initiator of episomal EBV DNA 
replication (Yates et al., 2000), and contains 4 binding sites for EBNA1, shown to function in 
pairs. Replication initiation is greatly stimulated by the FR enhancer region (Frappier and 
O'Donnell, 1991) which contains 20 EBNA1 binding sites (Reisman et al., 1985), and 
possesses additional roles in mediating chromatin association and partitioning of EBV 
episomes (Reisman and Sugden, 1986, Bashaw and Yates, 2001, Deutsch et al., 2010).  
 
EBNA1-mediated replication of OriP-containing plasmids occurs once per cell cycle, and is 
additionally facilitated by host chromosomal initiation factors, including ORC (Bashaw and 
Yates, 2001, Dhar et al., 2001), as well as interactions with the host mitochrondrial protein, 
p32 (Wang et al., 1997, Chen et al., 1998, Van Scoy et al., 2000), and histone chaperone 
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proteins such as nucleosome assembly protein 1 (NAP1) and template-activating factor (TAF-
I) (Holowaty et al., 2003, Wang and Frappier, 2009). 
 
Deletion of the gly-arg rich region between amino acids 325 and 376 has been shown to 
abrogate the ability to maintain OriP plasmids, and therefore a role in plasmid segregation has 
been assigned to this domain (Shire et al., 1999, Ceccarelli and Frappier, 2000, Wu et al., 
2000, Kapoor and Frappier, 2003, Nayyar et al., 2009). The same deletion is seen to decrease 
association with metaphase chromosomes, thought to be mediated via an interaction with 
EBP2, and consistent with the requirement of chromosome tethering for efficient segregation 
(Marechal et al., 1999, Wu et al., 2000, Kapoor and Frappier, 2003, Nayyar et al., 2009). 
 
Residues 325-376 are also deemed essential for transcriptional activation activity (Wu et al., 
2002), while the vital contribution of amino acids 61-83 to transcriptional activation is, at 
least in part, thought to be mediated through its interaction with Brd4 (Lin et al., 2008). A 
further regulatory role in viral gene transactivation and episomal viral genome maintenance is 
contributed by amino acids 8-67, while the region between residues 395 and 450 has been 
shown to participate in an interaction with the cellular deubiquitinating enzyme, USP7 
(Holowaty et al., 2003), as will be mentioned later. 
 
Recent work has demonstrated that post-translational modifications may participate in the 
regulation of EBNA1 function. Phosphorylation sites of EBNA1 are thought to be involved in 
transcriptional activation and EBV plasmid maintenance (Duellman et al., 2009, Kang et al., 
2011). Specifically, serine phosphorylation of the 325-376 region can enhance binding to 
EBP2 so increasing segregation efficiency, while arginine methylation of the same region by 
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arginine methyltransferases PRMT1 and PRMT5 is postulated to influence EBNA1 
localisation (Shire et al., 2006). Furthermore, the specific patterns of serine phosphorylation 
within the NLS are speculated to impact upon the dynamic rate of nuclear transport (Kitamura 
et al., 2006).  
 
Also, Deng and colleagues have found that EBNA1 is subjected to PAR modification in vivo. 
EBNA1 binds the poly(ADP-ribose) polymerase (PARP), tankyrase 1 and 2 proteins that 
function to maintain telomere length via interactions with telomere-repeat binding factor 
(TRF1) (Smith et al., 1998). Interestingly, tankyrase 1 and 2 negatively regulate OriP 
replication and maintenance. This modification may alter EBNA1’s ability to interact with 
and recruit certain cellular proteins or, alternatively, decrease EBNA1 stability (Deng et al., 
2002, Deng et al., 2005, Tempera et al., 2010). 
 
1.5.1.4 The role of EBNA1 in the modulation of cellular transcription and tumourigenesis 
While EBNA1 is principally regarded as a genome maintenance protein, an accumulating 
body of evidence now suggests that EBNA1 may contribute to cellular transformation and 
oncogenesis, largely through its ability to deregulate key cellular processes. However, the 
exact contribution of EBNA1 to the development of EBV-associated malignancies still 
remains controversial. 
 
Early experiments targeting the expression of EBNA1 to the B-cell compartment in two 
lineages of transgenic mice reported increased frequencies of lymphoma formation, 
suggesting that EBNA1 may have oncogenic activity in vivo (Wilson et al., 1996). However 
these findings were later challenged by Kang and colleagues (Kang et al., 2005, Kang et al., 
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2008), who dismissed a potential role for EBNA1 in lymphomagenesis. Further doubt was 
cast on the absolute requirement for EBNA1 in EBV-induced immortalisation, when growth-
transformed LCLs were successfully established using an EBV strain deleted for EBNA1 
(Humme et al., 2003). It is suggested that, while EBNA1 may increase the efficiency of B-cell 
transformation, its expression is not mandatory (Lee et al., 1999). 
 
However, EBNA1 was found to enhance the tumourigenicity and metastatic capability of 
NPC cells in SCID mice (Sheu et al., 1996), and was observed to interact with the known 
suppressor of metastasis and cell migration, Nm23-H1, thereby overriding its repressive 
effects on cell migration (Murakami et al., 2005). It additionally confers a survival advantage 
to EBV-positive BL cells through inhibition of apoptosis (Kennedy et al., 2003, Sengupta et 
al., 2006), potentially through up-regulation of the inhibitor of apoptosis, survivin (Lu et al., 
2011). 
 
The observed interaction of EBNA1 with the deubiquitinating enzyme, USP7, is predicted to 
contribute to host cell immortalisation through sequestration of USP7 and destabilisation of 
p53 (Holowaty et al., 2003, Holowaty and Frappier, 2004), which may reduce sensitivity to 
DNA damage (Cheng et al., 2010). Further characterisation of this interaction has uncovered 
its involvement in the disruption of cellular promyelocytic leukaemia (PML) nuclear bodies, 
eliciting the degradation of their principal component (Sivachandran et al., 2008), which is 
additionally enhanced by a distinct interaction between EBNA1 and host CK2 kinase 
(Sivachandran et al., 2010), and potentially promotes the survival of cells harbouring DNA 
damage. 
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Furthermore, there is growing evidence to substantiate a role for EBNA1 in the modulation of 
cellular gene transcription in both B cells and epithelial cells, predicted to be related to 
EBNA1-mediated regulation of genes involved in chromatin remodelling complexes 
(Sompallae et al., 2010). Increased levels of the V(D)J recombinase-activating genes, RAG1 
and RAG2, have been attributed to the presence of EBNA1 in EBV-positive BL cells 
(Srinivas and Sixbey, 1995), and may contribute to the observed genomic instability in BL 
tumours. Induction of the IL2 receptor α chain CD25 and the chemokine CCL20 have been 
attributed to the expression of EBNA1 in EBV-positive HL (Kube et al., 1999, Baumforth et 
al., 2008), which is also responsible for the down-regulation of the tumour suppressor, and 
TGFβ target gene, protein tyrosine phosphatase receptor kappa (PTPRK) following EBV 
infection of HL cells (Flavell et al., 2008). 
 
Furthermore, evidence is gathering to support EBNA1 as a potent regulator of cellular gene 
transcription in carcinoma cell lines. In addition to priming cellular response to IFNγ through 
an induction of STAT1, EBNA1 has been shown to repress TGFβ-induced transcription via 
increased protein turnover of the Smad2 protein, modulate AP-1 transcription factor 
signalling through up-regulation of c-Jun and ATF2 subunits, and abrogate NFκB signalling 
through inhibition of IKKα/β phosphorylation (Wood et al., 2007, O'Neil et al., 2008, 
Valentine et al., 2010). Additionally, a recently discovered facet of EBNA1 behaviour is its 
ability to enhance EBER expression through increased cellular RNA polymerase III 
transcription and the induction of associated cellular transcription factors (Owen et al., 2010). 
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1.5.2 EBNA-2, -LP, -3A, -3B and -3C 
Although frequently silenced in EBV-associated tumours, there is an unquestionable role for 
the transitory expression of these EBNAs in the initial establishment of latent infection in B 
lymphocytes. Indeed, recombinant EBV mutants lacking EBNA2, EBNA-LP, EBNA-3A or 
EBNA-3C are rendered transformation-incompetent in vitro (Tomkinson et al., 1993, Humme 
et al., 2003). However, EBNA3B is not considered essential (Tomkinson and Kieff, 1992). 
 
EBNA2 and EBNA-LP are temporally the first EBV latent proteins to be detected following 
EBV infection (Kieff and Rickinson, 2007), and their importance is emphasised by the 
transformation-incompetent P3HR-1 EBV strain lacking all of the EBNA2 gene and the last 
two exons of the EBNA-LP gene (Bornkamm et al., 1980, Hammerschmidt and Sugden, 
1989, Cohen et al., 1989, Rabson et al., 1982), and proven by reintroduction of deleted 
sequences, which restores the ability to immortalise B lymphocytes in vitro (Hammerschmidt 
and Sugden, 1989, Young et al., 2000). 
 
EBNA2 is a transcriptional activator of both cellular and viral genes, inducing B-cell 
activation molecules such as the EBV receptor CD21 and the B-cell activation antigen CD23 
(Cordier et al., 1990, Wang et al., 1990, Wang et al., 1987), as well as the proto-oncogene c-
myc (Kaiser et al., 1999), and up-regulating the expression of LMP1 and LMP2 (Laux et al., 
1994, Young et al., 2000), which is coactivated by EBNA-LP (Peng et al., 2005). Crucially, 
EBNA2 also transactivates the viral Cp promoter during the early stages of EBV infection 
(Woisetschläger et al., 1991, Sung et al., 1991, Chen et al., 1999, Young et al., 2000), and 
thereby governs the mutually exclusive usage of Wp and Cp promoters in B lymphocytes 
(Woisetschläger et al., 1989, Woisetschläger et al., 1990). 
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EBNA2 transactivation capabilities are not thought to be direct and appear to be mediated via 
interaction with the ubiquitous DNA binding protein, RBP-Jκ; in doing so, EBNA2 partially 
mimics aspects of Notch function (Henkel et al., 1994, Grossman et al., 1994, Young et al., 
2000, Sakai et al., 1998, Zimber-Strobl and Strobl, 2001). 
 
1.5.3 LMP1 
Latent membrane protein 1 (LMP1) is a 63kDa integral membrane protein and is considered 
the major transforming protein encoded by EBV. LMP1 behaves as a classical oncogene in 
rodent fibroblast transformation assays (Wang et al., 1985) and has been shown to be 
absolutely essential for EBV-mediated transformation of primary B lymphocytes in vitro 
(Kaye et al., 1993). LMP1 expression in B cells is associated with the up-regulation of 
particular cell-surface proteins, notably CD21, CD23, CD39, CD40 and CD44 activation 
markers, and the cellular adhesion molecules LFA-1, ICAM-1 and LFA-3 (Wang et al., 
1990), while LMP1-induced up-regulation of the anti-apoptotic proteins bcl2 and A20 may 
also have important implications for cell survival (Henderson et al., 1991, Rowe et al., 1994, 
Fries et al., 1996). 
 
LMP1 functions as a constitutively active viral mimic of the TNF receptor (TNFR) family 
member, CD40, sustaining B-cell proliferation in vitro (Gires et al., 1997, Kilger et al., 1998, 
Uchida et al., 1999), primarily through recruitment of TRAFs and TRADD to its CTAR1 and 
CTAR2 signalling domains (Mosialos et al., 1995, Mainou et al., 2007, Floettmann and 
Rowe, 1997, Floettmann et al., 1998, Kilger et al., 1998). In this way, LMP1 is able to engage 
the NFκB, JNK and p38 MAPK cellular signalling pathways (Eliopoulos and Young, 1998, 
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Eliopoulos et al., 1999). Signal transduction by LMP1 has been more extensively reviewed in 
(Lam and Sugden, 2003, Kieser, 2007, Graham et al., 2010). 
 
When expressed in epithelial cells, LMP1 induces profound phenotypic changes and inhibits 
terminal differentiation (Dawson et al., 1990), reviewed in (Tsao et al., 2002), through 
mechanisms that involve the generation of an “inflammatory wound” response (Morris et al., 
2008). LMP1 activation of PI3-kinase (PI3K), which maps to CTAR1, is associated with actin 
filament remodelling and cell survival through the activation of Akt (Dawson et al., 2003), 
while activation of ERK-MAPK via the canonical Raf-MEK-ERK-MAPK pathway enhances 
cell motility and invasive properties (Lo et al., 2003, Dawson et al., 2008). Moreover, the 
ability of LMP1 to induce an epithelial-mesenchymal transition (EMT) in MDCK cells has 
been evidenced by characteristic morphological changes and an accompanying loss of E-
cadherin (Kim et al., 2000)(Laverick et al. – manuscript in preparation). 
 
1.5.4 LMP2A and LMP2B 
The LMP2 gene gives rise to the expression of two distinct mRNA species, LMP2A and 
LMP2B, generated by transcription from two different promoters (Sample et al., 1989). The 
resulting proteins share structural similarity in 12 hydrophobic transmembrane domains and a 
27 amino acid cytoplasmic C-terminal domain, and differ only in the first exon, which for 
LMP2A encodes a 119 amino acid N-terminal cytoplasmic domain, but is non-coding in 
LMP2B. There is evidence to suggest that LMP2B may act as a competitive regulator of 
LMP2A function (Rovedo and Longnecker, 2007), and both are generally considered 
dispensable for B-cell transformation in vitro (Speck et al., 1999), reviewed in (Longnecker, 
2000). 
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 LMP2A has been shown to block BCR signal transduction in EBV-infected B lymphocytes 
in vitro by sequestering key signalling proteins such as Syk and Lyn protein tyrosine kinases, 
and promoting their degradation, mediated by binding to the immunoreceptor tyrosine 
activation motif (ITAM) located in the cytoplasmic amino-terminal domain (Fruehling and 
Longnecker, 1997, Caldwell et al., 1998). Importantly, this impedes B-cell differentiation, 
thereby protecting against fortuitous lytic reactivation in latently infected cells (Miller et al., 
1994, Miller et al., 1995). Phosphotyrosine (PY) motifs also present within the amino-
terminal domain of LMP2A additionally serve as specific binding sites for Nedd4-like 
ubiquitin protein ligases, AIP4, WWP2/AIP2 and Nedd4 promoting the degradation of both 
LMP2A and Lyn to further modulate signalling (Ikeda et al., 2000).  
 
Signalling of LMP2A in EBV latency and in malignant states has recently been reviewed 
(Pang et al., 2009). Specifically in carcinoma cells, LMP2A has demonstrated the ability to 
activate the PI3K-Akt pathway, to modulate both STAT and NFκB signalling activities, and 
to attenuate signalling from endosomal localised TLRs (Scholle et al., 2000, Stewart et al., 
2004, Murphy, PhD thesis, 2010). In addition, both LMP2A and LMP2B were found to 
inhibit interferon (IFN)-mediated transcription, as a consequence of increased IFN receptor 
turnover (Shah et al., 2009). 
 
Expression of LMP2A and LMP2B in squamous epithelial cells also confers an increased 
capacity for cell spreading and migration (Allen et al., 2005) which, at least for LMP2A, may 
be related to an up-regulation of the cellular protein ITGα6 (Pegtel et al., 2005). Similarly, 
LMP2A-expressing HaCaT cells demonstrated anchorage-independent growth and colony 
formation in soft agar, and induced the formation of aggressive, poorly differentiated and 
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metastatic tumours in vivo (Scholle et al., 2000). LMP2A has also recently been implicated in 
the induction of EMT in NPC cells (Kong et al., 2010). 
 
1.5.5 EBERs 
The small non-polyadenylated, untranslated RNAs, EBER1 and EBER2, 166 and 172 
nucleotides long respectively, are encoded by the EcoRI-J fragment of EBV (B95-8) DNA, 
transcribed by host RNA polymerase III and are the most abundantly (up to 10
7
 copies per 
cell) and consistently expressed EBV gene products in latently infected cells (Lerner et al., 
1981, Rosa et al., 1981, Arrand and Rymo, 1982, Jat and Arrand, 1982, Howe and Steitz, 
1986, Minarovits et al., 1992). They therefore serve as valuable diagnostic markers for EBV 
latent infection. 
 
EBERs, although not essential for B-lymphocyte transformation, have been shown to enhance 
the transforming potential of EBV (Ruf et al., 2000, Yajima et al., 2005, Wu et al., 2007), 
through changes to cellular transcription machinery, specifically cellular RNA polymerase III-
related factors (Felton-Edkins et al., 2006). Recognition of EBERs by retinoic acid-inducible 
gene I (RIG-I) results in the induction of type I IFNs and IFN-stimulated genes (ISGs) 
(Samanta et al., 2006). EBER1 additionally acts further downstream by interacting with the 
IFN-inducible, dsRNA-activated protein kinase PKR, so as to confer resistance to IFNα-
induced apoptosis and also prevent its phosphorylation of the protein synthesis initiation 
factor, eIF2a, and its associated inhibition of protein synthesis (Young and Rickinson, 2004, 
Clarke et al., 1990, Clarke et al., 1991). 
 
 
 28 
1.5.6 EBV-encoded miRNAs 
EBV was the first human virus identified to encode microRNAs (miRNAs) (Pfeffer et al., 
2004). Currently, a total of 25 EBV miRNA precursors and 48 mature miRNAs have thus far 
been identified. EBV encodes miRNAs from two primary transcripts: BHRF1 and the 
BamHI-A rightward transcripts (BARTs). The BHRF1 transcript encodes three miRNA 
precursors (ebv-miR-BHRF1-1, -2 and -3), which produce 4 mature miRNAs. Within the 
BART region, two clusters of miRNAs have been identified, producing 44 mature miRNAs 
from 22 miRNA precursors. BART Cluster 1 is located between BART exon I and IB, and 
gives rise to 8 miRNA precursors (ebv-miR-BART1, -BART3 to 6, and –BART15 to 17). 
BART Cluster 2 is located between BART exon II and III, and gives rise to 13 miRNA 
precursors (ebv-miR-BART7 to 14, and –BART18 to 22). The ebv miR-BART2-3p and 2-5p 
mature miRNA are located between exon IV and V (Zhu et al., 2009, Lung et al., 2009, Chen 
et al., 2005, Cai et al., 2006, Grundhoff et al., 2006, Pfeffer et al., 2004). The expression of 
BHRF1-encoded miRNAs is limited to B lymphocytes displaying type III latency (Pfeffer et 
al., 2004). As with the original BART transcripts, the BART miRNAs can be detected in all 
forms of EBV latency, but appear to be more abundantly expressed in EBV-associated 
epithelial cancers, NPC and EBVa-GC, compared to BL or LCLs. Whilst the function of 
BHRF1 and BART-encoded miRNAs are still being uncovered, several recent reports have 
shown that a number of BART miRNAs target EBV latent gene transcripts. At least three 
BART cluster 1 miRNAs (ebv-miR-BART1-5p, -BART16 and –BART17-5p) target the 
3’UTR of the LMP1 gene, thereby regulating expression of LMP1 (Lo et al., 2007), whilst 
ebv-miR-BART22, which is abundantly detected in NPC specimens, targets the 3’UTR of 
LMP2A (Lung et al., 2009). BART miRNAs have also been shown to target cellular genes. 
Ebv-miR-BART5 targets and suppresses the expression of p53 up-regulated modulator of 
 29 
apoptosis (PUMA) (Choy et al., 2008), whilst BART2-5p targets viral lytic BALF5 to 
maintain viral latency (Barth et al., 2008). EBV BART miRNAs expressed in NPC cells have 
been found to be involved in immune evasion. Nachmani and colleagues identified that ebv-
miR-BART2-5p targets the 3’UTR of MHC class I-related chain B (MICB) gene, a cellular 
ligand for NKG2D (Nachmani et al., 2009), whilst importin 7 (IPO7) was also identified as a 
target of ebv-miR-BART3 (Dolken et al., 2010). 
 
1.6 EBV-associated malignancies 
EBV has been implicated as an etiologic agent in malignancies of both lymphoid and 
epithelial origin, reflecting the natural tropism of the virus in vivo. Such tumours are typified 
by the presence of multiple extrachromosomal copies of the viral genome in tumour cells 
(Young and Murray, 2003). B-cell malignancies can be traced and found to originate from 
different stages of the B-cell differentiation process. Indeed, the malignant cells detected in 
Hodgkin’s disease (HD) are thought to arise from crippled germinal centre cells, supported by 
the observed constitutive expression of the default latency programme. Burkitt’s lymphoma 
(BL) is predicted to derive from a cell exiting the germinal centre, but arrested at a point of 
continual proliferation owing to constitutive activation of the c-myc oncogene. If the immune 
system is compromised, such as following iatrogenic immunosuppression for transplant 
surgery, or in patients with AIDS, bystander B-cell blasts which would normally be destroyed 
by CTLs can give rise to post-transplant lymphoproliferative disorders (Lopes et al., 2003, 
Thorley-Lawson and Gross, 2004, Young and Rickinson, 2004). EBV has also been linked 
with a subset of nasal T-cell/NK cell lymphomas, which has recently been reviewed in (Fox et 
al., 2011). 
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EBV-associated epithelial malignancies include undifferentiated nasopharyngeal carcinoma 
and a subset of gastric carcinomas, both of which will be discussed in more detail, as well as 
undifferentiated squamous cell carcinomas of the salivary glands and uterine cervix. Potential 
relationships with hepatocellular carcinoma and breast cancer have also been described in 
recent years (Young and Murray, 2003, Hippocrate et al., 2011). 
 
1.6.1 Nasopharyngeal carcinoma (NPC) 
NPC is a distinctive type of head and neck cancer, arising from the squamous epithelial cells 
of the nasopharynx. The World Health Organisation (WHO) has acknowledged the 
histological classification of NPC into three distinct subgroups, differentiated, keratinising 
squamous cell carcinomas (type I), and non-keratinising carcinomas, the latter group being 
further divided into differentiated non-keratinising (type II) and undifferentiated carcinomas 
(type III) (Shanmugaratnam and Sobin, 1993). 
 
Undifferentiated type III NPC is a highly metastatic disease (Spano et al., 2003), and is 
frequently described as a “lymphoepithelioma” due to a prominent lymphocyte infiltrate 
(Klein et al., 1974, Niedobitek et al., 1996, Raab-Traub, 2002, Lo et al., 2004). This form 
demonstrates the most consistent association with EBV infection (Nicholls et al., 1997), and 
comprises over 95% of NPC cases in high-incidence areas (Chang and Adami, 2006). NPC 
tumours generally display the default programme of gene expression with consistent 
expression of the EBER and BART RNAs, Qp-driven EBNA1, LMP2 and variable levels of 
LMP1 (Brooks et al., 1992, Busson et al., 1992). Also, elevated IgG and IgA reactivity to the 
EBV viral capsid antigen (VCA) and early antigen (EA) complex have been detected in NPC 
sera compared to healthy controls (Henle and Henle, 1976, Ho et al., 1976) and serve as 
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useful diagnostic markers for this disease. Furthermore, the detection of EBV in 
nasopharyngeal preinvasive lesions (Pathmanathan et al., 1995, Cheung et al., 2004) indicates 
the viral infection may be a relatively early event in NPC pathogenesis. In further support of 
this, tumour monoclonality can be deduced from the homogeneity of EBV with regard to the 
number of terminal repeats within individual tumours, suggesting tumours are the result of 
clonal proliferations of a single EBV-infected progenitor cell (Raab-Traub and Flynn, 1986, 
Raab-Traub, 2002). 
  
The age-standardised incidence rate of NPC is generally under 1 per 100,000 persons per year 
in most parts of the world (Yu and Yuan, 2002, Lo et al., 2004, Parkin, 2006). However, a 
much higher incidence is reported among the Southern Chinese (~25-30 per 100,000 persons 
per year), particularly among the Cantonese who inhabit the central region of the Guangdong 
Province in Southern China (Yu and Yuan, 2002, Lo et al., 2004). Other populations with 
elevated rates include natives of Southeast Asia, the Arctic region, Maghrebi Arabic regions 
of North Africa and parts of the Middle East (Yu and Yuan, 2002, Chang et al., 2009). In 
addition, a unique peak incidence age plateau of ~40-50 years, and male: female ratio of 2-3:1 
are consistently observed (Hildesheim and Levine, 1993, Spano et al., 2003, Parkin, 2006, 
Tao and Chan, 2007). 
 
The remarkably distinct geographical and ethnic distribution suggests a strong association of 
NPC with both genetic and environmental factors. There is now a general consensus that the 
pathogenesis and development of NPC is a multistep process involving the accumulation of 
stochastically acquired features, that emerge in response to the interaction of multiple factors 
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(Lo et al., 2004, Young and Rickinson, 2004, Tao and Chan, 2007). A proposed schematic of 
events is illustrated in Figure 1.3. 
 
Perhaps one of the most well-documented environmental risk factors is the consumption of 
salted fish traditional to the Cantonese diet, and other preserved foods containing volatile 
nitrosamine compounds (Yu and Yuan, 2002, Lo et al., 2004, Chang and Adami, 2006) (Yuan 
et al., 2000b, Ward et al., 2000, Ho et al., 1978, Yu et al., 1986, Zheng et al., 1994, Guo et al., 
2009). Convincingly, an experimental salted fish diet was seen to induce malignant tumours 
in the nasal cavities of rats (Yu et al., 1989), and of particular interest, certain allelic 
polymorphisms of the cytochrome P450 2E1 enzyme (CYP2E1), responsible for the 
metabolic activation of nitrosamines, are more frequently detected in the high-risk Chinese 
population, and are associated with an increased risk of developing NPC (Hildesheim et al., 
1995, Hildesheim et al., 1997). 
 
Case-control studies in endemic regions have identified additional risk factors, including the 
consumption of Chinese medicinal herbs, and lack of vitamin C, as well as exposure to 
domestic wood cooking fires and occupational exposure to chemical fumes, smoke and dusts, 
particularly from wood and metals (Lo et al., 2004, Zheng et al., 1994, Guo et al., 2009, 
Armstrong et al., 2000, Hildesheim et al., 2001, Yuan et al., 2000b). The association of NPC 
with cigarette smoking or formaldehyde exposure is either weak or controversial (Lo et al., 
2004), while alcohol consumption is unlikely associated with risk in high-incidence 
populations (Cheng et al., 1999). 
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(FIGURE 1.3) 
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The concept of a genetic predisposition is supported by studies documenting a family history 
of NPC, and by observations of significantly elevated risk of NPC in the first-degree relatives 
of probands with NPC, among the high-risk subgroup of the Cantonese population in the 
Guangdong province (Yuan et al., 2000a, Guo et al., 2009, Jia et al., 2004). A high NPC 
incidence is also retained among Southern Chinese who migrate to other nonendemic 
countries (Buell, 1974, Lo et al., 2004, Tao and Chan, 2007, Grulich et al., 1995) confirming 
this genetic importance. However, successive generations of Chinese immigrants appear to be 
at a progressively lower risk of developing NPC, emphasising the influence of environmental 
agents (King et al., 1985, Yu and Hussain, 2009). 
 
Analyses of studies in the high-risk Southern Chinese also predict that specific HLA 
haplotypes may be associated with NPC susceptibility, by virtue of their comparative 
efficacies in triggering host immune responses (Lu et al., 1990, Lu et al., 2003, Lo et al., 
2004, Chang and Adami, 2006). A positive correlation with the presence of NPC has been 
found for HLA alleles, A2, B14 and B46, while negative associations were identified for 
alleles A11, B13 and B22 (Goldsmith et al., 2002). 
 
Cytogenetic or array-based CGH studies have uncovered multiple chromosomal abnormalities 
and identified consistent findings of gain of chromosomes 1q, 3q, 8, 12, 19 and loss of 1p, 3p, 
9p, 9q, 11q, 13q, 14q and 16q (Lo and Huang, 2002, Tao and Chan, 2007). The highest 
frequencies of allelic loss are found on 3p (75%) and 9p (87%) (Lo and Huang, 2002), with 
most the commonly affected TSG regions at 3p21.3 (RASSF1A) and 9p21 (p16, p15, p14
ARF
) 
(Lo et al., 1995, Lo et al., 2001, Tao and Chan, 2007). High incidence of chromosome 3p and 
9p deletions are found in both low-grade and high-grade dysplastic lesions, and additionally 
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commonly observed in histologically normal nasopharyngeal epithelia from Southern 
Chinese, the high-risk population (Chan et al., 2000, Chan et al., 2002, Lo et al., 2004). In 
contrast, EBV is not detected in low-grade dysplastic lesions or normal nasopharyngeal 
epithelium, as determined by EBER1 ISH (Fan et al., 2006), suggesting the effect of these 
specific genetic changes precedes EBV infection during the initiation of NPC development.  
 
1.6.2 EBV-associated gastric carcinoma (EBV-aGC) 
The worldwide occurrence of EBV-associated gastric carcinoma (EBV-aGC) is estimated at 
more than 50,000 cases per year, with approximately 10% of all gastric cancers harbouring a 
latent EBV infection (Imai et al., 1994, Takada, 2000, Fukayama et al., 2008). While some 
cases have been found to bear resemblance to nasopharyngeal lymphoepithelioma (Shibata et 
al., 1991), EBV involvement has also been reported in a subset of typical gastric 
adenocarcinomas (Shibata and Weiss, 1992, Tokunaga et al., 1993).  
 
In the EBV-positive subgroup, all malignant cells carry copies of the EBV genome, as 
demonstrated by EBER ISH (Takada, 2000), and, as in NPC, terminal repeat analysis detects 
a single genotype, indicating tumours are of monoclonal origin (Shibata et al., 1991, Imai et 
al., 1994). Elevated IgG antibody titres against VCA and EA are also observed (Takada, 
2000), as is a similar gene expression pattern. However, while EBNA1, EBER1/2 and BART 
transcripts are routinely detected, LMP2A is only occasionally expressed, and in small 
amounts, whilst expression of LMP1 is absent (Takada, 2000, Fukayama, 2010). 
 
In contrast to NPC, EBV-aGC demonstrates a worldwide incidence, irrespective of ethnic or 
geographical influences (Fukayama et al., 2008, Boysen et al., 2009). However, a key 
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molecular abnormality is the observation of global and non-random CpG island methylation 
of the promoter region of many cancer-related genes. In particular, repression of gene 
expression as a result of promoter methylation has been observed for the p16
INK4A
, E-cadherin 
and p73 genes (Fukayama et al., 2008, Uozaki and Fukayama, 2008, Fukayama, 2010). 
 
1.7 TGFβ superfamily signalling 
As already stated (section 1.5.1.4), EBNA1 has been implicated in the deregulation of 
transforming growth factor (TGFβ) signalling. The TGFβ superfamily comprises over 40 
members of functionally related proteins with conserved structures, and includes the TGFβs, 
activins/inhibins, nodal, bone morphogenetic proteins (BMPs), myostatin, GDFs and anti-
Muellerian hormone (AMH) (ten Dijke and Hill, 2004, Massagué and Gomis, 2006). 
Extensive research has demonstrated pleiotropic functions both in vitro and in vivo 
(Miyazawa et al., 2002), particularly in early embryonic development, tissue homeostasis and 
specification of cell fate (Yue and Mulder, 2001, Herpin et al., 2004, Javelaud and Mauviel, 
2004). 
 
Its prototypical member, TGFβ was discovered through its ability to induce a transformed 
phenotype in rat kidney fibroblasts in cell culture (Roberts et al., 1980, Roberts et al., 1981, 
Roberts et al., 1983). It has since been exposed as a fundamental ubiquitous cellular signalling 
ligand and modulates a plethora of biological functions including cell proliferation, 
differentiation, migration, adhesion, apoptosis, extracellular matrix production, tissue repair, 
immune surveillance, epithelial-mesenchymal transition and early embryonic development 
(Yue and Mulder, 2001, Jakowlew, 2006, Massagué and Gomis, 2006, Javelaud and Mauviel, 
2004). It is perhaps best characterised for its potent growth inhibitory effects, which have 
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been demonstrated in a wide variety of cell types, including epithelial, endothelial, fibroblast, 
neuronal, lymphoid, osteoblast, and hematopoietic cells (Yue and Mulder, 2001). 
 
BMPs were originally identified by Marshall Urist in 1965, who demonstrated that 
demineralised bone extracts could induce de novo bone formation when implanted in ectopic 
sites in rats (Urist, 1965). BMPs were later isolated from bone extracts and further defined by 
virtue of their capabilities in inducing bone and cartilage formation in vivo (Wozney et al., 
1988). Indeed, BMPs are perhaps still best characterised for their roles as osteogenic proteins 
in the regulation of osteoblast differentiation and subsequent bone formation (ten Dijke et al., 
2003, Peng et al., 2003, Cao and Chen, 2005), but were later found to possess additional roles 
in diverse biological processes including cell differentiation, regulation of stem cell self-
renewal and fate determination, cell growth, migration, neurogenesis, morphogenesis, 
apoptosis and early embryonic development (Hogan, 1996, Yue and Mulder, 2001, Miyazawa 
et al., 2002, Zhang and Li, 2005, Sieber et al., 2009). 
 
Despite such a diverse array of physiological functions, the core pathway is, in itself 
comparatively simple, and is essentially conserved among TGFβ superfamily members 
(Figure 1.4). It is largely reliant upon a family of essential intracellular mediators called 
Smads, which constitute key points of integration for relaying ligand-induced signals from 
TGFβ family receptors at the cell surface directly into the nucleus (Attisano and Wrana, 
2002). Type II and type I receptors are encoded by five and seven genes in the human 
genome, respectively (Schmierer and Hill, 2007). 
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(FIGURE 1.4) 
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Signalling is initiated by the binding of ligand to constitutively active type II serine/threonine 
kinase receptor homodimers, inducing their association with type I receptor homodimers to 
form an active tetrameric complex, in which type I receptors are subsequently phosphorylated 
at a unique glycine-serine rich regulatory GS domain (Wrana et al., 1992, Wrana et al., 1994, 
Franzén et al., 1995, Yamashita et al., 1994). BMPs exhibit slightly different binding 
properties in that they appear to bind optimally to heteromeric type I/type II receptor 
complexes (Liu et al., 1995, Piek et al., 1999, Josso and di Clemente, 1997).  
 
Following phosphorylation, primed type I receptors then recruit Smad effector proteins. The 
discovery of Smads originates from genetic analyses of related signalling pathways in 
Drosophila melanogaster, Caenorhabditis elegans, and Xenopus (Sekelsky et al., 1995, 
Massagué and Hata, 1997, Savage et al., 1996, Graff et al., 1996), and a total of eight 
mammalian Smads have been identified (Zhang et al., 1996, Massagué et al., 2005). Receptor-
regulated (R-Smads) Smads 1, 2, 3, 5 and 8, are directly recruited and phosphorylated by type 
I receptors, specifically on two conserved serine residues within an SXSS motif in their C-
terminal domain (Macías-Silva et al., 1996, Kretzschmar et al., 1997), Smads 2 and 3 by 
activin/nodal and TGFβ type I receptors, and Smads 1, 5 and 8 by BMP type I receptors 
(Miyazawa et al., 2002, Massagué et al., 2005). This activation converts basally monomeric 
R-Smads into active heteromeric complexes, through increasing their affinity for the universal 
co-Smad, Smad4 (Kawabata et al., 1998, Qin et al., 2002). This partnering with Smad4 is 
essential for mediating the appropriate transcriptional responses (Lagna et al., 1996, 
Schmierer and Hill, 2007). The resulting active complexes accumulate in the nucleus where 
they interact with the appropriate DNA binding factors, as well as various transcriptional 
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coactivators or corepressors, to bind specific recognition sites on target gene promoters for 
effective positive or negative regulation of target gene transcription (Massagué, 2000). 
 
Smad6 and Smad7 comprise a third class of Smad molecules, the inhibitory Smads (I-Smads) 
which form autoinhibitory feedback loops (Park, 2005), and are largely antagonistic, 
competitively inhibiting R-Smad association with type I receptors (Hayashi et al., 1997, 
Imamura et al., 1997, Nakao et al., 1997), as well as interfering with Smad complex formation 
(Hata et al., 1998, Massagué et al., 2005). They lack the C-terminal SXSS motif so are not 
themselves targets for receptor phosphorylation, and do not bind DNA, and thus have no 
direct effect on transcriptional responses. 
 
R-Smad proteins share extensive sequence homology in conserved N-terminal and C-terminal 
regions, designated the Mad-homology domain 1 (MH1) and MH2 domains, respectively 
(Yue and Mulder, 2001). These form globular regions, flanking a divergent proline-rich linker 
segment containing multiple phosphorylation sites for several classes of protein kinases and a 
PY motif for recognition by ubiquitin ligases. Smads lack intrinsic catalytic activity and so 
exert their effects through protein-protein or protein-DNA interactions (Lutz and Knaus, 
2002). The MH1 domain primarily mediates DNA binding activity, while MH2 regulates 
Smad homo- and hetero-oligomerisation and Smad-receptor interactions, as well as 
interacting with important transcription factors (Shi et al., 1998, Yue and Mulder, 2001, 
Massagué et al., 2005). In the inactive conformation, the MH1 and MH2 domains physically 
associate, and MH1 imposes an autoinhibitory effect over MH2 to prevent its transcriptional 
activity (Yue and Mulder, 2001, Miyazawa et al., 2002). This effect ensures Smads remain 
transcriptionally inert until relieved by phosphorylation-induced structural changes. The 
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linker region is poorly conserved, but contains several important consensus MAPK 
phosphorylation sites that effectively modulate its function (Yue and Mulder, 2001). 
 
Smad-independent TGFβ signalling mechanisms have been additionally characterised, and 
often involve the integration of other signal transduction pathways, engaging a variety of 
protein kinases including ERK-MAPK, JNK and p38 MAPK, and also PI3K. Furthermore, 
PP2A phosphatases and Rho-like GTPases including RhoA, Rac and Cdc42 have also been 
identified as potential TGFβ targets. Such activity is reviewed in (Derynck and Zhang, 2003, 
Levy and Hill, 2005, Guo and Wang, 2009). Similar non-Smad pathways have also been 
described in BMP signalling (Miyazono et al., 2010) 
 
1.7.1 TGFβ superfamily signalling in cancer 
Dysregulation of TGFβ signalling has been reported as a common feature of cancer 
progression, and TGFβ is seen to exert both tumour suppressor and pro-oncogenic activities in 
accordance with tumour stage (Akhurst and Derynck, 2001, Heldin et al., 2009, Meulmeester 
and ten Dijke, 2011). Abrogation of the pathway is commonly accomplished by either 
selective blockade of TGFβ cytostatic responses and/or the acquisition of genetic alterations 
and epigenetic modifications in TGFβ pathway components (Levy and Hill, 2006, Seoane, 
2006), often inactivating tumour-suppressing TGFβ functions, whilst conferring oncogenic 
traits. In this characteristic switch, TGFβ can promote many cellular responses associated 
with the “defined” hallmarks of cancer, including resistance to TGFβ-mediated cytostasis, 
inducing cell cycle progression and cancer cell survival, inhibiting immune surveillance, 
inducing EMT, tumour angiogenesis, and tissue invasion and metastasis, and promoting 
cancer cell immortality (Tian et al., 2011). 
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BMP signalling in cancer has been much less extensively characterised; however, evidence 
suggests that BMPs have similar actions to TGFβ, in that BMPs can both act as tumour 
suppressors and function to promote tumourigenesis. This has been reviewed recently in 
(Alarmo and Kallioniemi, 2010, Singh and Morris, 2010). 
 
1.8 Aims and Objectives 
The aim of this thesis was to develop existing observations pertaining to the specific role of 
EBNA1 in the modulation of the TGFβ signalling pathway, with the intent to elucidate 
defined mechanisms through which its effects are achieved. Initial work focussed on the 
reported inhibition of TGFβ-induced transcription, and involved investigating the potential of 
EBNA1 to influence specific regulators of Smad function. This was extended to determine 
whether EBNA1 could encourage the characteristic switch in TGFβ action during 
carcinogenesis, as a means by which to directly promote the progression of EBV-associated 
epithelial malignancies. This was studied by monitoring characteristic pro-oncogenic features 
of TGFβ behaviour, including differential Smad phosphorylation, TGFβ secretion and cell 
migration, in EBNA1-expressing carcinoma cell lines. This study further aimed to explore the 
novel hypothesis that the closely-related BMP signalling pathway, as yet uncharacterised in 
EBV-associated malignancies, may be specifically modulated by EBV infection, and more 
specifically by the expression of EBNA1, and may function in parallel with the observed 
effects in the TGFβ signalling pathway to precipitate the tumourigenic phenotype. 
  
When studying the behaviour of EBV in an epithelial background, extensive investigation is 
largely challenged by difficulties in achieving stable infection. The development of a 
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lentiviral system for EBNA1 expression was designed to facilitate further research, providing 
a model system with enhanced efficiency of infection. The intention is that this may 
eventually be used to achieve infection of a wider variety of target cells, including primary 
epithelial cells, in the hope that the precise effects of EBNA1 in the pathogenesis of EBV-
associated carcinomas may be more conclusively determined. 
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CHAPTER 2 
 
Materials and Methods 
 
2.1 Tissue Culture 
2.1.1 Tissue culture media 
RPMI 1640 (1X) liquid supplemented with 2mM L-Glutamine and adjusted to pH7.0 was 
purchased in sterile 500ml bottles from Sigma and stored at 4°C. 
Dulbecco’s Modified Eagle’s Medium (DMEM) high glucose (1X) liquid supplemented with 
2mM L-Glutamine and adjusted to pH7.0 was purchased in sterile 500ml bottles from Sigma 
and stored at 4°C. 
Keratinocyte serum-free medium (SFM) (1X) liquid adjusted to pH7.0 was purchased in 
sterile 500ml bottles from Gibco
®
 (Invitrogen) and stored at 4°C. 
 
2.1.2 Other sterile solutions and supplements 
Foetal Calf Serum (FCS):  pre-screened for virus/mycoplasma contamination and purchased 
in sterile 500ml bottles from Gibco
®
 (Invitrogen). FCS was aliquoted into 50ml sterile tubes 
and stored at -20°C. 
Ciprofloxacin solution:  purchased from Bayer. Filter sterilisation was performed before use 
at 2.5ml/500ml media. 
Penicillin/Streptomycin:  solution (10,000 units/ml penicillin-G and 10mg/ml streptomycin) 
was purchased from Sigma-Aldrich and filter sterilised before use at 5ml/500ml media. 
Geneticin (G418):  purchased in powder form from Sigma-Aldrich. 5g was dissolved in 
100ml sterile distilled H2O before filter sterilisation and storage in 5ml aliquots at 4°C. 
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TrypLE
™
 Express Stable Trypsin Replacement:  supplied as 1X solution in a PBS-EDTA 
buffer in 100ml sterile bottles from Gibco
®
 (Invitrogen) and stored at 4°C. 
Phosphate-buffered saline (PBS):  purchased from Oxoid Ltd and supplied in tablet form, 
containing 8g/L NaCl, 0.2g/L KCl, 1.15g/L Na2HPO4, 0.2g/L KH2PO4. 10 tablets were 
dissolved in 1L of distilled H2O. 500ml aliquots were sterilised by autoclaving at 15psi, 
120°C for 20 minutes. 
Fibronectin:  Purchased from Sigma-Aldrich, fibronectin solution from human plasma (0.1%) 
was supplied at a concentration of 1mg/ml and stored at 4
o
C. 
 
2.1.3 Cell lines 
Ad/AH:  an immortalised human cell line derived from an adenocarcinoma of the 
nasopharynx. 
HONE-1:  a human EBV-negative tumour cell line established from an NPC biopsy that was 
originally EBV-positive but lost the viral genome during culture. 
AGS:  an immortalised tumourigenic human gastric-derived carcinoma cell line. 
Ad/AH-, HONE-1- and AGS-EBNA1 and –Neo control lines:  generated by transfection of an 
EBNA1 or neomycin control plasmid into the parental lines followed by drug selection and 
isolation of individual clones. 
Ad/AH, HONE-1 and AGS-rEBV lines:  stably infected with recombinant Akata strain of 
EBV, carrying a neomycin resistance cassette for drug selection. 
 All Ad/AH, HONE-1 and AGS lines were maintained in RPMI 1640 supplemented with 5% 
FCS and antibiotics. Ad/AH- and AGS-Neo, -EBNA1 and –rEBV lines were drug selected at 
400μg/ml G418, while HONE-1 derivatives were selected at 200μg/ml G418. 
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Mv1Lu:  a mink lung epithelial cell line. 
MLEC-clone32:  a mink lung epithelial cell line stably transfected with an 800bp fragment of 
the human plasminogen activator inhibitor (PAI-1) gene fused to the firefly luciferase reporter 
gene in a p19LUC-based vector containing the neomycin-resistance gene from pMAMneo. 
This cell line was a kind gift from the Rifkin Laboratory, Department of Cell Biology, New 
York University Medical Centre. 
Mink cell lines were maintained in DMEM supplemented with 10% FCS and antibiotics, and 
MLEC-clone32 cells were additionally drug selected with 200μg/ml G418. 
 
OKF6:  a human immortalised normal oral epithelial line, maintained in Keratinocyte SFM 
supplemented with 25mg bovine pituitary extract (BPE) and antibiotics. 
  
C666-1:  a subclone of the parental line, C666, derived from an NPC xenograft of Southern 
Chinese origin. 
X50-7: an LCL expressing the full array of EBV latent genes. 
SL: an LCL immortalised with the B95-8 strain of EBV, generated within the University of 
Birmingham. 
C666-1 cells and B-cell lines were maintained in RPMI 1640 supplemented with 10% FCS 
and antibiotics. 
 
2.1.4 Maintenance of cell lines 
All cell lines were maintained in 37°C incubators supplied with 5% CO2. 
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Adherent cells were grown in 75cm
2
 tissue culture flasks (Iwaki, Corning) until 90-95% 
confluent. Cells were washed with PBS and subsequently incubated with 3-4ml TrypLE
™
 
Express for 5-10 minutes at 37°C to allow cell dissociation. Cells were recovered in an excess 
of complete growth medium to neutralise the trypsin reaction, and pelleted by centrifugation 
at 1500rpm for 5 minutes. Cells were resuspended in 10ml complete medium. 2ml was taken 
into a fresh flask to achieve a 1 in 5 dilution and 18ml fresh growth medium added. The 
appropriate concentration of drug was then applied if necessary. All tissue culture vessels 
used for C666-1 cells required pre-coating with 10μg/ml fibronectin solution for at least 1 
hour at 37°C. 
 
Non-adherent cells were maintained in 75cm
2
 Iwaki tissue culture flasks in 10ml medium. 
Cells were passaged twice weekly by removal of 8ml cell suspension and replacement with 
complete growth medium (1 in 5 dilution). 
 
For experiments, cell suspensions of both adherent and non-adherent cells were taken to 
perform haemocytometer counts and the required volumes added to the appropriate tissue 
culture vessels. 
 
2.1.5 Cryopreservation 
Cell suspensions were pelleted as described in section 2.1.4. Pellets were resuspended in 1ml 
freezing medium containing 50% complete medium, 40% FCS and 10% DMSO (Fisher 
Scientific). 1ml cell suspensions were added to cryovials (Nunc) and transferred to a Mr 
Frosty (Nalgene), before storage at -80°C overnight to enable gradual freezing, and 
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subsequent transfer to the vapour phase of a liquid nitrogen freezer (-140°C) for long-term 
storage. 
 
Cryopreserved cells were recovered by rapid thawing in a 37°C water bath. Warmed growth 
medium was added drop-wise, followed by centrifugation at 1500rpm for 5 minutes. The 
supernatant was discarded and cells were resuspended in complete growth media and 
transferred to a tissue culture flask. 
 
2.2 DNA transfection of mammalian cells 
Transfection of plasmid DNA into eukaryotic cells was conducted using Lipofectamine
™
 
LTX reagent (Invitrogen). The efficiency of transfection was enhanced by the addition of 
Plus
™
 reagent (Invitrogen) which pre-complexes DNA prior to the addition of the 
lipofectamine reagent. Briefly, for 6-well plates, cells were seeded at a density of 2-5x10
5
 
cells/well and allowed to adhere until approximately 70% confluent. Typically, 1-1.5μg DNA 
was diluted in 500μl serum-free Opti-MEM® (Invitrogen), before addition of Plus™ reagent at 
a 1:1 ratio of DNA (μg) to Plus reagent (μl) and incubation at room temperature for 5 minutes 
to allow DNA complex formation. Lipofectamine
™
 LTX was then added at a 3:1 ratio of LTX 
(μl) to Plus reagent (μl), and was followed by a further incubation at room temperature for 30 
minutes, while 2ml OptiMEM
®
 was added to cells to be transfected. Following incubation, 
DNA:lipid complexes were applied to the cells in a random drop-wise manner and mixed by 
gently rocking plates back and forth to ensure even distribution of complexes before 
incubation at 37°C. The following day cells were re-fed with the appropriate complete growth 
medium and subsequently harvested at the desired time points. DNA plasmids used for 
transfection are provided in Table 2.2.1. 
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Table 2.2.1:  Plasmids used in DNA transfection 
Plasmid Control Source 
pcDNA3-WT-TβRI pcDNA3 Kindly provided by Dr. J. Wrana, Samuel Lunenfeld 
Research Institute, Toronto pcDNA3-TβRI (T204D) pcDNA3 
pSG5-EBNA1 pSG5 Kindly provided by Dr. J. Sample, St. Jude Children’s 
Research Hospital, Memphis 
pLXIN-TβRII pLXIN Kindly provided by Dr. W. Grady, Fred Hutchinson 
Cancer Research Center, Seattle pLXIN-TβRII D522N pLXIN 
pSRG-shPPM1A881 pSRG Kindly provided by Prof. X.-H. Feng, Baylor College of 
Medicine, Houston 
shPPM1B-1 pSUPER.retro.puro Synthesis described in section 2.12.2 
shPPM1B-2 pSUPER.retro.puro 
pc3oriP-EBNA1 mutant 
plasmids 
pc3oriP Kindly provided by Dr. L. Frappier, University of 
Toronto, Toronto 
pLenti6/R4R2/V5-DEST 
EBNA1 mutant plasmids 
pLenti6/R4R2/V5-
DEST 
Generation of wild-type and dominant-negative EBNA1 
constructs described in Chapter 5. Remaining mutants 
made by Miss S. Maia (University of Birmingham) 
 
 
2.3 Tissue culture treatment of cells 
2.3.1 Stimulation of cells with human recombinant cytokines 
Cells were seeded at appropriate densities according to the tissue culture vessel and left to 
adhere overnight. Cells were then grown in 0.5% serum for 16 hours prior to stimulation to 
remove any traces of cytokines and soluble growth factors from the growth medium. 
Recombinant human cytokines (see Table 2.3.1) were then added at the appropriate 
concentrations in medium containing 0.5% serum, and incubated for varying lengths of time 
depending on the nature of the experiment, or left unstimulated as a control. 
 
Table 2.3.1:  Recombinant human cytokines 
 
Cytokine Concentration Supplier 
BMP2 50ng/ml PeproTech 
TGFβ1 5ng/ml PeproTech 
 
 
2.3.2 Treatment of cells with specific pharmacological inhibitors 
Cells were seeded at appropriate densities according to the tissue culture vessel and left to 
adhere overnight. Cells were then grown in 0.5% serum for 16 hours prior to addition of 
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inhibitors. Pharmacological inhibitors, or the carrier solvent DMSO as a control (see Table 
2.3.2), were then added at the indicated concentrations in medium containing 0.5% serum, 
and incubated for varying lengths of time depending on the nature of the experiment. 
 
Table 2.3.2:  Pharmacological inhibitors 
 
Inhibitor Concentration Pathway targeted Supplier 
Cycloheximide 20μg/ml Protein synthesis Sigma 
DMSO - Inert carrier solvent Fisher 
Flavopiridol 0.3μM CDK Sigma 
Noggin 100ng/ml BMP PeproTech 
SB203580 10μM p38 MAPK Tocris Bioscience 
SB216753 10μM GSK3 Tocris Bioscience 
SB431542 10μM TGFβ Tocris Bioscience 
SP600125 10μM JNK Sigma 
UO126 10μM MEK-ERK MAPK Promega 
 
 
2.4 Luciferase Reporter Assay 
Reporter assays were conducted using the Dual-Luciferase Reporter Assay System 
(Promega), in which the luciferase activities of both firefly (Photinus pyralis) and Renilla 
(Renilla reniformis) can be sequentially measured from the same sample. While firefly 
luciferase is used to measure the activity of the experimental promoter of interest, Renilla 
activity provides an internal control for cell viability and transfection efficiency. 
 
Cells were transfected according to the protocol described in section 2.2. Cells were co-
transfected with a luciferase reporter plasmid (either empty control vector or test promoter 
under study) and Renilla plasmid, p-RL-TK, as well as additional effector DNA plasmids if 
required. For transfections in 6-well plates, 0.5μg test promoter and Renilla plasmids were 
normally used. Typically, cells were harvested 48 hours post-transfection by lysis in 500μl 1X 
Passive Lysis Buffer (Promega), then subjected to one cycle of freeze-thaw and repetitive 
pipetting to achieve complete lysis and homogenisation of samples. 20μl sample was added in 
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triplicate into a 96-well plate. To determine luciferase activity, 50μl LARII (Promega) was 
added to each sample, and firefly luciferase activity immediately quantified using a Victor 
plate reader (Wallac). Subsequent addition of 50μl Stop & Glo reagent to each sample 
simultaneously quenched firefly luciferase activity and initiated Renilla luciferase activity, 
which was immediately determined using the Victor plate reader. 
 
Relative luciferase activity was determined by normalising the firefly luciferase activity 
against Renilla activity, and made relative to the appropriate firefly control plasmid to account 
for background activity. A list of reporter plasmids and their appropriate control plasmids are 
listed in Table 2.4.1. 
 
Table 2.4.1:  Plasmids used in luciferase assays 
 
Reporter 
plasmid 
Control 
plasmid 
Source 
p-RL-TK N/A Promega 
p3TP-lux pGL3-basic Kindly provided by Dr. J. Massagué, Memorial Sloan-Kettering Cancer 
Centre, New York 
p(ARE)3-luc pGL3-basic Kindly provided by Dr. C. Hill, Cancer Research UK London Research 
Institute, London 
Xfast1 in EF-
Flag 
N/A Kindly provided by Dr. C. Hill, Cancer Research UK London Research 
Institute, London 
pBRE-luc pGL3-basic Kindly provided by Dr. P. ten Dijke, Leiden University Medical Centre, 
Leiden 
p(CAGA)12-luc pGL3-basic Kindly provided by Dr. C. Hill, Cancer Research UK London Research 
Institute, London  
pQp-luc pGL2-basic Kindly provided by the Rickinson group, University of Birmingham, 
Birmingham 
 
 
2.5 Immunofluorescence (IF) staining 
Cells were trypsinised and seeded at a density of 2x10
4
 onto sterile Teflon coated slides 
(Henley) in a sterile petri dish with 1ml PBS to prevent dessication. Slides were incubated for 
24 hours at 37
o
C before fixation for 10 minutes in either 4% PFA at room temperature 
followed by permeabilisation in 0.5% Triton X-100 for 5 minutes, or in ice-cold 
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methanol:acetone (1:1) at -20°C. Cells were then incubated with 50 l 20% heat-inactivated 
goat serum (HINGS) for 1 hour in a wet box at room temperature to minimise non-specific 
binding. Primary antibodies (see Table 2.5.1) diluted in 20% HINGS were applied to cells and 
incubated for 1 hour at room temperature. Following three washes in PBS, cells were 
incubated for 1 hour at room temperature in the dark with the appropriate Alexa Fluor
®
 
secondary antibody (see Table 2.5.2) also diluted in 20% HINGS. To control for background 
staining, cells were stained with secondary antibody alone. Slides were then washed three 
times for 5 minutes in PBS before mounting in DABCO anti-fading agent (90ml glycerol, 
10ml PBS, 2.5g DABCO powder) and coverslips for viewing by fluorescence microscopy. 
Additional confocal microscopy was performed by Miss Rebecca Port (University of 
Birmingham). 
 
Table 2.5.1:  Primary antibodies used in IF staining 
 
Antibody Species Dilution Supplier 
Cav-1 Rabbit 1:400 Cell Signalling Technology (#3267) 
EBNA1 (R4) Rabbit 1:1000 A kind gift from Dr. Lori Frappier 
NEDD4-2 Rabbit 1:50 Cell Signalling Technology (#4013) 
PPM1A Rabbit 1:400 Cell Signalling Technology (#3549) 
Smad2 Mouse 1:50 Santa Cruz (sc-101153) 
Smad3 Mouse 1:50 Santa Cruz (sc-101154) 
 
Table 2.5.2:  Secondary antibodies used in IF staining 
 
Antibody Dilution Supplier 
Alexa Fluor
®
 488 goat anti-mouse
 
1:1000 Molecular Probes 
Alexa Fluor
®
 594 goat anti-rabbit 1:1000 Molecular Probes 
 
 
 
2.6 Immunoblotting 
2.6.1 Preparation of protein extracts 
On attainment of 80-90% confluency, cells were washed with cold PBS and lysed on ice in 
RIPA buffer (50mM Tris pH8.0, 150mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% 
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SDS), to which complete protease inhibitor cocktail (Roche), and also PhosSTOP 
phosphatase inhibitor cocktail (Roche) if analysing phosphorylated proteins, were added 
immediately prior to use. Lysates were scraped into pre-chilled eppendorfs and sonicated to 
ensure full cell lysis. Samples were then centrifuged at 13,000rpm for 5 minutes at 4
o
C to 
pellet any cellular debris and supernatants were transferred to fresh chilled eppendorfs. 
Sample protein concentrations were determined using a Bio-Rad Protein Assay kit (500-
0112). Briefly, 5μl bovine serum albumin (BSA) protein standards in sterile distilled water 
(SDW) (0, 0.1, 0.2, 0.5, 1 and 2μg/μl) and 5μl samples diluted 1 in 4 in SDW were aliquoted 
in triplicate into a 96-well plate. 25μl reagent A, followed by 200μl reagent B were added to 
each well and the plate was incubated on a shaker for 5 minutes at room temperature. 
Absorbance values were read on a Bio-Rad Model 680 Microplate Reader at 595nm, and 
protein concentrations determined from a standard curve constructed using the BSA 
standards. 10-50μg protein lysate was used for immunblotting, dependent on the abundance of 
the protein of interest, and the quality of the specific primary antibody. Samples were diluted 
in 4X Laemmli loading buffer (250mM Tris-HCl pH 6.8, 8% w/v SDS, 40% glycerol, 0.05% 
w/v bromophenol blue, 10% β-mercaptoethanol), denatured at 95oC for 5 minutes and 
returned to ice, prior to loading on to SDS-polyacrylamide gels. 
 
2.6.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed using the Mini-PROTEAN 3 Electrophoresis Kit (Bio-Rad).  
Percentage composition of polyacrylamide gels was adjusted in accordance with the 
molecular weight of the protein of interest so as to achieve optimum fractionation. Typically, 
polyacrylamide gels were prepared from the appropriate percentage of UltraPure ProtoGel 
acrylamide stock solution (30% w/v acrylamide and 0.8% v/v bis-acrylamide) (Geneflow), 
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25% v/v resolving buffer (1.5M Tris-HCl pH 8.8, 0.4% w/v SDS, 0.24% w/v TEMED) and 
SDW to the required volume. Polymerisation was initiated by the addition of 20% ammonium 
persulphate (APS) to a final concentration of 0.1%. Once the resolving gel was set, it was 
overlaid with a stacking gel consisting of 4% acrylamide, 50% v/v stacking buffer (0.75M 
Tris pH6.8, 0.2% w/v SDS, 0.12% v/v TEMED) and SDW to the required volume. 20% APS 
was added to a final concentration of 0.15% to catalyse polymerisation. Gel combs were 
inserted for the duration of the polymerisation. Gel combs were then removed, and gels were 
placed in an electrophoresis tank and submerged in running buffer (30g Tris, 144g glycine 
and 10g SDS in 10L distilled H2O). Equal concentrations of protein samples were loaded 
alongside Spectra
™
 Multicolour Broad Range Protein Ladder, and electrophoresis was 
performed at 125V for 90-120 minutes.     
 
2.6.3 Immunoblotting 
Proteins separated by SDS-PAGE were transferred to a nitrocellulose membrane (Pall Life 
Sciences) using the Mini Trans-blot wet transfer system (Bio-Rad). The gel and membrane 
were sandwiched between two layers of 3MM filter paper (Whatman, UK) and sponges pre-
soaked in transfer buffer (30g Tris, 144g glycine, 2L methanol and 8L distilled H2O) and 
pressed to remove any air bubbles. Gel transfer was performed in transfer buffer on ice at 90V 
for 90 minutes. Following transfer, membranes were then incubated for 1 hour with gentle 
agitation in either 5% powdered non-fat milk in Tris-buffered saline (TBS)-Tween (20mM 
Tris, 150mM NaCl, 0.1% Tween-20)  (for total protein-specific antibodies), or 5% BSA in 
TBS-Tween (for phospho-specific antibodies), to prevent non-specific binding. Membranes 
were then transferred into the relevant blocking buffer containing the appropriate antibody at 
the required concentration (see Table 2.6.1) and incubated with agitation overnight at 4
o
C. 
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The following day, membranes were subjected to 3 x 5 minute washes in 1x TBS-Tween prior 
to incubation with the relevant horseradish peroxidase (HRP)-conjugated secondary antibody 
(see Table 2.6.2) in 5% milk blocking buffer for 1 hour at room temperature. Membranes 
were washed as earlier, then incubated with EZ-ECL reagents (Geneflow) (1:1 ratio of 
reagents A and B) for one minute to enable detection of protein-antibody complexes. 
Membranes were wrapped in saran wrap, and exposed to X-ray film (Thermo Scientific) for 
an appropriate period of time, which was subsequently developed in an automated film 
processor (X-Ograph Ltd).      
 
For re-probing, immunoblots were incubated in stripping buffer (62.5mM Tris-Hcl pH6.8, 
100mM β-mercaptoethanol, 2% (w/v) SDS) pre-heated to 55°C, for 30 minutes in a sealed 
container. The membrane was then washed five times in TBS-Tween, then blocked and 
probed as above. 
 
Table 2.6.1:  Primary antibodies used in immunoblotting 
 
Antibody Species Dilution Product 
size (kDa) 
Supplier 
β-actin Mouse 1:10000 42 Abcam (ab8226) 
βig-h3 Rabbit 1:500 68 Santa Cruz (sc-28660) 
BMP2 Rabbit 1:1000 45 Abcam (ab14933) 
EBNA1 (K67) Rabbit 1:1000 ~70 Kind gift from Jaap Middeldorp (Dept. 
Pathology, VU University Medical 
Centre, Amsterdam) 
p44/42 MAPK (ERK1/2) Rabbit 1:1000 42, 44 Cell Signalling (#9102) 
p44/42 MAPK (ERK1/2) 
Thr202/Tyr204 
Rabbit 1:1000 42, 44 Cell Signalling (#9101) 
GSK3β Rabbit 1:1000 46 Cell Signalling Technology (#9315) 
pGSK3α/β Ser21/9 Rabbit 1:1000 46, 51 Cell Signalling Technology (#9331) 
Id1 Rabbit 1:500 15 Santa Cruz (sc-488) 
JNK Rabbit 1:1000 46, 54 Cell Signalling Technology (#9258) 
pJNK Thr183/Tyr185 Rabbit 1:1000 46, 54 Cell Signalling Technology (#9251) 
NEDD4-2 Rabbit 1:1000 110, 135 Cell Signalling Technology (#4013) 
p21 Rabbit 1:500 21 Santa Cruz (sc-397) 
p38 MAPK Rabbit 1:1000 43 Cell Signalling Technology (#9212) 
p-p38 MAPK Thr180/Tyr182 Rabbit 1:1000 43 Cell Signalling Technology (#9215) 
PAI-1 Mouse 1:500 47 BD Transduction (612024) 
PPM1A Rabbit 1:2000 43 Cell Signalling Technology (#3549) 
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PPM1B Rabbit 1:2000 53 Abcam (ab70804) 
pSmad1 (Ser463/465)/Smad5 
(Ser463/465)/Smad8 (Ser426/428) 
Rabbit 1:1000 60 Cell Signalling Technology (#9511) 
Smad2 Rabbit 1:1000 60 Cell Signalling Technology (#3122) 
pSmad2 Thr220 Rabbit 1:500 55-60 Santa Cruz (sc-135644 
pSmad2 Ser245/250/255 Rabbit 1:1000 60 Cell Signalling Technology (#3104) 
pSmad2 Ser 465/467 Rabbit 1:1000 60 Cell Signalling Technology (#3101) 
Smad3 Rabbit 1:1000 52 Cell Signalling Technology (#9523) 
pSmad3 Thr179 Rabbit 1:1000 48 Abcam (ab74062) 
pSmad3 Ser204 Rabbit 1:1000 48 Abcam (ab63402) 
pSmad3 Ser208 Rabbit 1:500 54 Santa Cruz (sc-130218) 
pSmad3 Ser213 Rabbit 1:1000 48 Abcam (ab63403) 
pSmad3 Ser423/425 Rabbit 1:1000 52 Cell Signalling Technology (#9520) 
Smad6 Rabbit 1:1000 62 Zymed (51-0900) 
Smad7 Mouse 1:1000 46 Abcam (ab55493) 
TβRI Rabbit 1:500 53 Santa Cruz (sc-398) 
TβRII Rabbit 1:500 70 Santa Cruz (sc-220) 
 
Table 2.6.2:  Secondary antibodies used in immunoblotting 
 
Antibody Dilution Supplier 
Goat anti-mouse HRP 1:1000 Dako 
Goat anti-rabbit HRP 1:1000 Dako 
 
 
2.7 Electrophoretic mobility shift assay (EMSA) 
2.7.1 Nuclear and cytosolic protein extracts 
Cells were seeded into 10cm dishes and left to adhere overnight. The following day, cells 
were incubated in 0.5% serum for 16 hours, before being stimulated, or left untreated in 0.5% 
serum for 1 hour. Nuclear and cytosolic protein extractions were performed using the NE-
PER
™
 Nuclear and Cytoplasmic Extraction kit (Pierce) following the manufacturer’s 
instructions. Briefly, cells were harvested by addition of 100μl CERI reagent and scraping 
into pre-chilled eppendorfs. 5.5μl CERII reagent was added before vortexing on the highest 
setting for 5 seconds, returning to ice for 1 minute and vortexing again for a further 5 seconds. 
The nuclear fraction was pelleted by centrifugation at 16,000g for 5 minutes, and the 
supernatant (cytoplasmic fraction) was transferred to a fresh pre-chilled eppendorf and stored 
at -80°C. The nuclei-containing pellet was resuspended in 50μl NER reagent and incubated on 
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ice for a total of 40 minutes, with vortexing for 15 seconds every 10 minutes. Nuclear 
membrane fragments were pelleted by subsequent centrifugation at 16,000g for 10 minutes, 
and the nuclear protein fraction was transferred to a fresh pre-chilled eppendorf and stored at -
80°C until use. Protein concentrations were determined as described previously (Section 
2.6.1). 
  
2.7.2 Preparation of native polyacrylamide gels 
Native polyacrylamide gels were prepared using 13.3ml 30% w/v acrylamide (Bio-Rad), 44ml 
1X TBE (10.8g Tris, 4.5g boric acid, 0.74g EDTA in 1L SDW), 22.7ml SDW and 45μl 
TEMED. 450μl 20% APS was added to induce polymerisation and the gel mixture was added 
to novex cassettes (Invitrogen) followed by careful insertion of a gel comb to avoid air 
bubbles. Once cast, gels were wrapped in moist paper towels and saran wrap, and stored at 
4°C until use. 
 
2.7.3 Preparation of EMSA probes 
Synthetic oligonucleotides 5´-end-labelled with IRDye
®
 700 infrared dye (MWG-Biotech) 
were diluted to 100pmol using PCR grade H2O. 5μl sense and antisense oligonucleotides were 
mixed with 90μl restriction buffer B (Roche). Probes were annealed by incubating at 95°C in 
a heat block for 10 minutes, before the heat block was turned off and probes were left to cool 
to room temperature overnight. The following day, annealed probes were wrapped in foil and 
stored at -20°C. Unlabelled “cold competitor” oligonucleotides were used as a control 
reaction. These were diluted to 1000pmol and annealed as above. Oligonucleotide sequences 
are provided in Table 2.7.1. 
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Table 2.7.1:  EMSA oligonucleotide sequences 
 
Probe Oligonucleotide sequence 
SBE sense TCGACAGGGTGTCTAGACGGCCACG 
SBE antisense CGTGGCCGTCTAGACACCCTGTCGA 
 
 
2.7.4 EMSA binding reactions and visualisation 
Optimal binding reaction conditions were first established, then binding reaction mastermixes 
were prepared as detailed in Table 2.7.2. 
 
Table 2.7.2:  EMSA binding reaction mastermix 
 
Reagent Volume (μl) 
10X Binding Buffer (100mM Tris, 500mM KCl, 10mM DTT; pH 7.5) 2 
25mM DTT/2.5% Tween-20 2 
1μg/μl Poly (dI·dC) 1 
1M KCl 1 
IRDye
®
 end labelled SBE oligo (50nM) 1 
Protein extract (5μg/μl) 1 
PCR grade H2O 12 
 
 
Samples were gently mixed and incubated for 20 minutes in the dark to allow formation of 
protein-DNA complexes, before addition of 2μl DNA loading buffer (0.025g bromophenol 
blue, 0.025g Xylene Cyanol FF and 6ml glycerol made up to 20ml with H2O). Binding 
reactions were loaded onto pre-cast native polyacrylamide gels, which had been pre-
electrophoresed in 0.5X TBE for 30 minutes at 70V to remove gel contaminants. 
Electrophoresis was then performed in the dark at 70V for 1-2 hours depending on dye front 
progression. Cold competitor reactions were assembled, containing 10μl annealed “cold” 
probe to give a 100-fold excess, with 5μg nuclear extract, adjusted to 19μl with PCR grade 
H2O. Reactions were allowed to proceed for 1 hour, before addition of 1μl labelled probe and 
incubation for 20 minutess as above. Protein-DNA complexes were detected and 
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densitometric analysis performed using the Odyssey
®
 Infrared Imaging System (LI-COR 
Biosciences). 
  
2.8 Flow cytometry analysis 
2.8.1 Flow cytometric analysis for cell surface expression 
Cells were grown to 70-80% confluence in 10cm dishes and washed twice in EDTA before 
incubation at 37°C in fresh EDTA solution until cells had detached. Dissociation was 
conducted in the absence of trypsin in order to prevent cleavage of cell surface receptors. Cell 
suspensions were pelleted, counted and 5x10
5
 cells/well were seeded into a pre-chilled 96 V-
well plate. Cells were then pelleted by centrifugation at 2,000rpm for 2 minutes at 4°C and 
supernatants discarded. Cells were then washed three times with 50μl ice-cold 1%FCS/PBS 
solution and re-pelleted by centrifugation as above. 50μl 1%FCS/PBS containing the 
appropriate dilution of primary antibody (see Table 2.8.1) was used to resuspend cells in each 
well, and incubated on ice for 1 hour on ice. The cells were then pelleted by centrifugation 
and washed three times in 50μl 1%FCS/PBS as described previously. 50μl of the relevant 
secondary antibody (see Table 2.8.2) at the appropriate dilution was added to each well and 
incubated for 1 hour on ice in the dark. Following incubation, cells were pelleted as above and 
resuspended in 150μl, which was then added to 500μl 1% PFA in a FACs tube, wrapped in 
foil and stored at 4°C until ready for analysis. Samples were run on a XL-MCL Beckman-
Coulter FACs analyser, and subsequent data analysis performed using the WinMDI program. 
 
Table 2.8.1:  Primary antibodies used in flow cytometry 
 
Antibody Species Dilution Supplier 
TβRI Rabbit 1:50 Abcam (ab31013) 
TβRII Goat 1:10 R&D Systems (AF-241-NA) 
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Table 2.8.2:  Secondary antibodies used in flow cytometry 
 
Antibody Dilution Supplier 
Alexa Fluor
®
 488 donkey anti-goat 1:1000 Molecular Probes 
Alexa Fluor
®
 488 goat anti-rabbit 1:1000 Molecular Probes 
 
 
2.8.2 Propidium iodide (PI) staining for cell cycle analysis 
Cells were seeded into 10cm dishes and grown to approximately 60-70% confluence. 
Following trypsinisation and centrifugation to pellet cells, cells were resuspended in 
1%FCS/PBS, counted, and adjusted to 1x10
6
 cells/ml 1%FCS/PBS. To fix the cells, 1ml ice-
cold 95% ethanol was added drop-wise to 1ml cells with gentle vortexing, before an overnight 
incubation at 4°C. The following day, cells were pelleted by centrifugation, and the 
supernatants were carefully aspirated. Cells were washed in 1ml 1%FCS/PBS and 
resuspended in 500μl propidium iodide (PI) working solution. 10ml 50μg/ml PI working 
solution is composed of 1ml PI stock solution (0.5mg/ml in 0.038M sodium citrate, pH7.0), 
100μl 1M Tris (pH7.5), 50μl 1M MgCl2, 20μl RNase A and 8.9ml DEPC-treated H2O, 
covered in foil and stored at 4°C. Following incubation in the dark for 30 minutes at 37°C, 
samples were immediately subjected to cell cycle analysis on a XL-MCL flow cytometer 
(Beckman-Coulter) and data analysed using the MultiCycle AV DNA analysis software 
(Phoenix Flow Systems). 
 
2.9 PAI-1L (PAI-1/luciferase) assay 
The PAI-1L (PAI-1/luciferase) assay for TGFβ was carried out according to a protocol 
provided by the Rifkin Laboratory, Department of Cell Biology, New York University 
Medical Centre. Prior to the assay, serum-free media, conditioned over 24-, 48- and 72-hour 
incubation periods, were collected from cells grown in 6cm dishes, and stored at -80°C until 
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use. For the assay, subconfluent MLEC-clone32 cells were trypsinised, pelleted and counted, 
and resuspended in complete growth media at 1.6x10
5
 cells/ml. Cells were seeded at 
100μl/well into a 96-well plate and incubated at 37°C for 3 hours to allow attachment. 
Following incubation, medium was aspirated from the attached cells, and 100μl test samples 
added directly to cells, alongside dilutions of recombinant hTGFβ1 ranging from 1.5625 
pg/ml to 500 pg/ml in DMEM (100μl/well). In order to assess total TGFβ, conditioned media 
test samples were heat-activated at 80°C for 5 minutes, and diluted to 25% before application 
to MLEC-clone32 cells. Samples were also incubated for 1 hour at room temperature with 
10μg/ml mouse monoclonal TGFβ1/2/3 neutralising antibody, clone #1D11 (R&D Systems) 
prior to addition in order to confirm the specificity of the assay. Samples were then incubated 
for 16 hours at 37°C, before aspiration of culture media, and three washes in ice-cold PBS. 
Cells were then lysed in 1X Passive Lysis Buffer (Promega) and stored at -20°C, before 
analysis for luciferase activity. 
 
2.10 Transwell migration assay 
Subconfluent cultures of cells were incubated in 0.5% serum for 16 hours and recovered as 
single-cell suspensions in EDTA. Cells were then seeded in 0.5% serum growth media, 
containing the appropriate recombinant cytokine stimuli or small molecule inhibitors if 
required, at 5x10
4
 cells per well into the upper chamber of 24-well transwell inserts (8μm 
pore size; Corning), pre-coated with fibronectin (10μg/ml in PBS overnight at 4°C). 
Migration was measured over 16 hours by contacting the chambers with medium containing 
0.5% serum at 37°C. This serum concentration was increased to 10% as a necessary 
chemoattractant for promoting migration of C666-1 cells. Following incubation, transwells 
were fixed in 30% ice-cold methanol for 5 minutes and air-dried prior to staining with 1% 
 62 
crystal violet. Transwells were inverted and air-dried, and any non-migrating cells were 
removed using cotton swabs. Representative fields were photographed using an Axiovert 
40CFL inverted microscope (Zeiss). 
 
2.11 Molecular Biology Techniques 
2.11.1 RNA extraction 
RNA extractions were carried out using the EZ-RNA total RNA isolation kit (Geneflow) in 
accordance with the manufacturer’s instructions, with reagent volumes adjusted appropriately 
according to the volume of the tissue culture vessel. Cells were grown to 70-90% confluence, 
before harvesting through lysis in denaturing solution (0.5ml/10cm
2
 culture dish area), 
followed by cell scraping into 1.5ml eppendorfs. Homogenates were incubated for 5 minutes 
at room temperature to ensure cell lysis. Subsequently, an equal volume of extraction solution 
was added, and samples were mixed by vigorous shaking for 15 seconds, followed by a 10-
minute incubation at room temperature. Samples were then centrifuged at 12,000g for 15 
minutes at 4°C to separate the aqueous phase from the organic phase and interphase. The 
upper aqueous phase was transferred to a clean eppendorf and RNA precipitated by addition 
of 0.5ml isopropanol per 0.5ml denaturing solution and overnight incubation at -20°C. 
 
Precipitated RNA was then pelleted by centrifugation at 12,000g for 8 minutes at 4°C, and the 
pellet washed in 75% ethanol. RNA was re-pelleted by centrifugation at 7,500g for 5 minutes 
at 4°C before careful aspiration of the ethanol. The pellet was air-dried before resuspension in 
PCR grade H2O. RNA concentration was determined using a NanoDrop spectrophotometer 
(Thermo Scientific) and samples diluted to the appropriate working concentration and stored 
at -80°C. 
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 2.11.2 cDNA synthesis 
cDNA synthesis was performed using Superscript
®
 III reverse transcriptase (Invitrogen). 1μg 
RNA, 1μl random primers (0.4μg/μl) (Promega) and 1μl dNTP mix (10mM) (Invitrogen) 
were adjusted to a total volume of 13μl with PCR grade H2O, and heated at 65°C for 5 
minutes to denature any dsRNA, then cooled on ice. 4μl 5X First-Strand buffer, 1μl DTT 
(0.1M), 1μl RNaseOUT™ Ribonuclease Inhibitor (40U/μl) (Invitrogen) and 1μl Superscript III 
(200U/μl) were added to each and mixed by pipetting. cDNA synthesis was performed in a 
thermal cycler under the following conditions: 25°C for 5 minutes, 50°C for 1 hour, 70°C for 
15 minutes, with a final hold at 4°C. The cDNA was then diluted in 80μl PCR grade H2O and 
stored at -20°C. 
 
2.11.3 Reverse-transcriptase polymerase chain reaction (RT-PCR) 
For RT-PCR, reaction components were assembled as outlined in Table 2.11.1, and typical 
PCR thermal cycler conditions are given in Table 2.11.2. 
 
Table 2.11.1:  Mastermix for RT-PCR 
 
Reagent Volume (μl) 
DreamTaq
™
 Green PCR Master Mix (2x) (Fermentas) 25 
5´ Forward primer (100pmol) 1 
3´ Reverse primer (100pmol) 1 
DEPC-treated H2O 18 
cDNA 5 
 
Table 2.11.2:  RT-PCR thermal cycler conditions 
 
Temperature Time (minutes) Number of cycles 
94°C 5 1 
94°C 0.5  
25-35 x°C 0.5 
72°C 2 
72°C 5 1 
4°C HOLD  
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Oligonucleotide primers for RT-PCR were synthesised by Sigma-Aldrich. Primer sequences, 
specific annealing temperatures and predicted product size are shown in Table 2.11.3. 
  
Table 2.11.3:  RT-PCR primer sequences and annealing temperatures 
 
Gene Sequence Annealing 
temperature (°C) 
Product size (bp) 
ActRI Forward:  GCTGCCCACTAAAGGAAAAT 
Reverse:  GCGAGCCACTGTTCTTTGTA 
56 300 
ActRIIB Forward:  TCCCTCACGGATTACCTCA 
Reverse:  CCTCCTCAAAAGGCAGCA 
56 440 
Βig-h3 Forward:  GGAAGGAGTCTACACAGTCTTT 
Reverse:  CCTCTGGGAAGCCCTGGAAAA 
51 399 
BMP2 Forward:  CCTGAAACAGAGACCCACC 
Reverse:  GCATTCTGATTCACCAACCT 
56 417 
BMP4 Forward:  GCCAGCATGTCAGGATTA 
Reverse:  GGGCACACAACAGGCTTT 
55 380 
BMP6 Forward:  CGACAAGCAGCCCTTCAT 
Reverse:  GCACGGTTTGGGGACATA 
59 373 
BMP7 Forward:  GGTCCACTTCCGCAGCAT 
Reverse:  GGCACACTCCCCCTCACA 
61 238 
BMPRIA Forward:  GTGGGTCTGGACTACCTT 
Reverse:  GGGCACATCAACTTCATT 
52 539 
BMPRIB Forward:  CCACCCTAGACGCTAAAT 
Reverse:  GCTCTCGTCCAACACTTCT 
52 278 
BMPRII Forward:  CCTGATGTTCTGCCTACT 
Reverse:  GCTCTTCTGGGCTTTGAT 
52 602 
Cav-1 Forward:  GGAACAGGGCAACATCTACAA 
Reverse:  CACGGCTGATGCACTGAAT 
55 383 
Dab2 Forward:  GGTCAACAACAAGCCCTT 
Reverse:  CTGGCAAAGGCACTCAAA 
55 301 
EBNA1 Forward:  GGGTGGTTTGGAAAGCAT 
Reverse:  TGGAAACCAGGGAGGCAAAT 
58 447 
GAPDH Forward:  GCCTCCTGCACCACCAACTG 
Reverse:  CGACGCCTGCTTCACCACCTTCT 
52 351 
Id1 Forward:  CCTCAACGGCGAGATCAG 
Reverse:  GAGACCCACAGAGCACGTAA 
58 148 
Id2 Forward:  CGTGAGGTCCGTTAGGAAAA 
Reverse:  GGTGATGCAGGCTGACAATA 
51 504 
Id3 Forward:  GCTTGCTGGACGACATGAA 
Reverse:  CGTTGGAGATGACAAGTT 
55 222 
NEDD4-2 Forward:  CCGGTTACTGCAGTTTGT 
Reverse:  CCACCCCTTCAAATCCTT 
55 236 
PAI-1 Forward:  GTGGTCTGTGTCACCGTATC 
Reverse:  GTAGTTGAATCCGAGCTGCC 
55 440 
PPM1A Forward:  CTGGGATGTTATGGGAAAT 
Reverse:  CGGCTTCAATAACATTCCTCTT 
55 359 
PPM1B Forward:  GGCAGCGTGATGATACAA 
Reverse:  CCCGTGATTCCAAGTGCTTAT 
55 406 
SARA Forward:  GGCTATCAGTATTCACAA 
Reverse:  CCTCTGTCCATCTGATTA 
50 403 
Smad1 Forward:  CTCTCCCACCAGCTCAGA 
Reverse:  CACTAAGGCATTCGGCAT 
57 452 
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Smad5 Forward:  CGCCTCCTCCTGCCTATA 
Reverse:  GCTGCTGGGAATCTTACA 
54 470 
Smad7 Forward:  CAGATTCCCAACTTCTTCTG 
Reverse:  GTTGAAGATGACCTCCAGCC 
53 533 
Smad8 Forward:  CGCCTACTATGAACTGAA 
Reverse:  GGAAGCCGTGTTGATAGT 
52 278 
Smurf2 Forward:  GGCTCTGCAGAAAGGATT 
Reverse:  GGGCTTTCGGCAGGTTGT 
53 344 
TβRI Forward:  ATGGGCTTAGTATTCTGGGAAA 
Reverse:  GGCATACCAACATTCTCTCATA 
57 221 
TβRII Forward:  GCAGTGGGAGAAGTAAAAGAT 
Reverse:  GGGAGCCGTCTTCAGGAAT 
56 301 
TGFβ1 Forward:  GTTGAGCCGTGGAGGGGAAA 
Reverse:  CTGCGTGTCCAGGCTCCAAAT 
58 386 
TGFβ2 Forward:  AAATGGATACACGAACCCAA 
Reverse:  GCTGCATTTGCAAGACTTTAC 
55 250 
TGFβ3 Forward:  AAGTGGGTCCATGAACCTAA 
Reverse:  GCTACATTTACAAGACTTCAC 
55 250 
 
 
2.11.4 Agarose gel electrophoresis 
PCR products were fractionated on 1% agarose gels. Agarose powder was weighed and 
dissolved in the appropriate volume of 1X TBE by boiling in a glass conical flask. The 
agarose solution was cooled to approximately 50°C before addition of SYBR
®
 Safe DNA gel 
stain (Invitrogen) (0.5μl per 100ml). The solution was subsequently poured into a sealed 
casting tray with gel combs inserted and left to set. Once set, the gel was placed into a 
horizontal electrophoresis tank (Eurogentec). Gel combs were removed and the gel was fully 
submerged in 1X TBE. 20μl PCR product was loaded into each well alongside either 
GeneRuler
™
 100bp Plus or GeneRuler
™
 1kb Plus DNA ladders (Fermentas). Gel 
electrophoresis was typically performed at 130V for 1 hour, and PCR products were 
visualised using a UV transilluminator.
 
 
2.11.5 Real-time quantitative PCR (QPCR) 
QPCR for cellular genes was performed on cDNA generated as described in section 2.11.2 
using commercially available TaqMan
®
 Gene Expression Assays purchased from Applied 
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Biosystems (see Table 2.11.4), in reactions assembled as in Table 2.11.5. Probes in cellular 
target primer and probe sets were FAM
™
 dye-labelled, while that of the internal baseline 
control, huGAPDH primer/probe set (Applied Biosystems) used for data normalisation was 
VIC
™
 dye-TAMRA
™
 dye-labelled. 
 
Table 2.11.4:  TaqMan
®
 Gene Expression Assays used in QPCR 
 
Gene TaqMan
®
 Gene Expression Assay 
BMP2 Hs00154192_m1 
PPM1A Hs00221372_m1 
TβRI Hs00610318_m1 
TβRII Hs00559660_m1 
TGFβ1 Hs00998133_m1 
TGFβ2 Hs00234244_m1 
TGFβ3 Hs01086000_m1 
 
Table 2.11.5:  Mastermix for QPCR 
 
Reagent Volume (μl) 
cDNA 5 
TaqMan
®
 Gene Expression Assay 1 
huGAPDH primer and probe 0.5 
2X Sensimix
™
 (dU) (Quantace) 10 
PCR grade H2O 3.5 
 
 
Reactions were performed in technical triplicate and analysed on an ABI 7500 Fast Real-time 
PCR machine. Analysis was performed using the 2
-ΔΔCt
 method (Livak and Schmittgen, 
2001). In brief, cycle threshold (Ct) values were obtained by determining the point at which 
amplification occurred above background in the linear range of amplification for each 
reaction. The test primer data was then normalised against the multiplexed endogenous 
reference GAPDH data to obtain the ΔCt values and the average determined for each triplicate 
to obtain the mean ΔCt. These values were then made relative to a calibrator (often the 
neomycin control cell line counterpart) to derive ΔΔCt values, from which the fold changes 
relative to the control were calculated using the formula 2
-ΔΔCt
. 
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2.12 Molecular cloning 
2.12.1 Solutions 
L-Broth (LB):  10g L-broth base (Gibco
®
) dissolved in 500ml SDW and sterilised by 
autoclaving. 
LB-agar plates:  7.5g agar dissolved in 500ml LB before autoclaving. Agar was melted prior 
to use and cooled to approximately 55°C before adding antibiotic. Plates were poured and, 
once set, inverted and stored at 4°C. 
Ampicillin:  100mg/ml stock was prepared in SDW, sterilised through a 0.45μm filter and 
stored in 5ml aliquots at -20°C. 
Spectinomycin:  100mg/ml stock was prepared in SDW, sterilised through a 0.45μm filter and 
stored in 5ml aliquots at -20°C. 
 
2.12.2 shRNA preparation 
Oligonucleotides for generation of shRNAs were purchased from Invitrogen, and were 
designed to encompass the unique 19-nucleotide target sequence in both sense and antisense 
orientation, separated by a 9-nucleotide spacer sequence, and inclusive of BglII and HindIII 
ends to assist ligation into the pSUPER.retro.puro vector (OligoEngine). PPM1B target 
sequences were obtained from (Sun et al., 2009), and the complete oligonucleotide sequences 
are given in Table 2.12.1. 
 
Table 2.12.1:  PPM1B shRNA oligonucleotide sequences 
shRNA 
name 
Oligonucleotide sequence 
shPPM1B-1 
sense 
5´-gatccccAATGCAGGAAAGCCATACTGAttcaagaggTCAGTATGGCTTTCCTGCATTttttta-3´ 
shPPM1B-1 
antisense 
5´-agcttaaaaaAATGCAGGAAAGCCATACTGAcctcttgaaTCAGTATGGCTTTCCTGCATTggg-3´ 
 
shPPM1B-2 
sense 
5´-gatcccAACTTCTGGAGGAGATGCTGAttcaagaggTCAGCATCTCCTCCAGAAGTTttttta-3´ 
 
shPPM1B-2 
antisense 
5´-agcttaaaaaAACTTCTGGAGGAGATGCTGAcctcttgaaTCAGCATCTCCTCCAGAAGTTggg-3´ 
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Oligonucleotides were reconstituted in TE buffer (10mM Tris-HCl pH 8.0, 1mM EDTA) to 
give a 100μM stock, and annealed in annealing buffer (100mM NaCl, 50mM HEPES pH7.4) 
by heating to 100°C for 5 minutes, before cooling gradually to room temperature, and 
subsequent storage overnight at 4°C. The pSUPER.retro.puro vector was linearised by 
sequential restriction-endonuclease cutting with HindIII and BglII as described in section 
2.12.4, and annealed shRNA oligonucleotides were ligated into the digested 
pSUPER.retro.puro using T4 DNA ligase (see section 2.12.5). This was then subjected to a 
further BglII restriction-endonuclease reaction for 30 minutes at 37°C prior to bacterial 
transformation to reduce the level of background. 
 
2.12.3 PCR amplification 
PCR amplification of desired sequences for use in the TOPO
®
 cloning procedure (Invitrogen) 
was performed on 0.01ng DNA per reaction, using primers listed in Table 2.12.2, and carried 
out according to conditions given in Table 2.12.3. 
 
Table 2.12.2:  Dominant-negative EBNA1 cloning oligonucleotide sequences 
 
Primer Oligonucleotide sequence 
dnEBNA1 fwd 5´-ATGAAGAGGCCCAGGAGTCCCA-3´ 
dnEBNA1 rev 5´-CTCCTGCCCTTCCTCACCCTCA-3´ 
 
Table 2.12.3:  Thermal cycler conditions for PCR cloning 
 
Temperature Time (minutes) Number of cycles 
94°C 5 1 
94°C 0.5  
35 58°C 0.5 
72°C 2 
72°C 5 1 
4°C HOLD  
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2.12.4 Restriction endonuclease digestion 
For a typical restriction endonuclease digestion, 1μg purified DNA was digested in a total 
volume of 20μl with the appropriate restriction enzymes and buffers (Roche Diagnostics, New 
England Biolabs, Promega). Briefly, a reaction was composed of 2μl 10X BSA stock 
(10mg/ml), 2μl 10X restriction enzyme buffer, 1μl each restriction enzyme and nuclease-free 
water up to a final volume of 20μl. The reaction mixture was incubated for 1.5 hours in a 
37°C water bath and if required, reactions were stopped by heating the sample at 65°C for 20 
minutes. Digested DNA was analysed by agarose gel electrophoresis. 
 
2.12.5 Ligation of DNA insert into vectors 
For shRNA cloning, ligation reactions were performed using T4 DNA ligase (Promega). 
Vector and insert were added, typically in a ratio of 1:3, to a total volume of 20μl, including 
2μl 10X T4 ligase buffer, 1μl T4 ligase and sterile water. The reaction was incubated at 16°C 
overnight to allow ligation to occur. 
 
For TOPO
®
 cloning, sequences were ligated in the presence of a salt solution (1.2M NaCl, 
0.06M MgCl2) into the linearised pCR
®
8/GW/TOPO
®
 entry vector supplied in the 
pCR
®
8/GW/TOPO
®
 TA Cloning
®
 kit (Invitrogen), for 5 minutes at room temperature, then 
cooled to 4°C. 
 
2.12.6 Bacterial transformation of competent cells 
2μl ligation reaction was used to transform either One Shot® TOP10 E.coli cells (Invitrogen), 
ONE SHOT
®
 Stabl3
™
 strain of E.coli (Invitrogen) or Gold Efficiency α-select chemically 
competent cells (Bioline). The ligation reaction was gently mixed with the cells, incubated on 
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ice for 30 minutes, heat-shocked for 30 seconds at 42°C, and then immediately returned to ice 
for 5 minutes. 250μl S.O.C. medium (Invitrogen) was added to cells prior to incubation in an 
orbital shaker at 37°C for 1 hour. The transformed cell mixture was then spread onto pre-
warmed LB-agar plates containing 100μg/ml ampicillin or 100μg/ml spectinomycin as 
required. Plates were inverted and incubated at 37°C overnight before examination of plates 
for drug-resistant bacterial colony growth the following day. 
 
2.12.7 Isolation of DNA from bacterial cultures 
2.12.7.1 Mini-preps 
Colonies on bacterial transformation plates were picked with a sterile pipette tip and 
incubated in 3ml LB supplemented with the required antibiotic for 16 hours at 37°C in an 
orbital shaker. To extract plasmid DNA, 1.5ml overnight bacterial culture was processed 
using the Qiagen QIAprep Spin Miniprep Kit (Qiagen) according to the manufacturer’s 
protocol. Briefly, cells were pelleted by centrifugation at 13000rpm for 10 minutes, 
supernatants discarded, and resuspended in 250μl Buffer P1. Cells were then lysed by 
addition of 250μl Buffer P2 and mixed by inversion, then neutralised by addition of 350μl 
Buffer N3 and again mixed by inversion. Samples were centrifuged at 13000rpm for 10 
minutes, and supernatants were transferred to supplied QIAprep spin DNA binding columns. 
Following centrifugation at 13000rpm at 4°C for 1 minute, samples were washed with 750μl 
Buffer PE and centrifuged again. Complete removal of wash buffer from the DNA binding 
column was ensured by a second centrifugation upon emptying the waste. The inner sleeve of 
the column was transferred into a clean labelled 1.5ml eppendorf and 50μl Buffer EB added 
to the centre of the binding column for elution of DNA. After incubation for 2 minutes at 
room temperature, the column was centrifuged as before, and a further 20μl Buffer EB added 
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and re-centrifuged. DNA concentrations were measured using a NanoDrop spectrophotometer 
and samples stored at -20°C. 
 
2.12.7.2 Maxi-preps 
Validated cultures were used to inoculate 400ml LB supplemented with the required 
antibiotic, and were incubated at 37°C for 16 hours in an orbital incubator. Using the 
Invitrogen PureLink HiPure Plasmid Filter Maxiprep kit, DNA was extracted and purified 
according to the manufacturer’s instructions. Bacterial cells were first pelleted using a Sorvall 
bucket centrifuge at 4000g for 10 minutes, and supernatants carefully decanted off and 
discarded. 15ml Buffer R3 was added to resuspend the pellet, which was subjected to 
repetitive pipetting and vortexing until homogenous. Cells were then lysed by addition of 
15ml L7 Lysis Buffer, gently mixed by inversion, and incubated at room temperature for 5 
minutes. 15ml Precipitation Buffer N3 was added to each sample and mixed by inversion, to 
both neutralise the lysis buffer and precipitate cellular debris and solutions. DNA binding 
columns were equilibrated by addition of 30ml Equilibration Buffer EQ1 to each column, 
allowed to drain by gravity flow. Samples were carefully transferred into the equilibrated 
columns and allowed to drain by gravity. Residual bacterial lysate was washed with 10ml 
Wash Buffer (W8) and, once drained, the inner filtration cartridge was removed and the 
columns washed with 50ml W8 wash buffer. DNA was then eluted by addition of 15ml E4 
elution buffer to the column. 10.5ml 100% isopropanol was added to each collection tube 
before centrifugation at 15000g for 30 minutes at 4°C. Supernatants were discarded, pellets 
washed in 5ml 70% ethanol and samples centrifuged at 15000g for 5 minutes at 4°C. All 
residual ethanol was carefully removed and the pellet air-dried prior to resuspension in 500μl 
DEPC-treated water, and transfer to clean 1.5ml eppendorfs. The concentration of each 
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plasmid was determined using a NanoDrop spectrophotometer and samples were diluted to a 
stock concentration of 1μg/μ1 before storage at -20°C. 
 
2.12.8 DNA sequencing 
The authenticity of cloned plasmids was verified by DNA sequencing using the BigDye
®
 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). Briefly, this involved 
amplifying the gene sequence of interest with primers specific to the entry plasmid (either 
GW1 or GW2 for cloning into TOPO
®
 vectors, and H1 sequencing primer for shRNA 
constructs contained in pSUPER.retro.puro – see Table 2.12.4). The PCR reaction mix was 
set up according to Table 2.12.5 and run using the thermocycler program outlined in Table 
2.12.6. 
 
Table 2.12.4:  Primers used for sequencing 
 
Primer Sequence Source 
GW1 5´-GTTGCAACAAATTGATGAGCAATGC-3´ Invitrogen 
GW2 5´-GTTGCAACAAATTGATGAGCAATTA-3´ Invitrogen 
H1 5´-TCGCTATGTGTTCTGGGAAA-3´ Addgene 
 
Table 2.12.5: Sequencing reaction PCR mastermix 
 
Reagent Volume (μl) 
DNA (100ng/μl) 1 
Ready Reaction Premix 2 
Big Dye sequencing buffer 2 
Primer (3.2pmol) 1 
DEPC-treated H2O 14 
 
Table 2.12.6:  Sequencing PCR thermal cycler conditions 
 
Temperature Time Number of cycles 
96°C 1min 1 
96°C 10s  
25 50°C (55°C for shRNAs) 5s 
60°C 4min 
4°C HOLD  
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PCR products were subsequently purified by addition of 2μl 125mM EDTA, 2μl 3M sodium 
acetate and 50μl 100% ethanol to each reaction, and mixed by inversion. Reactions were 
incubated for 15 minutes at room temperature, followed by centrifugation at 2000g for 45 
minutes at 4°C. Supernatant was carefully aspirated and 70μl 70% ethanol added to each 
pellet before further centrifugation at 1650g for 15 minutes at 4°C. Supernatant was aspirated 
and pellets were air-dried at 37°C for 30 minutes. Pellets were resuspended in HiDi 
formamide buffer (Applied Biosystems) and samples were stored at 4°C until use. 
 
Samples were loaded into a 96-well plate and run using a standard sequencing protocol on a 
3130xl Genetic Analyser (Applied Biosystems). Collected data was subsequently analysed 
using Chromas Version 1.45, and the NCBI website sequence alignment tool 
(http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi) utilised to verify homology to the 
desired sequence. 
 
2.12.9 Multisite Gateway
®
 LR Recombination 
pENTR
™
5´-TOPO
®
 and pCR
®
8/GW/TOPO
®
 entry vectors carrying the desired sequences 
were added in combination with the lentiviral destination vector, pLenti6/R4R2/V5-DEST 
(Invitrogen), in a LR clonase II
®
-driven homologous recombination reaction, incubated at 
room temperature for 16 hours, followed by addition of 1μl 2μg/μl Proteinase K solution 
(Invitrogen), and incubation for 10 minutes at 37°C. 
 
2.13 Statistics 
Statistical significance of data was established using the Student’s t-test, following 
determination of equal or unequal variance of samples using an f-test. 
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CHAPTER 3 
 
Modulation of the TGFβ signalling pathway by the EBV-encoded 
EBNA1 protein 
 
3.1 Introduction 
The initial suggestion that EBNA1 may act as a modulator of cellular gene transcription 
provided the catalyst for an accumulating body of evidence in support of this hypothesis. 
These findings are particularly pertinent as they demonstrate that the transactivation 
capabilities of EBNA1 can now be extended beyond its well-established role in the 
transactivation of viral genes, and intimate that, in the context of an EBV infection, EBNA1 
may specifically modify host cellular signalling pathways, perhaps simply in order to assist its 
genome maintenance function but, more intriguingly, to foster malignant progression. To 
date, reports have documented the ability of EBNA1 to induce the expression of CD25, 
RAG1, RAG2 and CCL20 genes in B cells (Kube et al., 1999, Srinivas and Sixbey, 1995, 
Baumforth et al., 2008), whilst deregulating the STAT1, AP-1, TGFβ and NFκB signalling 
pathways in epithelial cells (Wood et al., 2007, O'Neil et al., 2008, Valentine et al., 2010). 
 
In this laboratory, EBNA1-related research has centred around microarray-based gene 
expression analyses carried out on Ad/AH carcinoma cells stably expressing EBNA1 (Wood 
et al., 2007, Valentine et al., 2010), which identify key signalling pathways as potential 
targets of EBNA1. Here, the focus of the work has been to expand upon existing observations 
relating to the effect of EBNA1 expression on the TGFβ signalling pathway, with particular 
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emphasis on the effect on phosphorylation status of Smad mediator proteins as an essential 
means of controlling signalling output.  
 
The ability of EBNA1 to modulate the TGFβ signalling pathway was considered particularly 
deserving of further exploration due to the well-established roles of TGFβ in many critical 
cellular processes, including cell proliferation and apoptosis, differentiation, migration and 
extracellular matrix production (Massagué and Gomis, 2006, Jakowlew, 2006). Disruption of 
TGFβ signalling and, by default, these fundamental cellular mechanisms, invariably yields 
oncogenic results. It is therefore not surprising that aberrant TGFβ signalling is a common 
event in many cancers (Akhurst and Derynck, 2001, Jakowlew, 2006, Massagué, 2008) and, 
significantly, dysregulation of the TGFβ pathway has already been documented in NPC (Harn 
et al., 2002, Sriuranpong et al., 2004). In normal epithelial cells, TGFβ performs homeostatic, 
largely growth inhibitory and pro-apoptotic functions, responses which are characteristically 
lost during tumourigenesis in favour of its tumour promoting roles in enhancing cell motility, 
invasion and metastasis (Massagué, 2008). Abrogation of the TGFβ pathway has already been 
attributed to EBV infection and, more specifically, the presence of EBNA1, in carcinoma 
cells (Wood et al., 2007), and it is therefore feasible that the observed alterations will directly 
impact upon NPC pathogenesis. 
 
Normally, negative regulation of the Smad signal is used to precisely control Smad signal 
termination (Itoh and ten Dijke, 2007). However, if this balance becomes deregulated, this can 
adversely affect TGFβ signalling and encourage tumour progression. Previous work has 
revealed the ability of EBNA1 to repress the transcription of the well-recognised TGFβ-
responsive target genes, PAI-1 and βig-h3, and this effect has been specifically correlated 
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with diminished levels of Smad2-activating phosphorylation in response to TGFβ stimulation, 
coupled with enhanced Smad2 protein turnover in both EBV-infected B cells and carcinoma 
cell lines (Wood et al., 2007, Flavell et al., 2008). 
 
While many mutations of Smad proteins, particularly Smad2 and Smad4, have been 
characterised (Riggins et al., 1997, Massagué et al., 2000, Xu and Attisano, 2000, Miyaki et 
al., 1999, Qiu et al., 2007, Bornstein et al., 2007, Losi et al., 2007, Levy and Hill, 2006), there 
are no reports to date of their occurrence in NPC, indicating that the Smad proteins may be 
adversely regulated rather than mutated in this cancer. Subsequent investigations therefore 
focussed on negative regulation or attenuation of TGFβ signalling in the context of EBV-
infected epithelial cells. Termination of the Smad signal is achieved either irreversibly 
through ubiquitination and degradation of the R-Smads (Lo and Massagué, 1999), or by 
dephosphorylation in the nucleus which permits the R-Smads to translocate back into the 
cytoplasm to participate in further signalling (Wrighton et al., 2009). Several proteins have 
been implicated in these processes, including PPM1A, MTMR4, TMEPAI, NEDD4-2, 
Smurf2, WWP1/Tiul1, CHIP, CKIγ2 and Pin1 (Lin et al., 2006, Yu et al., 2010a, Watanabe et 
al., 2010, Gao et al., 2009, Lin et al., 2000b, Zhang et al., 2001, Seo et al., 2004, Xin et al., 
2005, Guo et al., 2008, Nakano et al., 2009). In order to select potential candidate proteins for 
further investigation, the existing Affymetrix gene expression array data was scrutinised for 
deregulated expression of the above genes. With the fold change threshold set at ≥1.5, both 
PPM1A and NEDD4-2 were identified as being significantly up-regulated in the Ad/AH 
EBNA1 cells, with respective fold changes of 2.18 and 1.73 in comparison to control cells. 
The expression of these two genes was therefore examined in EBNA1-expressing carcinoma 
cell lines. 
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Inhibition of TGFβ signalling in cancer is often acquired progressively as the tumour 
advances and generally confers resistance to TGFβ-mediated cytostatic effects (Roberts and 
Wakefield, 2003). Several potential mechanisms have been proposed for this effect, including 
down-regulation or loss of TGFβ receptor expression, and increased production of TGFβ 
ligands, both of which have been associated with a higher risk of developing invasive and 
metastatic traits, and inversely correlated with clinical stage (Kang, 2006, Diamond et al., 
2008, Peng et al., 2006). Each of these features will be addressed in this chapter. 
 
TGFβ receptors, in particular TβRII, are frequently lost or down-regulated in several cancers, 
including oesophageal squamous cell carcinoma, renal cell carcinoma, gastric cancer, lung 
cancer, prostate cancer and breast cancer (Fukai et al., 2003, Peng et al., 2006, Miyajima et 
al., 2003, Tateishi et al., 2000, Osada et al., 2001, Yamashita et al., 2008b, Park et al., 2002), 
although mutations have been the most extensively studied in colorectal cancer (Grady et al., 
1999, Biswas et al., 2008). This loss of TβRII is thought to accelerate TGFβ-associated 
malignant changes, as is evidenced by the introduction of a dominant negative TβRII 
construct into the transgenic adenocarcinoma of mouse prostate (TRAMP) in vivo model (Pu 
et al., 2009). Multiple mechanisms have been proposed including gene silencing through 
methylation, histone hypoacetylation, reduced or altered binding activities of distinct 
transcription factors at TβRII gene promoter regions, and post-transcriptional down-regulation 
of the TβRII protein (Chen et al., 2007, Osada et al., 2001, Yamashita et al., 2008b, Park et 
al., 2002, Kim et al., 1997, Lee et al., 2007, Fukasawa et al., 2010). Some TβRI mutations 
have been characterised (Kim and Ahn, 1996, Chen et al., 1998), but are found to be 
comparatively rare, possibly as the TβRI gene is structurally less susceptible to mutation (Kim 
et al., 2000). 
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Tumour cells, particularly of late-stage carcinomas, often secrete higher, non-physiological 
levels of TGFβ, compared to their normal cell counterparts (Yu et al., 2010b). This over-
expression has been reported for many cancer types, including NPC (Xiao et al., 2010), and is 
strongest in the most advanced stages of malignancies (Miyajima et al., 2003). The effect of 
this is two-fold; it exhibits autocrine effects, mostly concerning remodelling of the 
extracellular matrix and augmentation of invasion and metastasis, and also acts in a paracrine 
manner to modify the neighbouring stroma, evade immunosurveillance, and overall create a 
microenvironment more conducive to tumour growth (Leivonen and Kähäri, 2007, Teicher, 
2007).  
 
It is common to find mutations in the TβRII gene in cells resistant to TGFβ growth inhibition, 
as shown in human gastric cancer cell lines among many others (Park et al., 1994, Inman and 
Allday, 2000, Osada et al., 2001, Fukuda et al., 2006). Similarly, the production of TGFβ is 
often increased once cells are no longer susceptible to its anti-proliferative effects (Gold et al., 
2000, Di Bartolo et al., 2008). It follows that the anti-proliferative response can be inversely 
correlated with malignant potential. The expression levels of both TGFβ receptors and TGFβ 
ligands, and their putative consequences on cell cycle distribution were therefore studied to 
determine whether EBNA1 promotes these mechanisms to inhibit TGFβ signalling. 
 
Although the canonical Smad pathway is the most-characterised and commonly enlisted 
method of relaying TGFβ signals, there is growing evidence to substantiate a role for Smad-
independent responses in some aspects of TGFβ signalling (Moustakas and Heldin, 2005). In 
this scenario, TGFβ is able to establish connections with various other signalling pathways, 
including the MAPKs, ERK-MAPK, JNK and p38, PI3K/Akt, PP2A and RhoA/Rac/Cdc42 
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(Funaba et al., 2002, Javelaud and Mauviel, 2005, Massagué and Gomis, 2006, Derynck and 
Zhang, 2003, Seoane, 2006, Matsuzaki et al., 2009, Nagata et al., 2009). These pathways can 
function to further fine-tune Smad-dependent responses, but may also occur independently of 
Smads. For example, TGFβ is able to activate both JNK and p38 by targeting TβRI-associated 
TRAF6 in a process independent of receptor kinase activity, and resulting in activation of 
TAK1-mediated pathways leading to apoptosis (Yamashita et al., 2008a, Sorrentino et al., 
2008). Non-Smad signalling pathways are reviewed in more detailed in (Zhang, 2009). 
 
Many of these interconnecting signalling pathways have also been implicated in the 
differential phosphorylation of the R-Smad proteins. Recent evidence suggests that, in 
addition to the canonical phosphorylation of the Smad proteins within their C-terminal SXSS 
motif by TβRI, Smads can also be phosphorylated at residues within their divergent 
serine/threonine linker region (Moustakas et al., 2001) by a variety of kinases, including 
ERK-MAPK, JNK, p38 MAPK, CDK4 and GSK3 (Matsuzaki and Okazaki, 2006, Matsuzaki 
et al., 2009, Wang et al., 2009) thus giving rise to different Smad phospho-isoforms, the C-
terminally phosphorylated pSmad2/3C and the linker phosphorylated pSmad2/3L. While 
pSmad2/3C primarily transmits the classical tumour suppressive TGFβ signal (Nagata et al., 
2009), linker Smads have been associated with late-stage, more invasive cancers (Matsuzaki 
and Okazaki, 2006, Matsuzaki et al., 2009). In cancer, oncogenic Ras mutations can play a 
predominant role in this effect. Hyperactive Ras has been reported to activate both ERK and 
JNK pathways (Kretzschmar et al., 1999, Sekimoto et al., 2007), and this can override 
canonical TGFβ signalling by promoting Smad2/3 linker phosphorylation. Work presented 
here tested the hypothesis that EBNA1 may be able to enlist other signalling pathways so as 
to modulate Smad activity. 
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To conclude, work was extended to the more relevant NPC model cell line, C666-1, 
fortuitously found to consistently carry EBV genomes in long-term culture and to resemble an 
EBV latency II pattern of gene expression (Cheung et al., 1999). Innate defective TGFβ 
signalling within this cell line is thought to be a consequence of an absence in expression of 
TβRII (Wood et al., 2007). TGFβ signalling was also investigated in the highly TGFβ-
sensitive Mv1Lu mink lung epithelial cell line, with the aim of highlighting any common 
mechanisms employed by EBNA1 in dysregulation of the pathway. 
 
3.2 EBNA1 modulates the canonical TGFβ signalling pathway 
3.2.1 The level of EBNA1 expression in Ad/AH EBNA1 cl8 cells is more physiologically 
relevant than that in Ad/AH EBNA1 cl3 cells 
Initial experiments were designed to confirm the previously observed effects of EBNA1 on 
TGFβ signalling (Wood et al., 2007). However, in the aforementioned study, the clone used, 
Ad/AH EBNA1 clone 3, was found to express higher levels of EBNA1 than those observed in 
stable, latently infected Ad/AH cells, or in the EBV-positive NPC cell line, C666-1. With this 
in mind, it was decided to perform Affymetrix gene expression profiling on an additional 
clone, Ad/AH EBNA1 clone 8, which expressed physiological levels of EBNA1 (Owen et al., 
2010, Valentine et al., 2010). The EBNA1 expression levels of these cells, when compared to 
a variety of EBV-infected epithelial and B cell lines was examined by immunoblotting 
analysis (Figure 3.1A). It is evident that the level of EBNA1 expressed in the EBNA1 clone 8 
cells more closely resembles expression levels not only of Ad/AH cells latently infected with 
wild-type recombinant EBV (rEBV), but also levels in C666-1 cells and EBV-transformed 
LCLs. 
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A)
Figure 3.1:  EBNA1 is expressed at physiological levels in Ad/AH EBNA1 clone 8 
cells and has similar effects to clone 3 cells on TGFβ signalling
A) Immunoblotting for levels of EBNA1 protein in Ad/AH Neo, Ad/AH EBNA1 clone 
3, Ad/AH EBNA1 clone 8, Ad/AH rEBV, the EBV-positive C666-1 and the 
lymphoblastoid cell lines X50-7 and SL (immortalised with the B95-8 strain of 
EBV). β-actin was included as a loading control The larger size of C666-1 EBNA1 
is presumably due to a larger gly-ala repeat in this strain of EBV.
B) Immunoblotting for protein levels of total and serine 465/467 phosphorylated form 
of Smad2, and total and serine 423/425 phosphorylated form of Smad3, in serum-
starved Ad/AH Neo, Ad/AH EBNA1 clone 3, Ad/AH EBNA1 clone 8 and Ad/AH 
rEBV cells, under basal conditions or following stimulation with 5ng/ml 
recombinant hTGFβ1 for 24 hours. β-actin was included to confirm equal protein 
loading 
C) Immunoblotting for total Smad2 protein levels over a 12-hour time-course 
following cycloheximide treatment of Ad/AH Neo, Ad/AH EBNA1 clone 8 and 
Ad/AH rEBV cells, with β-actin included to confirm equal protein loading. 
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3.2.2 EBNA1 inhibits Smad2 and Smad3 SSXS motif phosphorylation in response to 
TGFβ and enhances Smad2 degradation 
A decline in levels of phosphorylated, and therefore active, Smad2 (pSmad2) was reported to 
be a key feature of the abrogated TGFβ response (Wood et al., 2007). Indeed it seems 
important in several cancers, including head and neck squamous cell carcinoma (HNSCC) and 
oesophageal squamous cell carcinoma (OSCC), where a lack of pSmad2 was positively 
correlated with tumour progression, whereas the loss of total Smad2 appeared much less 
common (Muro-Cacho et al., 2001, Fukuchi et al., 2006).  
 
To confirm this observation and determine whether Ad/AH EBNA1 clone 8 cells displayed 
the same trend, levels of the phosphorylated forms of both TGFβ-specific R-Smads were 
measured by immunoblotting. As is evident from Figure 3.1B, the reduction in the TGFβ-
induced phosphorylated forms of Smad2 (pSmad2 Ser465/467) was confirmed in both 
EBNA1-expressing clones and in the rEBV-infected cell line. Expression of the 
phosphorylated form of Smad3 (pSmad3 Ser423/425) was also found to be reduced in both 
EBNA1-expressing and rEBV-infected cell lines, further expanding the initial finding. 
 
Additionally, a time-course of treatment with the protein synthesis inhibitor cycloheximide 
was carried out in Neo control, EBNA1 clone 8 and rEBV-infected Ad/AH cells to examine 
the half-life of the Smad2 protein. Subsequent examination of the Smad2 protein levels by 
immunoblotting (shown in Figure 3.1C), confirmed increased turnover of Smad2 in Ad/AH 
EBNA1 clone 8 cells compared to Ad/AH Neo controls. 
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3.2.3 Smad2- and Smad3-specific TGFβ reporter activity is attenuated in the presence 
of EBNA1 
As final confirmation and justification for the use of Ad/AH EBNA1 clone 8 cells as opposed 
to the EBNA1-overexpressing clone 3, TGFβ/Smad luciferase reporter activity was also 
measured. Ad/AH cells stably expressing either EBNA1 or a control neomycin resistance 
cassette, and cells latently infected with rEBV were transiently transfected with either one of 
two synthetic TGFβ-responsive luciferase reporters, p(CAGA)12-Luc and p(ARE)3-Luc, or the 
p3TP-lux reporter containing fragments of the PAI-1 promoter. Cells used to measure 
p(ARE)3-Luc reporter activity were additionally transfected with the Xfast1 transcription 
factor, which is essential for mediating Smad2 DNA binding (Chen et al., 1996, Chen et al., 
1997). Relative luciferase activity is depicted graphically in Figure 3.2 and represents the 
mean of three independent experiments. The results show marked reductions of greater than 
50% in activity of the TGFβ/Smad-responsive luciferase reporters in Ad/AH EBNA1 and 
rEBV-infected cells compared to Neo controls for each of the three reporter constructs 
studied. The capacity of these EBNA1-expressing and rEBV-infected cells to respond to 
TGFβ was also noticeably reduced, as reflected by much smaller differences between basal 
and TGFβ1-stimulated levels of reporter activity in these cells in comparison with Neo 
control cells, supporting a defect specifically in the Smad activation mechanism. 
 
The ability of Ad/AH EBNA1 clone 8 cells to respond in a similar manner to Ad/AH EBNA1 
clone 3 cells, whilst expressing more physiological levels of the EBNA1 protein, affirmed the 
choice to hereafter use only the clone 8 cells, which will from now on be referred to as 
Ad/AH EBNA1. 
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A) 
B) 
C) 
Figure 3.2:  The effect of EBNA1 and EBV on TGFβ-induced promoter activity in 
stable Ad/AH cell lines
Dual luciferase reporter assays showing p(CAGA)12-Luc, p(ARE)3-Luc or p3TP-lux  
luciferase reporter activity in Ad/AH Neo, Ad/AH EBNA1 clone 8 and Ad/AH rEBV
cells stimulated with 5ng/ml recombinant hTGFβ1 for 24 hours, or left unstimulated as a 
control. Histograms are shown to depict the relative luminescence after normalising to 
Renilla luciferase values and expressing as a ratio of activity relative to the control vector 
pGL3-basic. Data from three independent experiments is presented as the mean fold 
differences in activity + SE, relative to that observed in unstimulated Ad/AH Neo control 
cells which is given an arbitrary value of 1 (** denotes a P-value <0.01 and * denotes a 
P-value <0.05).
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3.2.4 EBNA1 decreases TGFβ/Smad DNA binding basally and in response to TGFβ 
Having confirmed the ability of EBNA1 to attenuate TGFβ/Smad-responsive reporter activity 
and attenuate Smad activation, the binding of Smad transcriptional mediators to their target 
DNA sequences was explored. While Smad2 is intrinsically unable to directly bind DNA 
(Dennler et al., 1999), Smad3 and Smad4 recognise and bind through their MH1 domains (Shi 
et al., 1998) to an 8bp palindromic sequence (5´-GTCTAGAC-3´) termed the Smad binding 
element (SBE) (Zawel et al., 1998). To assess whether the observed decrease in TGFβ/Smad-
luciferase reporter activity was a direct result of reduced binding at TGFβ-responsive 
promoter regions, electrophoretic mobility shift assays were performed using a probe specific 
to the SBE motif, as described in section 2.7.3. Briefly, nuclear extracts were isolated from 
Neo control, EBNA1-expressing and rEBV-infected Ad/AH cells, and C666-1 cells following 
stimulation for 1hr with 5ng/ml TGFβ1 to activate the Smad transcriptional response. Nuclear 
extracts were then incubated with an IRDye
®
-700 labelled probe specific to the SBE motif 
and resulting protein:DNA complexes resolved by gel electrophoresis. Binding was measured 
after scanning of the EMSA gel using an Odyssey
®
 infrared imaging system and quantified by 
measuring relative fluorescence intensities. Densitometric analysis, represented graphically, 
along with a representative scanned EMSA gel, are shown in Figure 3.3A. Comparing the 
binding intensities of nuclear extracts at SBE sequences, it is apparent that protein binding to 
the SBE probe was significantly increased in response to TGFβ1 stimulation in Neo control 
cells, whereas binding in both EBNA1 and rEBV-infected Ad/AH cells was substantially 
reduced, showing only a modest increase in response to TGFβ stimulation. Although not 
found to be significant, the data suggests reductions of approximately 50% in SBE binding in 
these cells. Similarly, and significantly, protein binding in nuclear extracts taken from C666-1 
cells was reduced down to almost negligible levels and appeared unchanged by the addition of  
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A)
B)
Figure 3.3:  The effect of EBNA1 on binding at SBE sites in Ad/AH and C666-1 cells
A) EMSA analysis of SBE sequence binding in serum-starved Neo control, EBNA1-
expressing and rEBV-infected Ad/AH cells, and C666-1 cells, under basal conditions and 
in response to stimulation with 5ng/ml recombinant hTGFβ1 for 1 hour. Densitometry was 
performed on three independent experiments, and a histogram created depicting mean 
differences in binding affinities SE, between cell types with and without stimulation (** 
denotes a P-value <0.01 and * denotes a P-value <0.05). A representative image of the 
infrared scanning is shown.
B) EMSA analysis was repeated in the Ad/AH Neo control cells including an additional 
incubation step with a 100-fold excess of non-labelled SBE probe which functions as a cold 
competitor prior to incubation with the IRDye-700® end-labelled version.
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exogenous TGFβ1. This supports a hypothesis that an abrogation of Smad binding at TGFβ 
target gene promoters may largely contribute to the observed attenuation in TGFβ activity in 
these cells. To confirm the high degree of specificity of the EMSA assay, extracts from the 
control cells were additionally incubated with a 100-fold excess of unlabelled probe prior to 
incubation with the IRDye-700
®
 labelled version. A representative experiment, Figure 3.3B, 
shows complete abrogation of probe binding. 
 
3.2.5 Screening of Ad/AH EBNA1 Affymetrix Array data for Smad negative regulators 
With a view to ascertaining how EBNA1 might adversely influence TGFβ signalling, a list of 
acknowledged putative negative regulators of the TGFβ signalling pathway was used to 
interrogate gene expression microarray data of Ad/AH cells stably expressing EBNA1. Of 
these, PPM1A and NEDD4-2 were identified as potential candidates.  
 
3.2.5.1 EBNA1 increases the expression of the Smad-specific phosphatase PPM1A in 
carcinoma cell lines and NPC biopsies 
PPM1A (protein phosphatase, Mg
2+
/Mn
2+
 dependent, 1A) has recently been identified as a 
Smad-specific phosphatase, and is able to specifically dephosphorylate active Smad2 and 
Smad3 (pSmad2/3), inducing subsequent nuclear export, and hence acting to terminate the 
TGFβ-induced signal (Lin et al., 2006). RNA and protein samples were extracted from panels 
of Ad/AH and HONE-1 cells expressing either the neomycin resistance cassette, EBNA1, or 
stably infected with rEBV. RT-PCR, QPCR and immunoblotting techniques were employed 
to analyse the levels of PPM1A RNA and protein. As shown in Figure 3.4, compared to Neo 
control cells, the levels of PPM1A mRNA and protein were increased in both Ad/AH and 
HONE-1 cells expressing EBNA1 or stably infected with rEBV. QPCR analysis, represented  
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A)
Figure 3.4:  PPM1A expression in Ad/AH and HONE-1 carcinoma cell lines
A) RT-PCR analysis of PPM1A mRNA levels in Ad/AH and HONE-1 cells expressing 
either a control neomycin resistance cassette or EBNA1, or stably infected with 
rEBV. The housekeeping gene GAPDH was included as a positive control to confirm 
equal RNA input into the PCR reactions, while negative water controls confirmed the 
absence of contamination. QPCR analysis for PPM1A mRNA is also shown, in 
which GAPDH was included as an internal baseline control. Histograms are shown 
displaying the mean fold change differences SE (n=4) relative to Neo control cells 
(** denotes a P-value <0.01 and * denotes a P-value <0.05).
B) QPCR analysis was repeated in serum-starved Neo control, EBNA1-expressing and 
rEBV-infected Ad/AH cells either stimulated with 5ng/ml recombinant hTGFβ1 for 
24 hours or left unstimulated as a control. Again, the histogram shows the mean fold 
change differences SE (n=4) relative to unstimulated Neo control cells (** denotes 
a P-value <0.01 and * denotes a P-value <0.05).
C) Immunoblotting for levels of PPM1A protein in Ad/AH and HONE-1 cells 
expressing either a neomycin resistance cassette, or EBNA1, or stably infected with 
rEBV, with β-actin included to confirm equal protein loading. 
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in Figure 3.4A, indicates that, basally, EBNA1 induced a significant approximate 1.5-fold 
increase in PPM1A expression whilst a 1.2-fold increase was observed in rEBV-infected 
Ad/AH cells. As shown in Figure 3.4B, TGFβ stimulation did not markedly alter the 
expression of PPM1A, findings that are in broad agreement with the observations of others 
(Lin et al., 2006), showing that PPM1A is itself not a TGFβ-regulated gene. In HONE-1 cells, 
despite an apparent upregulation of PPM1A mRNA by RT-PCR in EBNA1-expressing cells 
(Figure 3.4A), QPCR failed to detect a significant change. However, immunoblotting 
indicated that the protein level was increased in these cells (Figure 3.4C), which may reflect 
an increase in PPM1A protein stability or altered turnover. However, this finding could not be 
replicated in the EBV-infected HONE-1 cells. 
 
Immunofluorescence staining of Neo control, EBNA1 and rEBV-infected Ad/AH cells was 
performed to examine the expression of PPM1A, Smad2 and Smad3 at the single cell level, 
using a rabbit polyclonal antibody to PPM1A, and mouse monoclonal antibodies to Smad2 
and Smad3, followed by subsequent detection with Alexa-Fluor
®
 546-conjugated goat anti-
rabbit and Alexa-Fluor
®
 488-conjugated goat anti-mouse Ig. Representative confocal images, 
in Figure 3.5, show increased levels of nuclear PPM1A in EBNA1-expressing cells compared 
to their Neo control counterparts and, in addition, show an overall increase in colocalisation 
of PPM1A with both Smad2 (Figure 3.5A) and Smad3 (Figure 3.5B). Surprisingly however, 
this phenomenon was not replicated in the rEBV-infected cells. 
 
Further examination of the expression levels in the in vivo context allows increased 
significance to be attributed to these findings in the context of NPC pathogenesis. The GCOS 
graph derived from normalised PPM1A expression levels in four normal and 15 NPC tumour  
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samples plus the C666-1 EBV-positive NPC cell line can be seen in Figure 3.6, and 
demonstrates an increase in PPM1A mRNA expression in 6/16 (38%) NPC tumours 
compared to normal epithelia (data kindly provided by Dr. J. Arrand, University of 
Birmingham). 
 
3.2.5.2 Validation of PPM1A shRNA vectors 
To further explore the possibility that EBNA1 may increase the expression of PPM1A as a 
mechanism to downregulate TGFβ signalling, it was hypothesised that shRNA-mediated 
knockdown of PPM1A in EBNA1-expressing cells might restore TGFβ responsiveness. A 
shRNA construct specific for PPM1A (pSRG-shPPM1A881) was kindly provided by 
Professor Xin-Hua Feng, Baylor College of Medicine, and was tested to confirm its ability to 
reduce PPM1A expression in vitro. Initially, the optimal conditions for shRNA knockdown 
were determined by transient transfection of increasing concentrations of the pSRG-
shPPM1A881 vector into Ad/AH cells. The level of PPM1A mRNA and protein was then 
examined 24 and 48 hours later by RT-PCR (Figure 3.7A), and 24, 48 and 72 hours post-
transfection by immunoblotting (Figure 3.7B). Compared to cells transfected with the empty 
vector, pSRG, a marked decrease in PPM1A mRNA and protein expression was observed in 
cells transfected with the shPPM1A881 plasmid; the most pronounced results were observed 
after 48 hours at the mRNA level, whereas a reduction in protein was more pronounced after 
72 hours. QPCR of cDNA samples derived from RNA extracted 48 hours post-transfection 
into Ad/AH stable cell lines confirmed that PPM1A knockdown could also be achieved in the 
presence of stable EBNA1 expression. As can be seen from Figure 3.7C, PPM1A mRNA 
levels were significantly reduced by greater than half by the introduction of the PPM1A 
shRNA into Ad/AH Neo, EBNA1 and rEBV-infected cells. 
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Figure 3.6:  PPM1A expression in EBV-positive NPC tumour cells
Existing expression array data analysed using GCOS (Affymetrix) was 
probed for PPM1A expression levels. Normalised expression array intensities 
for 4 normal samples (yellow) and 15 NPC tumours plus the C666-1 EBV-
positive NPC cell line (pink) are shown.
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A)
Figure 3.7:  Validation of PPM1A shRNA construct
A) RT-PCR analysis for PPM1A mRNA levels in Ad/AH cells transiently transfected
with increasing concentrations of either the shPPM1A881 construct or 
pSUPER.retro (pSRG) control vector, measured 24 and 48 hours post-transfection. 
GAPDH was included as a positive control. 
B) Immunoblotting for levels of PPM1A protein in Ad/AH cells transiently 
transfected with increasing concentrations of either the shPPM1A881 construct or 
pSUPER.retro (pSRG) control vector, measured 24, 48 and 72 hours post-
transfection. Blots were re-probed for β-actin to confirm equal protein loading.
C) QPCR analysis for PPM1A mRNA levels in Ad/AH cells expressing either the 
control neomycin resistance cassette or EBNA1, or infected with rEBV, 
transiently transfected with either the shPPM1A881 or control pSRG vector, and 
stimulated with 5ng/ml recombinant hTGFβ1 for 24 hours, or left unstimulated as 
a control. GAPDH was included as an internal baseline control. A histogram is 
shown displaying the mean fold change differences SE (n=3) relative to Neo 
control cells transfected with control vector (** denotes a P-value <0.01 and * 
denotes a P-value <0.05).
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3.2.5.3 RNAi-mediated knockdown of PPM1A in EBNA1-expressing cells does not 
significantly restore TGFβ activity 
Once the conditions required for successful knockdown of PPM1A had been established, the 
biological consequences of this were investigated. Neo control, EBNA1 and rEBV-infected 
Ad/AH cells were transiently transfected with either the shPPM1A881 or pSRG control 
vector, and the p(CAGA)12-Luc and Renilla luciferase reporter constructs. 48 hours post-
transfection, cells were either left untreated, or stimulated with 5ng/ml TGFβ for 24 hours. 
Cells were then assayed for luciferase reporter activity at a time, 72 hours, when maximal 
silencing of PPM1A had been achieved. Figure 3.8 represents the mean of three independent 
experiments, and shows that PPM1A knockdown only marginally increased the levels of 
p(CAGA)12-Luc activity in EBNA1-expressing and rEBV-infected cells, and did not 
significantly restore TGFβ reporter activity. 
 
3.2.5.4 EBNA1 increases the expression of PPM1B 
The closely related phosphatase PPM1B (protein phosphatase, Mg
2+
/Mn
2+
 dependent, 1B) has 
also been identified as exhibiting Smad specificity but is thought to play a less prominent role 
owing to its comparatively more cytoplasmic localisation (Lin et al., 2006). However, both 
PPM1A and PPM1B have been reported to negatively affect the phosphorylation of IKKβ in 
canonical TNFα-induced NFκB signalling (Sun et al., 2009), and so it was hypothesised that 
the two phosphatases may function in a similar fashion to effectively modulate Smad 
phosphorylation status. Expression of PPM1B transcripts in the Ad/AH cell panel was 
investigated using RT-PCR, and demonstrated an increase in PPM1B expression in both 
EBNA1-expressing and rEBV-infected Ad/AH cells (Figure 3.9A). In the HONE-1 cell line, 
an increase in mRNA level in EBNA1-expressing cells was also observed, yet no increase in  
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Figure 3.8:  The effect of shRNA-mediated knockdown of PPM1A on TGFβ
promoter activity in Ad/AH cells
Dual luciferase reporter assay showing p(CAGA)12-Luc activity in Ad/AH Neo, 
Ad/AH EBNA1 and Ad/AH rEBV cells transiently transfected with either the 
shPPM1A881 or pSUPER.retro (pSRG) control vectors, measured under basal 
conditions and in response to stimulation with 5ng/ml recombinant hTGFβ1 for 24 
hours. A histogram is shown to depict the relative luminescence after normalising to 
Renilla luciferase values and expressing as a ratio of activity relative to the control 
vector pGL3-basic. Data from three independent experiments is presented as the 
mean fold differences in activity + SE, relative to that observed in unstimulated
Ad/AH Neo control cells transfected with control vector, which is given an arbitrary 
value of 1 (* denotes a P-value <0.05). 
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Figure 3.9:  PPM1B expression in Ad/AH and HONE-1 carcinoma cell lines
A) RT-PCR analysis for PPM1B mRNA levels in Ad/AH and HONE-1 cells expressing either 
a control neomycin resistance cassette or EBNA1, or stably infected with rEBV. GAPDH 
was included as a positive control to confirm equal RNA input into the PCR reactions, 
while negative water controls confirmed the absence of contamination.
B) Immunoblotting for levels of PPM1B protein in Ad/AH and HONE-1 cells expressing 
either a neomycin resistance cassette, or EBNA1, or stably infected with rEBV, with β-
actin included to confirm equal protein loading. 
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mRNA expression was observed in rEBV-infected HONE-1 cells. However, protein levels 
appeared to be increased in EBNA1-expressing and rEBV-infected cells in both cell panels 
(Figure 3.9B). Subsequent data mining of the NPC gene expression data revealed a significant 
upregulation of PPM1B transcripts in approximately 13/16 (81%) NPC tumours compared to 
normal epithelia (Figure 3.10). 
 
3.2.5.5 Validation of PPM1B shRNA oligonucleotides 
To further investigate the actions of this particular phosphatase, shRNA vectors specific for 
PPM1B were generated. shRNA-encoding oligonucleotide sequences were previously defined 
by Sun et al. (Sun et al., 2009), and were designed accordingly. Following ligation into the 
linearised pSUPER.retro.puro vector and transformation of chemically competent cells, 
clones for each vector were selected and double restriction digests were performed using 
EcoRI and HindIII enzymes to confirm the correct insertion of the shPPM1B sequences. As 
shown in Figure 3.11, reactions A, C and D for shPPM1B-1, and B and C for shPPM1B-2 
contained the 281bp fragment indicative of positive clones. DNA sequencing was then used to 
confirm precise and error-free cloning. Representative traces of the sequencing outputs are 
shown in Figure 3.12. 
 
To validate the functionality of the two PPM1B shRNAs, the vectors were transiently 
transfected into Ad/AH cells, and immunoblotting performed at 24-hour, 48-hour and 72-
hours post-transfection. Representative immunoblots are shown in Figure 3.13. While, as 
expected, the control pSUPER.retro.puro vector did not affect PPM1B expression levels, 
there were no marked differences in the levels of PPM1B protein expression in response to 
increasing concentrations of either shRNA at any of the given timepoints, except for a  
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Figure 3.10:  PPM1B expression in EBV-positive NPC tumour cells
Existing expression array data analysed using GCOS (Affymetrix) was probed for 
PPM1B expression levels. Normalised expression array intensities for 4 normal 
samples (yellow) and 15 NPC tumours plus the C666-1 EBV-positive NPC cell line 
(pink) are shown.
0
500
1000
1500
2000
2500
3000
M
S
T
A
M
H
A
U
M
B
E
Z
T
3
_
N
P
H
K
_
6
8
(8
)
H
K
_
4
0
0
(3
)
Y
H
_
N
P
C
7
H
K
_
D
1
7
3
5
7
0
M
D
IG
M
O
U
Z
M
K
E
C
X
Y
3
_
N
P
C
6
H
K
_
C
1
2
5
8
5
5
M
M
A
H
C
6
6
6
M
K
A
V
X
Y
3
_
N
P
C
5
X
Y
3
_
N
P
C
2
3
X
Y
3
_
N
P
C
8
Y
H
_
N
P
C
8
G
C
O
S
 s
ig
n
al
PPM1B
 
 103 
shPPM1B-1pS
u
p
er
retro
.p
u
ro A B C D
6349bp
~227bp
281bp 281bp
6349bp
~227bp
shPPM1B-2
CA B D
p
S
u
p
er
retro
.p
u
ro
Figure 3.11:  Restriction digestion to confirm the presence of the correct 
shPPM1B insert within recombinant pSUPER.retro vectors
Diagnostic EcoRI and HindIII restriction digestions were performed on plasmid 
DNA extracted from selected clones to validate the insertion of the annealed 
shPPM1B oligonucleotides into the pSUPER.retro plasmid. The empty 
pSUPER.retro vector was included as a control for efficient enzyme cutting. 
Reactions were analysed by gel electrophoresis. The 6349bp fragment 
represents the pSUPER.retro vector. The 281bp fragment identifies positive 
clones carrying the oligonucleotide insert, while the ~227bp fragment is 
indicative of negative clones. Two different oligonucleotide pairs were tested 
(shPPM1B-1 and shPPM1B-2). A plasmid map of pSUPER.retro.puro,  
highlighting its key features and generated using ApE Plasmid Editor software, 
is shown, adapted from the map found at:  
http://www.oligoengine.com/products/psuper/documentation/maps/pSUPER_ret
ro_puro_map.pdf
1441 HindIII (1)
H1 promoter 1420...1668
1668 EcoRI (1)
PGK 1669...2177
PurR 2202...2801
3' delta LTR 2931...3224
pSUPER.retro.puro
6349 bp
5' LTR 1...515
AmpR 5415...4558
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Figure 3.12:  Sequencing reactions to confirm the presence of the correct shPPM1B 
insert within recombinant pSUPER.retro vectors
The ABI Prism 310 protocol was used to sequence the predicted positives generated from 
the cloning of shPPM1B oligonucleotide sequences into the pSUPER.retro vector. The 
output of the sequencing reaction was visualised using the Chromas program and 
schematic representations for shPPM1B-1 (A) and shPPM1B-2 (B) are shown. Each 
peak represents a discrete signal from each base of the analysed sequence (red = thymine, 
green = adenine, blue = cytosine and black = guanine). The shRNA sequences are 
underlined in purple.
A)
B)
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Figure 3.13:  Validation of PPM1B shRNA constructs
Immunoblotting for levels of PPM1B protein on lysates collected from Ad/AH cells 24, 
48 and 72 hours after transient transfection with increasing concentrations of either of 
the two shPPM1B constructs (shPPM1B-1 or shPPM1B-2) or the pSUPER.retro control 
vector. Blots were re-probed for β-actin to confirm equal protein loading.
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marginal knockdown after 72hours with 1.5 and 2μg of shPPM1B-2. The time-course was 
therefore extended to 120 hours, where the 2μg shRNA concentration dramatically reduced 
PPM1B expression for both constructs (Figure 3.14). Efficient knockdown was also 
accomplished with 2μg shPPM1B-2 after 96 hours. As the effect was more dramatic using 
shPPM1B-2, this construct was selected for use in subsequent experiments. 
 
3.2.5.6 Dual knockdown of PPM1A and PPM1B is not sufficient to restore TGFβ activity 
It was predicted that, in the absence of one phosphatase, the other may be able to compensate, 
and therefore the effect of a dual knockdown was studied. shPPM1A881 and shPPM1B-2 
constructs were transfected, both individually, and in combination, into Neo control, EBNA1 
and rEBV-infected Ad/AH cells, and the resultant effects on TGFβ signalling determined 
using TGFβ/Smad luciferase reporter assays. So as to ensure knockdown of both genes, 
maximal amounts of each were used for transfection and, after 72 hours, the assay was 
stimulated for 24 hours with 5ng/ml TGFβ1, and then harvested a total of 96 hours post-
transfection. Luciferase activity was measured and normalised data are represented in Figure 
3.15. Neither transfection of shPPM1A881 nor shPPM1B 2 alone had a pronounced effect on 
the levels of TGFβ-induced p(CAGA)12-Luc and p(ARE)3-Luc reporter activity in EBNA1-
expressing and rEBV-infected Ad/AH cells. However, in combination, shRNA-knockdown of 
both PPM1A and PPM1B partially restored levels to those observed in the Neo control cells. 
These observations however were not borne out in the rEBV-infected Ad/AH cells, reflecting 
also the pattern in PPM1A immunofluorescence staining, suggesting that this mechanism may 
not be of significant importance in the context of a latent EBV infection. 
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Figure 3.14:  Extended time-course of PPM1B knockdown
Immunoblotting for levels of PPM1B protein in Ad/AH cells transiently transfected with 
increasing concentrations of either of the two shPPM1B constructs (shPPM1B-1 or 
shPPM1B-2) or the pSUPER.retro control vector, on lysates harvested 48, 72, 96 and 120 
hours post-transfection. Blots were re-probed for β-actin to confirm equal protein loading.
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Figure 3.15:  The effect of dual shRNA-mediated knockdown of PPM1A and PPM1B 
on TGFβ promoter activity
Dual luciferase reporter assay showing levels of p(CAGA)12-Luc activity in Ad/AH Neo, 
Ad/AH EBNA1 and Ad/AH rEBV cells transiently transfected with either the control 
pSUPER.retro, shPPM1A881 or shPPM1B-2 vectors, measured under basal conditions 
and in response to stimulation with 5ng/ml recombinant hTGFβ1 for 24 hours. Histograms 
are shown to depict the relative luminescence after normalising to Renilla luciferase values 
and expressing as a ratio of activity relative to the control vector pGL3-basic. Data from 
three independent experiments is presented as the mean fold differences in activity + SE, 
relative to that observed in unstimulated Ad/AH Neo control cells transfected with control 
vector, which is given an arbitrary value of 1 (** denotes a P-value <0.01 and *  denotes a 
P-value <0.05). 
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3.2.5.7 EBNA1 increases the expression of the E3 ubiquitin ligase NEDD4-2 in 
carcinoma cell lines and tumour biopsies 
Although dephosphorylation is thought to contribute towards dissociation of active Smad 
complexes in the nucleus, inactivation of the phosphorylated R-Smads is thought to require 
ubiquitination, which targets them for proteasomal degradation (Lo and Massagué, 1999, 
Heldin and ten Dijke, 1999, Zhang and Laiho, 2003). Abnormally high expression of a Smad 
ubiquitin ligase would negatively impact upon Smad stability and thereby contribute to TGFβ 
pathway inactivation (Lönn et al., 2009), and indeed the observed attenuation of TGFβ 
signalling in the presence of EBNA1 has previously been attributed to an increase in Smad2 
protein turnover (Wood et al., 2007, Flavell et al., 2008). Interrogation of the Affymetrix gene 
expression array data also identified an up-regulation of the ubiquitin ligase, NEDD4-2 
(neural precursor cell-expressed developmentally down-regulated gene 4-2, also known as 
NEDD4L), in EBNA1-expressing Ad/AH cells. NEDD4-2 is a member of the NEDD4 
HECT-type E3 ubiquitin ligase family (Yang and Kumar, 2010) and its expression is found to 
be up-regulated in several human carcinoma cell lines including lung, colon, gastric, breast, 
ovary and melanoma lines (Kuratomi et al., 2005). Research into the NEDD4-2 protein was 
initially focussed on its regulation of the epithelial sodium channel (ENaC) (Kamynina et al., 
2001). However, since then, NEDD4-2 over-expression in invasive gallbladder cancers has 
been reported to promote invasion through an up-regulation of MMP1 and MMP13 (Takeuchi 
et al., 2011) and, of most interest, TGFβ-induced NEDD4-2 binding to R-Smads to induce 
their ubiquitin-dependent degradation has been demonstrated (Kuratomi et al., 2005). 
 
The purported increase in NEDD4-2 expression in EBNA1-expressing Ad/AH cells, was 
validated by RT-PCR and immunoblotting analysis, and was extended to both rEBV-infected 
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Ad/AH cells, and their counterparts in the HONE-1 cell panel (Figure 3.16). Additionally, 
immunofluorescence staining was performed on the Ad/AH cell panel using a polyclonal 
rabbit antibody to NEDD4-2. Representative confocal images in Figure 3.16C show increased 
cytoplasmic NEDD4-2 staining was observed in the EBNA1 and rEBV-infected Ad/AH cells. 
In further support of this, the GCOS analysis of NPC tumour microarray data shown in Figure 
3.17 demonstrates that NEDD4-2 expression is increased in approximately 14/16 (88%) NPC 
tumours compared to normal epithelia. 
 
3.2.6 EBNA1 modulates the expression levels of TGFβ receptors, TβRI and TβRII, in a 
range of epithelial cell lines 
TGFβ signal transduction is highly dependent on the formation of a hetero-oligomeric 
receptor complex of both TβRI and TβRII (Yamashita et al., 1994, Chen et al., 1995, Vivien 
et al., 1995). Aberration of TGFβ signalling in carcinoma cells, in particular the development 
of resistance to its anti-proliferative and pro-apoptotic effects, frequently derives from a 
defect at the receptor level. Whereas a previous study suggested no significant changes in the 
mRNA and protein levels of TβRI and TβRII in EBNA1-expressing Ad/AH cells (Wood et 
al., 2007), RT-PCR analyses conducted in this study demonstrate increases at the 
transcriptional level in the expression of both TβRI and TβRII in Ad/AH, HONE-1 and AGS 
cell panels, findings that were confirmed by QPCR in Ad/AH and AGS cell lines, but not for 
TβRI in the HONE-1 cell line (Figure 3.18). 
 
Although an increase in expression of TβRI and TβRII in EBNA1-expressing cells was 
observed, it was hypothesised that a reduction in cell surface expression levels may reduce the 
availability of receptors for active participation in TGFβ signalling at any particular time,  
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Figure 3.16:  NEDD4-2 expression in Ad/AH and HONE-1 carcinoma cell lines
A) RT-PCR analysis for NEDD4-2 mRNA expression in Ad/AH and HONE-1 cells 
expressing either a control neomycin resistance cassette or EBNA1, or stably 
infected with rEBV. The housekeeping gene GAPDH was included as a positive 
control to confirm equal RNA input into the PCR reactions, while negative water 
controls confirmed the absence of contamination. 
B) Immunoblotting for NEDD4-2 protein levels in Ad/AH and HONE-1 cells 
expressing either a neomycin resistance cassette, or EBNA1, or stably infected with 
rEBV, with β-actin included to confirm equal protein loading. 
C) Immunofluorescence staining for expression of NEDD4-2 protein in Ad/AH cells 
expressing either a control neomycin resistance cassette or EBNA1, or infected with 
rEBV. DAPI staining was included to stain cellular nuclei. Representative confocal
images are shown. Bar = 20μm.
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Figure 3.17:  NEDD4-2 expression in EBV-positive NPC tumour cells
Existing expression array data analysed using GCOS (Affymetrix) was probed for 
NEDD4-2 expression levels. Normalised expression array intensities for 4 normal 
samples (yellow) and 15 NPC tumours plus the C666-1 EBV-positive NPC cell 
line (pink) are shown.
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A)
Figure 3.18:  TGFβ receptor expression in Ad/AH, HONE-1 and AGS carcinoma 
cell lines
RT-PCR and QPCR analysis for levels of TβRI and TβRII mRNA in Ad/AH (A), 
HONE-1 (B) and AGS (C) cells expressing either a control neomycin resistance cassette 
or EBNA1, or stably infected with rEBV. For RT-PCR, GAPDH was included as a 
positive control to confirm equal RNA input into the PCR reactions, while negative water 
controls confirmed the absence of contamination. For QPCR, GAPDH was included as 
an internal baseline control. Histograms are shown displaying the mean fold change 
differences SE (n=3) (** denotes a P-value <0.01 and * denotes a P-value <0.05).
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which is a direct determinant of signalling capability. Flow cytometric analysis was therefore 
performed to compare the levels of cell surface TGFβ receptor expression between Neo 
control, EBNA1-expressing and rEBV-infected Ad/AH cells following incubation with either 
a rabbit polyclonal antibody to TβRI or a goat polyclonal antibody to TβRII. Data was 
analysed using the WinMDI program and graphical representations of the analyses are shown 
in Figure 3.19. Results indicated that levels of cell surface TGFβ receptors appeared to be 
reduced in EBNA1-expressing and rEBV-infected Ad/AH cells. While the relative mean 
fluorescence intensity (MFI) values indicate that this effect was only marginal for the surface 
expression of TβRI, a reduction of approximately fifty percent was observed for TβRII in 
EBNA1-expressing and rEBV-infected Ad/AH cells compared to Neo control cells. 
 
3.2.6.1 Degradation of the TGFβ type I receptor, TβRI, is increased in the presence of 
EBNA1 
Expression and activity of receptors is largely regulated by a variety of receptor-interacting 
proteins and distinct endocytic processes (Runyan et al., 2006, Chen, 2009). Traditionally 
considered a mechanism for terminating receptor signalling, endocytosis has since been 
recognised to have important consequences in signalling modulation (Penheiter et al., 2002, 
Penheiter et al., 2010). Endocytosis of TGFβ receptors is not only important in mediating 
rapid receptor degradative turnover, but also crucial in ensuring efficient recycling of 
receptors to the cell surface (Di Guglielmo et al., 2003, Chen, 2009). While internalisation of 
receptors into EEA1-positive endosomes is found to enhance TGFβ signal transduction 
through receptor recycling, partitioning via the lipid-raft-caveolar pathway promotes 
termination of the signal by controlling degradation (Hayes et al., 2002, Di Guglielmo et al., 
2003). It was hypothesised that the observed reduction in expression at the cell surface may  
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A)
Figure 3.19:  Flow cytometric analysis of TGFβ receptor expression in Ad/AH cells
Flow cytometric analysis of surface TβRI (A) and TβRII (B) expression in Ad/AH cells 
expressing either a neomycin resistance cassette or EBNA1, or stably infected with rEBV. 
Cells were incubated with antibodies specific to either TβRI or TβRII, or an anti-IgG
antibody as an isotype control. Graphical representations of the analyses are displayed. 
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be a result of an accelerated rate of receptor turnover. While TβRII is essential for the binding 
of the TGFβ ligand, it is TβRI that is directly responsible for Smad activation. Therefore the 
turnover rate of TβRI was examined following treatment of Neo control, EBNA1-expressing 
and rEBV-infected Ad/AH cells with the protein synthesis inhibitor, cycloheximide (CHX). 
The Ad/AH cell panel were seeded into 6-well plates and treated with 20μg/ml CHX; protein 
lysates were collected at 0, 1, 3, 6, 9 and 12 hours after CHX addition. Subsequent 
immunoblotting of the lysates for TβRI revealed a more rapid turnover of TβRI protein in 
both EBNA1-expressing and rEBV-infected Ad/AH cells compared to the Neo controls. 
Control treatment with DMSO as expected revealed no changes in expression level 
throughout the time-course. Densitometry was performed and data plotted on a scatterplot, 
shown in Figure 3.20, from which the half-life of TβRI was seen to be reduced from 6 hours 
in control cells to 4 and 3.5 hours in EBNA1 and rEBV-infected cells, respectively. 
 
3.2.6.2 EBNA1 modulates the expression of factors associated with TGFβ receptor 
endocytosis 
In an attempt to further characterise these observations, various components of the endocytic 
pathway machinery were investigated.  Dab2 which, at the time of its identification in 1994, 
was labelled a tumour suppressor gene (Mok et al., 1994), has since been found to be 
frequently down-regulated in human cancers, including human squamous cell carcinoma 
(Hannigan et al., 2010). Recently, epigenetic inactivation of the Dab2 gene promoter has also 
been reported in NPC (Tong et al., 2010). A role for Dab2 has been established in TGFβ 
receptor trafficking, specifically as a key adaptor protein in the clathrin-dependent recycling 
of receptors via endosomes (Morris and Cooper, 2001, Mishra et al., 2002, Gong et al., 2008, 
Penheiter et al., 2010). These EEA1-positive endosomes are also enriched for the Smad  
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Figure 3.20:  The effect of EBNA1 on the half-life of TβRI in Ad/AH cells
A) Immunoblotting for protein levels of TβRI in Ad/AH Neo, Ad/AH EBNA1 and Ad/AH 
rEBV cells following treatment with cycloheximide (CHX), or DMSO as a control, over a 
12-hour time-course. Blots were re-probed with a monoclonal antibody against β-actin to 
confirm equal protein loading. 
B) Densitometric scanning was performed on the TβRI immunoblot representing CHX-
treated samples and the corresponding β-actin. Following normalisation of densitometry 
values for TβRI against β-actin, an X and Y scatterplot was generated illustrating the half-
life of TβRI in Ad/AH EBNA1 and rEBV-infected cells compared with Ad/AH Neo 
control cells.
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anchor for receptor activation (SARA) protein (Itoh et al., 2002, Di Guglielmo et al., 2003, 
Runyan et al., 2005), which enhances TGFβ signalling by positioning R-Smads in close 
proximity with receptors (Tsukazaki et al., 1998).  
 
Representative RT-PCR analysis of Dab2 and SARA mRNA levels in the Ad/AH, HONE-1 
and AGS cell panels is shown in Figure 3.21. While the expression of Dab2 appeared to be 
elevated in EBNA1-expressing and rEBV-infected Ad/AH cell lines, relative to Neo control 
cells, its expression was decreased in HONE-1 and AGS cells expressing EBNA1 or infected 
with rEBV; no major differences in the transcription of SARA were observed between 
EBNA1-expressing and rEBV-infected cell lines. 
 
Caveolin-1 (Cav-1), a principal structural marker of lipids rafts (Razani et al., 2001), has been 
reported to impact both positively and negatively on aspects of tumour progression (reviewed 
in (Williams and Lisanti, 2005, Goetz et al., 2008)), but is reportedly over-expressed in NPC 
tumour samples (Du et al., 2009). These caveolin-positive lipid rafts also contain complexes 
of Smad7 and Smurf2, which facilitate receptor turnover (Kavsak et al., 2000, Di Guglielmo 
et al., 2003). The relative expression of all three genes was examined by RT-PCR; a 
representative analysis is shown in Figure 3.22. This analysis revealed increased levels of 
Cav-1, Smad7 and Smurf2 mRNA in EBNA1-expressing and rEBV-infected cells in all three 
cell backgrounds. To validate these findings, immunofluorescence staining for Cav-1 protein 
was performed on Neo control, EBNA1-expressing and rEBV-infected Ad/AH cells (Figure 
3.23). The relevance of these findings, as related to NPC pathogenesis, was examined by 
mining the Affymetrix gene expression profiles of 15 authentic NPC tumours and the EBV-
positive C666-1 cell line compared to 4 normal samples. GCOS analysis of microarray data,  
 122 
A)
Neo EBNA1 rEBV H2O
Ad/AH
EBNA1
GAPDH
Dab2
SARA
Figure 3.21:  Dab2 and SARA expression in Ad/AH, HONE-1 and AGS 
carcinoma cell lines
RT-PCR analysis for mRNA levels of Dab2 and SARA in Ad/AH (A), HONE-1 (B) 
and AGS (C) cells expressing either a control neomycin resistance cassette or 
EBNA1, or stably infected with rEBV. GAPDH was included as a positive control to 
confirm equal RNA input into the PCR reactions, while negative water controls 
confirmed the absence of contamination.
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Figure 3.22:  Cav-1, Smad7 and Smurf2 expression in Ad/AH, HONE-1 and 
AGS carcinoma cell lines
RT-PCR analysis for mRNA levels of Cav-1, Smad7 and Smurf2 in Ad/AH (A), 
HONE-1 (B) and AGS (C) cells expressing either a control neomycin resistance 
cassette or EBNA1, or stably infected with rEBV, with GAPDH was included as a 
positive control to confirm equal RNA input into the PCR reactions, while negative 
water controls confirmed the absence of contamination.
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showing relative normalised array intensities, revealed that the expression of Cav-1, Smad7 
and Smurf2 was up-regulated in approximately 9/16 (56%), 11/16 (69%) and 7/16 (44%) of 
NPC tumours (Figure 3.24). 
 
3.2.7 Expression levels of the TGFβ isoforms are augmented in the presence of EBNA1 
An important determinant of a cell’s response to TGFβ ligand stimulation is the concentration 
and species of ligand produced by the cells themselves. Such “autocrine” production of TGFβ 
ligands can dictate cellular responsiveness to additional ligand stimulation (Clarke et al., 
2009). To explore the possibility that EBNA1 and rEBV-infected cells were producing 
elevated levels of TGFβ family ligands, the relative expression levels of the canonical TGFβ 
ligands, TGFβ1, 2 and 3, were examined by RT-PCR, and subsequently by QPCR (Figure 
3.25) in the Ad/AH, HONE-1 and AGS panels of cell lines. RT-PCR indicated increased 
expression of TGFβ1, 2 and 3 in EBNA1-expressing Ad/AH cells, yet only of TGFβ2 in 
rEBV-infected Ad/AH cells. However, TGFβ1 levels were relatively unchanged in both 
EBNA1-expressing and rEBV-infected HONE-1 and AGS cells, yet expression of TGFβ2 
appeared to be significantly increased and TGFβ3 decreased in both EBNA1-expressing 
HONE-1 and AGS cells. These effects were further investigated by QPCR analysis which 
confirmed an increase in TGFβ1 in Ad/AH EBNA1 cells and showed a modest increase in 
EBNA1-expressing and rEBV-infected AGS cells. TGFβ2 meanwhile was increased in all 
three cell lines in both EBNA1-expressing and rEBV-infected cells, and TGFβ3, while 
increased in Ad/AH EBNA1, was decreased in AGS EBNA1 and HONE-1 EBNA1 and 
rEBV-infected cells. 
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Figure 3.24:  Cav-1, Smad7 and Smurf2 expression in EBV-positive NPC tumour 
cells
Existing expression array data analysed using GCOS (Affymetrix) was probed for Cav-1, 
Smad7 and Smurf2 expression levels. Normalised expression array intensities for 4 
normal samples (yellow) and 15 NPC tumours plus the C666-1 EBV-positive NPC cell 
line (pink) are shown.
A)
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A)
Figure 3.25:  TGFβ isoform expression in Ad/AH, HONE-1 and AGS carcinoma 
cell lines
RT-PCR and QPCR analysis for TGFβ1, TGFβ2 and TGFβ3 mRNA expression in 
Ad/AH (A), HONE-1 (B) and AGS (C) cells expressing either a control neomycin 
resistance cassette or EBNA1, or stably infected with rEBV. For RT-PCR, GAPDH 
was included as a positive control to confirm equal RNA input into the PCR reactions, 
while negative water controls confirmed the absence of contamination. For QPCR, 
GAPDH was included as an internal baseline control. Histograms are shown 
displaying the mean fold change differences SE (n=3) relative to Neo control cells 
(** denotes a P-value <0.01 and * denotes a P-value <0.05).
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3.2.7.1 The secretion of TGFβ is increased in EBNA1-expressing cells 
TGFβ is initially synthesised and secreted as a biologically inert prohormone precursor, 
designated the small latent complex (SLC), consisting of a C-terminal fragment, which 
constitutes the mature growth factor, and the N-terminal propeptide, termed the latency-
associated peptide (LAP) (Annes et al., 2003, Javelaud and Mauviel, 2004). This is often 
additionally covalently associated with latent TGFβ-binding protein (LTBP) forming the large 
latent complex (LLC), probably as a means of localising the inactive complex to the 
extracellular matrix. The majority of cell types secrete TGFβ as part of the LLC (Wipff and 
Hinz, 2008), and its activation from this complex, often involving proteolytic cleavage, is a 
critical rate-limiting step in determining its signalling potential (Khalil, 1999, Javelaud and 
Mauviel, 2004). The exact mechanism for activation of TGFβ in vivo is not fully understood, 
yet putative roles have been reported for plasmin, cathepsins B and D, calpain, 
thrombospondin-1, furin, matrix metalloproteinases, integrins and BMP1-like proteinases 
(Khalil, 1999, Jenkins, 2008, Munger et al., 1999, Wipff and Hinz, 2008, Ge and Greenspan, 
2006).  
 
Whilst the level and nature of intracellular TGFβ signalling can be extensively studied using 
an array of molecular and biochemical assays and techniques, it has proven more difficult to 
accurately quantify the levels of active TGFβ generated by particular cells (Mazzieri et al., 
2000). However, an integral PAI-1 luciferase assay using the mink lung cell line, MLEC-
clone32 can be used as a relatively sensitive assay technique. These cells are stably 
transfected with an 800bp fragment of the PAI-1 gene fused to the firefly luciferase reporter 
gene, the activity of which is directly translated into an appreciation of the levels of TGFβ 
actively secreted by cells. Activation of latent TGFβ can be artificially induced in vitro by 
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extreme pH, high heat, chaotropic agents and substances like SDS and urea (Khalil, 1999) 
and, advantageously, the assay can encompass treatments to activate the latent fraction in 
order to provide an overall estimate of the total TGFβ released (Mazzieri et al., 2000). 
 
In brief, conditioned supernatants collected from serum-starved Neo control, EBNA1-
expressing and rEBV-infected Ad/AH cells at 24-, 48-, and 72-hour time-points were 
incubated overnight with MLEC-clone32 cells, which were subsequently analysed for 
luciferase reporter activity. Results are represented graphically in Figure 3.28. An increase in 
the levels of active secreted TGFβ in EBNA1-expressing and rEBV-infected cells was 
observed in the untreated sample set (Figure 3.26A), while samples activated by heat 
treatment also demonstrated an increase in the total TGFβ levels in these cells (Figure 3.26B). 
Additionally, pre-treatment of samples with 10μg/ml pan-anti-TGFβ neutralising antibody 
(clone 1D11) to neutralise TGFβ bioactivity served to confirm the specificity of the assay by 
effectively reducing TGFβ levels back down to diminutive levels. The ratio of active: latent 
TGFβ measured in the conditioned media samples was calculated and data is shown, using the 
48-hour timepoint as an example, represented graphically as pie charts in Figure 3.26C. 
Although the effects are relatively small, the proportion of active TGFβ was increased in both 
EBNA1-expressing and rEBV-infected Ad/AH cells in comparison with Neo control cells. 
 
3.2.8 EBNA1 does not influence cell cycle distribution in response to TGFβ in Ad/AH 
carcinoma cells 
Several viral oncoproteins have shown the ability to override growth-suppressive signals, 
deregulating cell-cycle control so as to promote host cell proliferation (Jansen-Dürr, 1996), 
and cellular transformation driven by the adenovirus E1A oncogene has been specifically 
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A)
Figure 3.26:  Measurement of TGFβ secretion in Ad/AH cells using the PAI-1L assay
A) Conditioned media samples were collected after 24, 48 and 72 hours from serum-starved 
Ad/AH Neo, Ad/AH EBNA1 and Ad/AH rEBV cells, and were applied to MLEC-clone32 
cells. Luciferase activity was determined following incubation overnight. The histogram 
shown displays the relative luminescence after subtracting 0.5% serum medium control 
background values. Incubation of samples with anti-TGFβ antibody (clone 1D11) prior to 
addition to the reporter cells confirmed assay specificity. Data from three independent 
experiments is presented as the mean fold differences in activity + SE, relative to that 
observed in the 24-hour Ad/AH Neo control cell sample which is given an arbitrary value of 
1 (** denotes a P-value <0.01 and * denotes a P-value <0.05). 
B) The PAI-1L assay was performed as above using heat-inactivated conditioned media 
samples. Results are depicted as a histogram showing the relative luminescence after 
subtracting heat-treated 0.5% serum medium control background values. Data from three 
independent experiments is presented as the mean fold differences in activity + SE, relative 
to that observed in the 24-hour Ad/AH Neo control cell sample which is given an arbitrary 
value of 1 (** denotes a P-value <0.01 and * denotes a P-value <0.05).
C) Pie charts show the levels of active secreted TGFβ (untreated) expressed as a proportion of 
the total TGFβ (heat-activated) levels measured in conditioned media samples taken after 48 
hours incubation from Ad/AH Neo, EBNA1 and rEBV-infected cells.
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associated with development of cellular resistance to growth inhibitory effects of TGFβ (Kim 
et al., 1997). Due to its confirmed ability to inhibit TGFβ signalling, and particularly the 
alteration of cell surface receptor expression and increased TGFβ secretion, it was reasoned 
that EBNA1 may specifically aid the acquisition of resistance to TGFβ-mediated G1 growth 
arrest, as a direct means of promoting tumour cell proliferation. This was investigated by 
examining cell cycle distribution. To this end, cells were treated with TGFβ1 (5ng/ml) for 24 
hours and fixed in 95% ethanol, before staining with propidium iodide and analysis by flow 
cytometry. Cell cycle profiles were subsequently generated using MultiCycle, and 
representative traces from three independent experiments are shown in Figure 3.27. In all 
instances, Neo control, EBNA1-expressing and rEBV-infected Ad/AH cells failed to respond 
to TGFβ by undergoing cell cycle arrest in the G1 phase. No significant changes in cell cycle 
distribution were observed in any of the cell lines, regardless of the presence of EBNA1 or 
rEBV. 
 
3.3 EBNA1 augments a number of the tumour-promoting functions of TGFβ 
3.3.1 EBNA1 expression increases Smad2 and Smad3 phosphorylation at specific 
linker region residues 
While the anti-proliferative response appears unaffected by EBNA1, it was reasoned that 
EBNA1 may instead function to promote the pro-tumourigenic functions of TGFβ. Reports 
have suggested that increased phosphorylation at Smad linker regions can encourage this 
switch. Relative expression levels of various Smad2 and Smad3 phospho-isoforms were 
examined by immunoblotting of protein lysates from Ad/AH, HONE-1 and AGS cell panels, 
and representative immunoblots are shown in Figure 3.28. An increase in expression of 
pSmad2 Ser245/250/255 and Thr220, and pSmad3 Ser204, Ser208, Ser213 and Thr179 was  
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Figure 3.27:  Cell cycle analysis by propidium iodide staining of Ad/AH cells
Analysis of cell cycle in serum-starved Ad/AH cells expressing either a control neomycin 
resistance cassette or EBNA1, or infected with rEBV, treated with 5ng/ml recombinant 
hTGFβ1 for 24 hours or left unstimulated as a control. DNA content was measured by 
propidium iodide staining and subsequent flow cytometric analysis. Resulting histogram files 
were analysed for cell cycle distribution using MultiCycle. Representative traces from one of 
three independent experiments are shown, with percentages of cells in G1, S and G2-M 
phases indicated.
Untreated
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Figure 3.28:  Expression of linker phosphorylated Smad2 and Smad3 in Ad/AH, 
HONE-1 and AGS cells
Immunoblotting for protein levels of the serine 245/250/255 and threonine 220 
phosphorylated forms of Smad2, and the serine 204, serine 208, serine 213 and threonine 179 
phosphorylated forms of Smad3 in serum-starved Ad/AH (A), HONE-1 (B) and AGS (C) 
cells expressing either a control neomycin resistance cassette or EBNA1, or stably infected 
with rEBV, under basal conditions and following stimulation with 5ng/ml recombinant 
hTGFβ1 for 24 hours. Immunoblotting for levels of total Smad2 and Smad3, and also 
EBNA1 protein expression in cell lysates is also shown, with β-actin included to confirm 
equal protein loading.
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observed in Ad/AH EBNA1 cells, and was generally repeated in the rEBV cells, with the 
exception of pSmad2 Ser245/250/255 and pSmad3 Ser213. In the HONE-1 cell panel, 
increasing levels of pSmad2 Ser245/250/255 and Thr220, and pSmad3 Ser204 and Thr179 
were observed in the EBNA1-expressing cells, while in AGS EBNA1 cells, only pSmad3 
Ser204 and Thr179 expression were increased. 
 
3.3.2 EBNA1 may activate non-Smad signalling pathways to increase Smad linker 
phosphorylation 
A recent interpretation of the role of Smad linker region phosphorylation is that it can be used 
to regulate the potential for transcriptional activity of the oligomeric Smad complex (Burch et 
al., 2010). The result is variable, in some cases inhibiting transcriptional activity, whereas in 
others enhancing TGFβ-induced transcription (Wrighton et al., 2006, Alarcón et al., 2009, 
Gao et al., 2009). This discrepancy ultimately seems dependent on both the availability and 
location of the specific kinases involved. Linker phosphorylation by cytosolic MAPKs, for 
example, phosphorylation by p38 MAPK and ROCK (at Smad3 Ser204, Ser208 and Ser213), 
and JNK (at Smad3 Ser208 and Ser213) generally results in enhancement of gene 
transcription (Engel et al., 1999, Mori et al., 2004, Kamaraju and Roberts, 2005), particularly 
of the Smad-dependent expression of extracellular matrix protein-related genes and matrix 
metalloproteinases (Burch et al., 2010, Matsuzaki et al., 2009). Similarly, TGFβ-induced 
JNK1 phosphorylation at MAPK sites in linker region of Smad3 results in the induction of 
EMT-related genes in lung epithelial cells (van der Velden et al., 2011). In contrast, if linker 
phosphorylation is delayed until the protein has translocated to the nucleus following 
prerequisite C-terminal phosphorylation, the effect is largely antagonistic, inhibiting 
transcriptional activity, conferring resistance to growth inhibitory effects, and often priming 
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for degradation (Burch et al., 2010). CDK family members, as well as nuclear MAPKs, play a 
significant role here, as Smad3 Thr179 and Ser213 are reportedly phosphorylated by CDK2/4, 
and CDK phosphorylation of Smad3 at Ser208 acts as a priming site for the activity of GSK3, 
which phosphorylates Smad3 at Ser204, decreasing Smad3 transcriptional activity (Millet et 
al., 2009, Wang et al., 2009). Moreover, CDK4-dependent Smad2/3 linker phosphorylation 
can override the TGFβ growth response through an up-regulation of c-myc (Matsuzaki et al., 
2009), and phosphorylation in the nucleus by CDK8 and CDK9 is reported to render Smads 
subject to proteasome-mediated turnover (Alarcón et al., 2009). 
 
To further characterise this observed linker phosphorylation, the expression levels of 
associated kinases and their active forms were measured by immunoblotting analysis. Neo 
control, EBNA1-expressing and rEBV-infected Ad/AH cells were grown in 0.5% serum for 
16 hours before treatment with 5ng/ml TGFβ1 for 24 hours. Extracted protein samples were 
resolved by SDS-PAGE and membranes were probed using antibodies against JNK, pJNK, 
ERK, pERK, p38, p-p38, GSK3β and pGSK3α/β, with β-actin as a loading control. From 
Figure 3.29, it is apparent that the total levels of most kinases were largely unchanged, as was 
the case for most of the phosphorylated forms, with the exception of pERK and pJNK, whose 
expression was increased in the EBNA1-expressing and rEBV-infected Ad/AH cells. 
 
To extend these observations, Neo control, EBNA1-expressing and rEBV-infected Ad/AH 
cells were again cultured in 0.5% serum for 16 hours before treatment with a panel of 
inhibitors for 1 hour prior to stimulation with 5ng/ml TGFβ1 for 24 hours. Protein extracts 
were resolved by SDS-PAGE and subjected to immunoblotting with antibodies to the linker 
Smad phospho-isoforms. Representative immunoblots are shown in Figure 3.30. SB431542, a  
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Figure 3.29:  Expression of Smad linker region kinases in Ad/AH cells
Immunoblotting for protein levels of total GSK3β, serine 21/9 phosphorylated GSK3α/β, 
total JNK, threonine 183/tyrosine 185 phosphorylated JNK, total ERK 1/2 (p42/44 
MAPK), phosphorylated p42/44, total p38 and threonine 180/tyrosine 182 phosphorylated
p38 in serum-starved Ad/AH cells expressing either a control neomycin resistance cassette 
or EBNA1, or stably infected with rEBV, under basal conditions or following stimulation 
with 5ng/ml recombinant hTGFβ1 for 24 hours. Blots were re-probed for β-actin to 
confirm equal protein loading.
Ad/AH 
Neo
Ad/AH 
EBNA1
Ad/AH 
rEBV
p-p38
p38
GSK3β
pGSK3α/β
JNK
pJNK
ERK
pERK
β-actin
TGFβ (5ng/ml)            - +           - +     - +     
46kDa
46,51kDa
46,54kDa
54kDa
42,44kDa
43kDa
43kDa
42kDa
42,44kDa
MW
 
 143 
 
A
) F
ig
u
re
 3
.3
0
: 
 E
x
p
re
ss
io
n
 o
f 
li
n
k
er
 p
h
o
sp
h
o
ry
la
te
d
S
m
a
d
2
 a
n
d
 S
m
a
d
3
 i
n
 A
d
/A
H
 c
el
ls
 f
o
ll
o
w
in
g
 k
in
a
se
in
h
ib
it
o
r 
tr
ea
tm
en
ts
Im
m
u
n
o
b
lo
tt
in
g
fo
r 
p
ro
te
in
 l
ev
el
s 
o
f 
th
e 
se
ri
n
e 
2
4
5
/2
5
0
/2
5
5
 a
n
d
 t
h
re
o
n
in
e
2
2
0
 p
h
o
sp
h
o
ry
la
te
d
fo
rm
s 
o
f 
S
m
ad
2
, 
an
d
 t
h
e 
se
ri
n
e 
2
0
4
, 
se
ri
n
e 
2
0
8
, 
se
ri
n
e 
2
1
3
 a
n
d
 t
h
re
o
n
in
e
1
7
9
 p
h
o
sp
h
o
ry
la
te
d
fo
rm
s 
o
f 
S
m
ad
3
, 
in
 s
er
u
m
-s
ta
rv
ed
 A
d
/A
H
 c
el
ls
 e
x
p
re
ss
in
g
 e
it
h
er
 a
 c
o
n
tr
o
l 
n
eo
m
y
ci
n
 r
es
is
ta
n
ce
 c
as
se
tt
e 
o
r 
E
B
N
A
1
, 
o
r 
st
ab
ly
 i
n
fe
ct
ed
 w
it
h
 r
E
B
V
. 
C
el
ls
 w
er
e 
tr
ea
te
d
 w
it
h
 a
 p
an
el
 o
f 
sp
ec
if
ic
 k
in
as
e
in
h
ib
it
o
rs
 a
s 
in
d
ic
at
ed
 f
o
r 
1
 h
o
u
r 
b
ef
o
re
 s
ti
m
u
la
ti
o
n
 w
it
h
 5
n
g
/m
l 
re
co
m
b
in
an
t 
h
T
G
F
β
1
 f
o
r 
a 
fu
rt
h
er
 2
4
 h
o
u
rs
, 
o
r 
le
ft
 u
n
st
im
u
la
te
d
as
 c
o
n
tr
o
ls
. 
B
lo
ts
 
w
er
e 
re
-p
ro
b
ed
 f
o
r 
β
-a
ct
in
to
 c
o
n
fi
rm
 e
q
u
al
 p
ro
te
in
 l
o
ad
in
g
.
p
S
m
a
d
3
 T
1
7
9
E
B
N
A
1
β
-a
ct
in
T
G
F
β
(5
n
g
/m
l)
   
  
  
-
+
  
  
 -
+
  
  
  
-
+
  
  
 -
+
  
  
 -
+
  
  
  
-
+
  
  
  
-
+
  
  
-
+
  
  
 -
+
  
  
-
+
  
  
  
-
+
  
  
-
+
  
p
S
m
a
d
2
 
S
2
4
5
/2
5
0
/2
5
5
p
S
m
a
d
3
 S
2
0
4
p
S
m
a
d
3
 S
2
0
8
p
S
m
a
d
3
 S
2
1
3
S
B
4
3
1
5
4
2
 (
1
0
μ
M
) 
  
  
  
-
-
+
  
  
 +
  
  
  
-
-
-
-
-
-
+
  
  
+
  
  
  
-
-
-
-
-
-
+
+
  
  
  
-
-
-
-
S
P
6
0
0
1
2
5
 (
1
0
μ
M
) 
  
  
  
-
-
-
-
+
  
  
 +
  
  
 -
-
-
-
-
-
+
  
  
 +
  
  
 -
-
-
-
-
-
+
  
  
 +
  
  
 -
-
U
O
1
2
6
 (
1
0
μ
M
) 
  
  
  
-
-
-
-
-
-
+
  
  
 +
  
  
 -
-
-
-
-
-
+
  
  
 +
  
  
  
-
-
-
-
-
-
+
  
  
 +
 
A
d
/A
H
 N
eo
A
d
/A
H
 E
B
N
A
1
A
d
/A
H
 r
E
B
V
p
S
m
a
d
2
 T
2
2
0
6
0
k
D
a
4
8
k
D
a
5
4
k
D
a
4
8
k
D
a
4
8
k
D
a
5
5
-6
0
k
D
a
7
0
k
D
a
4
2
k
D
a
M
W
 144 
 
B
)
E
B
N
A
1
p
S
m
a
d
3
 S
2
1
3
p
S
m
a
d
3
 S
2
0
8
p
S
m
a
d
3
 S
2
0
4
p
S
m
a
d
2
 
S
2
4
5
/2
5
0
/2
5
5
p
S
m
a
d
2
 T
2
2
0
p
S
m
a
d
3
 T
1
7
9
S
B
2
0
3
5
8
0
 (
1
0
μ
M
) 
  
  
 -
-
-
-
+
  
  
+
  
  
 -
-
-
-
-
-
+
  
  
+
  
  
-
-
-
-
-
-
+
  
  
 +
  
  
 -
-
S
B
2
1
6
7
5
3
 (
1
0
μ
M
) 
  
  
 -
-
-
-
-
-
+
  
  
 +
  
  
 -
-
-
-
-
-
+
  
  
  
+
  
  
 -
-
-
-
-
-
+
  
  
+
 
F
la
v
o
p
ir
id
o
l
(0
.3
μ
M
) 
  
  
 -
-
+
  
  
 +
  
  
 -
-
-
-
-
-
+
  
  
  
+
  
  
 -
-
-
-
-
-
+
  
 
+
  
  
 -
-
-
-
T
G
F
β
(5
n
g
/m
l)
   
  
 -
+
  
  
  
 -
+
  
  
 -
+
  
  
 -
+
  
  
  
-
+
  
  
  
 -
+
  
  
 -
+
  
 -
+
  
  
 -
+
  
  
  
-
+
  
  
 -
+
  
  
 -
+
A
d
/A
H
 N
eo
A
d
/A
H
 E
B
N
A
1
A
d
/A
H
 r
E
B
V
β
-a
ct
in
6
0
k
D
a
4
8
k
D
a
5
4
k
D
a
4
8
k
D
a
4
8
k
D
a
5
5
-6
0
k
D
a
7
0
k
D
a
4
2
k
D
a
M
W
 145 
potent TβRI kinase inhibitor, was used to distinguish those responses that may rely on an 
initial C-terminal phosphorylation for nuclear targeting, and was seen to reduce 
phosphorylation at pSmad2 Ser245/250/255 and Thr220, and pSmad3 Ser208 and Ser213 
residues. The JNK inhibitor, SP600125 reduced expression of the Ser208-phosphorylated 
Smad3, while U0126, a MEK-ERK/MAPK inhibitor, reduced phosphorylation at pSmad2 
Ser245/250/255 and pSmad3 Ser208 residues. The greatest effects were seen with the CDK 
inhibitor, flavopiridol, which reduced phosphorylation of Smad2 at Ser245/250/255 and 
Thr220, and of Smad3 at Ser204, Ser213 and T179. This is consistent with the reported role 
for CDKs in the phosphorylation of these residues. The p38 MAPK inhibitor, SB203580, and 
GSK3 inhibitor, SB216753, in contrast appeared to have little effect in this context.  
 
3.3.3 EBNA1 increases the migration of carcinoma cells 
An increase in linker phosphorylation and also TGFβ over-expression have been specifically 
correlated with an increase in the invasive capacity of tumour cells (Matsuzaki and Okazaki, 
2006, Tobin et al., 2002). In agreement with this, transwell migration assays confirmed that 
EBNA1-expressing cells, like their rEBV-infected counterparts, displayed increased rates of 
migration on fibronectin compared to Neo control cells (Figure 3.31). However, whereas 
treatment with the TβRI inhibitor, SB431542 enhanced the migration of Ad/AH Neo control 
cells, SB431542 treatment reduced the rates of migration in EBNA1-expressing and rEBV-
infected cells, findings which suggest that dysregulated TGFβ signalling contributes to the 
increased motile responses in these cells. This feature was not confined to Ad/AH cells, as 
SB431542 treatment also potentiated the migration of HONE-1 and AGS Neo clones, yet 
reduced the migration of EBNA1-expressing and rEBV-infected AGS cell lines (Figure 
3.31B&C).  
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Figure 3.31:  The effect of inhibition of TGFβ signalling on the migration of Ad/AH, HONE-1 and 
AGS carcinoma cell lines
Serum-starved Ad/AH (A), HONE-1 (B) and AGS (C) cells expressing either a control neomycin 
resistance cassette or EBNA1, or stably infected with rEBV were seeded into the upper wells of transwell
migration chambers in serum-free medium with and without 10μM SB431542, and allowed to migrate for 
24 hours. The number of migrated cells in five representative fields were counted and histograms were 
created showing the mean number of cells migrated ( SD) (** denotes a P-value <0.01).
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Unexpectedly, SB431542 treatment failed to impact on the migration of EBNA1-expressing 
and rEBV-infected HONE-1 cell lines (Figure3.31A, B & C). 
 
3.4 Modelling TGFβ signalling in C666-1 cells 
3.4.1 A constitutively active TβRI mutant restores TGFβ activity in C666-1 cells 
In comparison to normal samples, the EBV-positive C666-1 cell line was found to 
approximate an authentic NPC tumour in terms of its gene expression pattern by microarray 
analyses, and can be considered a good in vitro model for NPC (Hu, PhD thesis, 2010). In 
attempting to model TGFβ signalling in this cell line, it was essential that inherent defects in 
the pathway, attributed to an absence in expression of TβRII (Wood et al., 2007), were taken 
into account. Signalling is strictly dependent on receptor complex formation, as TβRII is 
essential for phosphorylation of TβRI, which is unable to recognise free TGFβ ligand of its 
own accord, and requires this activation for further signal propagation (Wrana et al., 1994, 
Zwaagstra et al., 2008). It was hypothesised that the introduction of a constitutively active 
TβRI variant (T204D) may bypass the TβRII defect in C666-1 cells, thereby testing the 
functional integrity of the remainder of the pathway. To this end, increasing concentrations of 
TβRI (T204D) were transiently transfected into C666-1 cells and their effects studied by 
TGFβ/Smad-luciferase reporter assay (Figure 3.32). The introduction of the constitutively 
active TβRI was sufficient to significantly induce the otherwise absent activity of the TGFβ-
responsive p(CAGA)12-luciferase reporter, while titration of a wild-type version of TβRI had 
little or no effect. 
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Figure 3.32:  Bypassing of the TβRII defect in C666-1 cells using a 
constitutively active TβRI
Dual luciferase reporter assay showing p(CAGA)12-Luc activity in C666-1 cells 
following transient transfection with either a wild-type TβRI, a constitutively active 
TβRI T204D, or the control pcDNA3 vector. A histogram is shown to depict the 
relative luminescence after normalising to Renilla luciferase values and expressing 
as a ratio of activity relative to the control vector pGL3-basic. Data from four 
independent experiments is presented as the mean fold differences in activity + SE, 
relative to that observed in C666-1 cells transfected with the pcDNA3 vector only 
which is given an arbitrary value of 1 (** denotes a P-value <0.01 and * denotes a 
P-value <0.05). 
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3.4.2 Re-establishment of TβRII expression in C666-1 cells restores TGFβ activity and 
R-Smad C-terminal phosphorylation 
In a previous study, Biswas and colleagues reported that expression of the TβRII gene could 
be restored in colon cancer cells where microsatellite instability induces mutational 
inactivation (Biswas et al., 2008). These plasmids were obtained in an attempt to restore 
TβRII expression and TGFβ responsiveness in C666-1 cells. As is shown in Figure 3.33, 
transient transfection of increasing concentrations of the pLXIN-TβRII plasmid significantly 
restored both p(CAGA)12-Luc and p(ARE)3-Luc reporter activities in a dose-dependent 
manner, while the kinase inactive D522N mutant was intrinsically unable to induce reporter 
activity. Additionally, the effect of TGFβ stimulation on the reporter response was 
progressively enhanced with increasing concentrations of pLXIN-TβRII. 
  
This notable absence of TβRII expression in the C666-1 cell line would predictably render 
C666-1 cells incapable of R-Smad activation, as was characterised by the negligible levels of 
Smad2 C-terminal phosphorylation shown by immunoblotting, which could only be 
stimulated once this defect had been repaired (Figure 3.34); however, the ability of TGFβ to 
further augment phosphorylation levels still appeared defective, while linker phosphorylation 
appeared unimpeded by the defect. 
 
3.4.3 TGFβ target gene expression is restored by the introduction of a functional 
TβRII 
C666-1 cells transiently transfected with either the wild-type pLXIN-TβRII or kinase 
defective pLXIN-TβRII variant were cultured in 0.5% serum for 16 hours, prior to stimulation 
with 5ng/ml TGFβ1 for a further 24 hours. As indicated by both RT-PCR and immunoblotting  
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A)
B)
Figure 3.33:  The effect of repairing the TβRII defect on TGFβ reporter activity in C666-1 cells
Dual luciferase reporter assays showing levels of p(CAGA)12-Luc (A) or p(ARE)3-Luc (B) luciferase
reporter activity in C666-1 cells transiently transfected with either the wild-type pLXIN-TβRII, 
kinase inactive pLXIN-TβRII D522N or control vector, determined under basal conditions and 
following stimulation with 5ng/ml recombinant hTGFβ1 for 24 hours. Histograms are shown to 
depict the relative luminescence after normalising to Renilla luciferase values and expressing as a 
ratio of activity relative to the control vector pGL3-basic. Data from three independent experiments 
is presented as the mean fold differences in activity + SE, relative to that observed in unstimulated
C666-1 cells transfected with the pLXIN control vector only which is given an arbitrary value of 1 
(** denotes a P-value <0.01 and * denotes a P-value <0.05). 
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Figure 3.34: Expression of Smad2 phospho-isoforms following 
TβRII defect repair in C666-1 cells
Immunoblotting for protein levels of total, linker region serine 
245/250/255 and C-terminal serine 465/467 phosphorylated forms of 
Smad2 in serum-starved C666-1 cells following transient transfection
with either the wild-type pLXIN-TβRII or constitutively active 
pLXIN-TβRII D522N plasmids, under basal conditions and following 
stimulation with 5ng/ml recombinant hTGFβ1 for 24 hours. Blots 
were reprobed for β-actin to confirm equal protein loading.
TGFβ (5ng/ml)        - +     - +    - +
TβRII D522N        - - - - +   + 
TβRII          - - +  +     - -
C666-1
β-actin
pSmad2 
Ser245/250/255
pSmad2 
Ser465/467
Smad2
60kDa
60kDa
60kDa
42kDa
MW
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analysis (Figure 3.35), restoration of TβRII expression resulted in downstream effects on 
TGFβ-responsive genes. βig-h3 and PAI-1 are established TGFβ-responsive genes (Skonier et 
al., 1992, Skonier et al., 1994, Thapa et al., 2007, Dennler et al., 1998) and, as previously 
demonstrated, are negatively regulated in the presence of EBNA1 (Wood et al., 2007). In the 
presence of pLXIN-TβRII, expression of PAI-1 was basally detectable and dramatically 
induced by TGFβ, but remained absent with pLXIN-TβRII D522N, while the transcription of 
βig-h3 was significantly enhanced when the pathway was repaired. 
 
3.4.4 Repair of the TβRII defect in C666-1 cells is not sufficient to restore the TGFβ-
mediated growth arrest response 
After establishing that TGFβ1-mediated target gene responses could be restored, the 
possibility of resultant effects on C666-1 cell cycle progression following TβRII repair was 
investigated. C666-1 cells were transfected with either pLXIN-TβRII or pLXIN-TβRII 
D522N plasmids and, after incubation in 0.5% serum for 16 hours, stimulated with 5ng/ml 
TGFβ1. 24, 48, 72 and 96 hours after stimulation, cells were recovered as single-cell 
suspensions and stained with propidium iodide. Subsequently, cells were subjected to flow 
cytometric analysis to examine the impact of TβRII expression on TGFβ-mediated cell cycle 
inhibition. Examples of the subsequent analyses of resulting histograms using MultiCycle are 
shown in Figure 3.36. This analysis revealed no significant differences in cell cycle 
distribution between samples transfected with either wild-type or kinase inactive receptors, in 
untreated cells, or cells treated with TGFβ. These findings indicate that whilst re-expression 
of TβRII is sufficient to instigate Smad phosphorylation and subsequent downstream target 
activation, C666-1 cells may have defective responses linking TGFβ/Smad activity to 
pathways involved in growth inhibition. 
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A)
B)
Figure 3.35: Expression of TGFβ target genes following TβRII defect repair in C666-1 cells
A) RT-PCR analysis for mRNA levels of TβRII, and the TGFβ target genes, PAI-1 and βig-h3, in 
serum-starved C666-1 cells transiently transfected with either the wild-type pLXIN-TβRII or 
constitutively active pLXIN-TβRII D522N plasmids, under basal conditions or following 
stimulation with 5ng/ml recombinant hTGFβ1 for 24 hours. The housekeeping gene GAPDH 
was included as a positive control to confirm equal RNA input into the PCR reactions, while 
negative water controls confirmed the absence of contamination.
B) Immunoblotting for PAI-1, βig-h3 and TβRII protein expression levels in serum-starved 
C666-1 cells transiently transfected with either the wild-type pLXIN-TβRII or constitutively 
active pLXIN-TβRII D522N plasmids, under basal conditions of following stimulation with 
5ng/ml recombinant hTGFβ1 for 24 hours. Blots were reprobed for β-actin to confirm equal 
protein loading. A second immunoblot for PAI-1, exposed for the longer time of 5 minutes, is 
also shown.
TβRII      - - +    +     - -
PAI-1
TβRII
βig-h3
GAPDH
TGFβ (5ng/ml)     - +     - +      - +         H2O
TβRII D522N     - - - - +     +
C666-1
440bp
399bp
301bp
351bp
Product 
size
C666-1
TβRII       - - +            +         - -
TβRII D522N         - - - - +          +
TGFβ (5ng/ml)       - +            - +          - +
PAI-1
βig-h3
β-actin
TβRII
47kDa
47kDa
68kDa
70kDa
42kDa
(1min)
(5mins)
MW
 
 156 
 
2
4
h
rs
+
 T
β
R
II
+
 T
β
R
II
 +
 T
G
F
β
+
 T
β
R
II
 D
5
2
2
N
+
 T
β
R
II
 D
5
2
2
N
 +
 T
G
F
β
4
8
h
rs
G
1
 =
 6
6
.5
%
S
 =
 2
5
.2
%
G
2
-M
 =
 8
.2
%
G
1
 =
 6
5
.7
%
S
 =
 2
6
.0
%
G
2
-M
 =
 8
.2
%
G
1
 =
 6
7
.0
%
S
 =
 2
4
.3
%
G
2
-M
 =
 8
.7
%
G
1
 =
 6
4
.9
%
S
 =
 2
6
.7
%
G
2
-M
 =
 8
.3
%
G
1
 =
 6
8
.1
%
S
 =
 2
4
.4
%
G
2
-M
 =
 7
.5
%
G
1
 =
 6
9
.3
%
S
 =
 2
3
.0
%
G
2
-M
 =
 7
.7
%
G
1
 =
 7
0
.2
%
S
 =
 2
3
.1
%
G
2
-M
 =
 6
.6
%
G
1
 =
 7
0
.5
%
S
 =
 2
2
.7
%
G
2
-M
 =
 6
.8
%
F
ig
u
re
 3
.3
6
: 
 C
el
l 
cy
cl
e 
a
n
a
ly
si
s 
b
y
 p
ro
p
id
iu
m
io
d
id
e 
st
a
in
in
g
 o
f 
C
6
6
6
-1
 c
el
ls
 f
o
ll
o
w
in
g
 T
β
R
II
d
ef
ec
t 
re
p
a
ir
A
n
al
y
si
s 
o
f 
ce
ll
 c
y
cl
e 
in
 s
er
u
m
-s
ta
rv
ed
 C
6
6
6
-1
 c
el
ls
 a
ft
er
 t
ra
n
si
en
t 
tr
an
sf
ec
ti
o
n
w
it
h
 e
it
h
er
 t
h
e 
w
il
d
-t
y
p
e 
p
L
X
IN
-
T
β
R
II
o
r 
co
n
st
it
u
ti
v
el
y
 a
ct
iv
e 
p
L
X
IN
-T
β
R
II
D
5
2
2
N
 p
la
sm
id
s,
 a
n
d
 t
re
at
ed
 w
it
h
 5
n
g
/m
l 
re
co
m
b
in
an
t 
h
T
G
F
β
1
 o
r 
le
ft
 
u
n
st
im
u
la
te
d
as
 a
 c
o
n
tr
o
l.
 D
N
A
 c
o
n
te
n
t 
w
as
 m
ea
su
re
d
 a
t 
2
4
, 
4
8
, 
7
2
 a
n
d
 9
6
 h
o
u
rs
 b
y
 p
ro
p
id
iu
m
io
d
id
e 
st
ai
n
in
g
 a
n
d
 
su
b
se
q
u
en
t 
fl
o
w
 c
y
to
m
et
ri
c
an
al
y
si
s.
 R
es
u
lt
in
g
 h
is
to
g
ra
m
 f
il
es
 w
er
e 
an
al
y
se
d
 f
o
r 
ce
ll
 c
y
cl
e 
d
is
tr
ib
u
ti
o
n
 u
si
n
g
 
M
u
lt
iC
y
cl
e.
 R
ep
re
se
n
ta
ti
v
e 
tr
ac
es
 f
ro
m
 o
n
e 
o
f 
th
re
e 
in
d
ep
en
d
en
t 
ex
p
er
im
en
ts
 a
re
 s
h
o
w
n
, 
w
it
h
 p
er
ce
n
ta
g
es
 o
f 
ce
ll
s 
in
 G
1
, 
S
 a
n
d
 G
2
-M
 p
h
as
es
 i
n
d
ic
at
ed
.
 157 
 
7
2
h
rs
9
6
h
rs
+
 T
β
R
II
+
 T
β
R
II
 +
 T
G
F
β
+
 T
β
R
II
 D
5
2
2
N
+
 T
β
R
II
 D
5
2
2
N
 +
 T
G
F
β
G
1
 =
 7
4
.4
%
S
 =
 1
8
.2
%
G
2
-M
 =
 7
.4
%
G
1
 =
 7
3
.2
%
S
 =
 1
9
.7
%
G
2
-M
 =
 7
.1
%
G
1
 =
 7
3
.4
%
S
 =
 1
9
.3
%
G
2
-M
 =
 7
.3
%
G
1
 =
 7
5
.6
%
S
 =
 1
5
.8
%
G
2
-M
 =
 8
.7
%
G
1
 =
 7
7
.6
%
S
 =
 1
6
.0
%
G
2
-M
 =
 7
.3
%
G
1
 =
 7
4
.7
%
S
 =
 1
7
.4
%
G
2
-M
 =
 7
.9
%
G
1
 =
 7
5
.6
%
S
 =
 1
6
.7
%
G
2
-M
 =
 7
.8
%
G
1
 =
 7
5
.8
%
S
 =
 1
6
.7
%
G
2
-M
 =
 7
.5
%
 158 
3.4.5 Linker phosphorylated Smads are expressed in C666-1 cells 
While the absence of C-terminally phosphorylated Smads in C666-1 cells has been previously 
reported, and confirmed here, the expression of linker phosphorylated forms had not yet been 
characterised. Owing to the substantial involvement of non-Smad kinases in their generation, 
it was reasoned that phosphorylation at these linker residues may be induced in C666-1 cells. 
Immunoblotting analysis was performed on total cell lysates obtained from serum-starved 
cultures of C666-1 cells, either untreated or treated with TGFβ1 to examine the extent of 
Smad2/3 linker phosphorylation. A representative experiment, depicted in Figure 3.37, shows 
that the linker phosphorylated forms of both Smad2 and Smad3 were clearly visible in C666-1 
cells. Interestingly however, the extent of linker region phosphorylation appeared to be 
largely unaffected in response to TGFβ stimulation. 
 
3.4.6 TβRII expression increases Qp-luciferase reporter activity in C666-1 cells 
To determine whether restoring TβRII expression had any effect on EBNA1 protein function, 
the effect of TβRII repair on both EBNA1 expression and on native Qp promoter activity was 
examined. C666-1 cells were transiently transfected with either wild-type pLXIN-TβRII or 
kinase inactive pLXIN-TβRII D522N plasmids and, 48 hours later, the levels of endogenous 
Qp-driven EBNA1 mRNA examined by RT-PCR. This analysis revealed that, following 
complete TβRII repair, TGFβ1 stimulation served to reduce EBNA1 expression. In Figure 
3.38, a titration of the wild-type pLXIN-TβRII plasmid with the Qp-luciferase promoter 
construct demonstrated the ability of increasing amounts of the receptor to significantly 
enhance basal Qp-luciferase reporter activity, which was further increased by TGFβ 
stimulation. In contrast, the kinase inactive receptor variant had little or no effect on Qp-
luciferase reporter activity. 
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Figure 3.37:  Expression of linker phosphorylated Smad2 and Smad3 in C666-1 cells
Immunoblotting for protein levels of the serine 245/250/255 and threonine 220 
phosphorylated forms of Smad2, and the serine 204, serine 208, serine 213 and threonine
179 phosphorylated forms of Smad3 in serum-starved C666-1 cells stimulated with 5ng/ml 
recombinant hTGFβ1 for 24 hours, or left unstimulated as controls. Immunoblotting for 
EBNA1 is also shown, with β-actin included to confirm equal protein loading.
pSmad2 T220
pSmad2 
S245/250/255
pSmad3 S213
pSmad3 S208
pSmad3 S204
pSmad3 T179
β-actin
EBNA1
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A)
B)
Figure 3.38:  The effect of TβRII defect repair on EBNA1 expression and Qp promoter reporter 
activity in C666-1 cells
A) RT-PCR analysis for levels of EBNA1 mRNA expression in serum-starved C666-1 cells 
transiently transfected with either the wild-type pLXIN-TβRII or constitutively active pLXIN-
TβRII D522N plasmids, both basally and following stimulation with 5ng/ml recombinant hTGFβ1 
for 24 hours. GAPDH was included as a positive control to confirm equal RNA input into the PCR 
reactions, while negative water controls confirmed the absence of contamination. 
B) Dual luciferase reporter assay for pQp-Luc activity in C666-1 cells transiently transfected with 
either the wild-type pLXIN-TβRII, kinase inactive pLXIN-TβRII D522N or control vector, 
determined under basal conditions and following stimulation with 5ng/ml recombinant hTGFβ1 for 
24 hours. A histogram is shown to depict the relative luminescence after normalising to Renilla
luciferase values and expressing as a ratio of activity relative to the control vector pGL2-basic. 
Data from three independent experiments is presented as the mean fold differences in activity + SE, 
relative to that observed in unstimulated C666-1 cells transfected with the pLXIN control vector 
only which is given an arbitrary value of 1 (** denotes a P-value <0.01 and * denotes a P-value 
<0.05). 
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3.5 EBNA1 does not inhibit TGFβ signalling in Mv1Lu cells 
It was hypothesised that the propensity of EBNA1 to attenuate TGFβ signalling may reflect 
the oncogenic status of the cell, the levels of endogenous TGFβ ligand expression, and the 
integrity of the TGFβ signalling pathway. To this end, experiments were extended to examine 
the effects of EBNA1 on TGFβ signalling in cells containing an intact and fully functional 
TGFβ signalling pathway. Experiments were subsequently performed in the untransformed 
mink lung epithelial cell line, Mv1Lu, an established “indicator” cell line that has been used 
extensively to study TGFβ signalling. The Mv1Lu cell line proves most useful in studies of 
TGFβ signalling as it carries an intact TGFβ pathway, and demonstrates a well-characterised 
growth arrest response when stimulated with TGFβ. 
 
3.5.1 EBNA1 does not affect TGFβ luciferase reporter activity in Mv1Lu cells 
Initially, EBNA1 protein expression in Mv1Lu cells transiently transfected with increasing 
concentrations of pSG5-EBNA1 was confirmed by immunoblotting (Figure 3.39A). 
Subsequent dual luciferase reporter assays were used to demonstrate that transient transfection 
of pSG5-EBNA1 into Mv1Lu cells resulted in negligible differences in the level of activity of 
the TGFβ-responsive luciferase reporters, p(CAGA)12-Luc and p(ARE)3-Luc (Figure 
3.39B&C). As expected, cells demonstrated a robust increase in activity in response to TGFβ 
stimulation, which did not appear to be abrogated by the presence of EBNA1. 
 
3.5.2 EBNA1 does not affect TGFβ1-mediated growth arrest in Mv1Lu cells 
Mv1Lu cells are sensitive to TGFβ stimulation, arresting in the G1 phase of the cell cycle. 
The growth arrest response after 24 hours was examined in these cells using propidium iodide 
staining followed by flow cytometric analysis. Cell cycle profiles were subsequently  
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Figure 3.39:  The effect of EBNA1 on TGFβ-induced reporter activity in the Mv1Lu 
cell line
A)  Immunoblotting for EBNA1 protein expression in Mv1Lu cells transiently transfected
with increasing concentrations of pSG5-EBNA1 to confirm transfection efficiency. β-actin
was included to confirm equal protein loading.
Dual luciferase reporter assays showing p(CAGA)12-Luc (B) and p(ARE)3-Luc (C) 
luciferase reporter activity in Mv1Lu cells transiently transfected with increasing amounts 
of a pSG5-EBNA1 plasmid, and either stimulated with 5ng/ml recombinant hTGFβ1 for 
24 hours or left unstimulated as a control. Histograms are shown to depict the relative 
luminescence after normalising to Renilla luciferase values and expressing as a ratio of 
activity relative to the control vector pGL3-basic. Data from three independent 
experiments is presented as the mean fold differences in activity + SE, relative to that 
observed in unstimulated Mv1Lu cells expressing the empty pSG5 control vector only 
which is given an arbitrary value of 1. 
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generated using MultiCycle, and representative traces are shown in Figure 3.40. In accordance 
with previous reports, TGFβ stimulation increased the number of cells in the G1 phase of the 
cell cycle, with appropriate reductions detected in both S and G2-M phases, 24 hours post-
stimulation. The effect of TGFβ on cell cycle arrest appeared consistent, and was not altered 
with increasing concentrations of pSG5-EBNA1. 
 
3.6 Discussion and Future Work 
Data presented in this chapter confirm and extend the original observations of Wood et al. 
(Wood et al., 2007), demonstrating an ability of EBNA1 to modulate TGFβ signalling in 
established carcinoma cell lines. The inhibitory effect of EBNA1 on canonical TGFβ 
signalling is manifest at multiple levels as a decline in Smad2/3 C-terminal phosphorylation, 
increased Smad2 protein degradation, diminished activity of TGFβ-responsive reporters, 
reduced binding at SBE sites, and reduced expression of classical TGFβ target genes, overall 
indicative of an attenuation of Smad activity. The ability of exogenous Smad2 to overcome 
the inhibitory effect of EBNA1 on p3TP-lux reporter activity in EBNA1-expressing cells 
(Wood et al., 2007) implied that the main defect was mainly Smad-related, and the repression 
of both the Smad2-responsive p(ARE)3-Luc reporter and Smad3-responsive p(CAGA)12-Luc 
reporter, as well as reduction in the C-terminal phosphorylation of both Smad2 and Smad3 
suggests this is a general effect, not specific to a particular R-Smad.  
 
The reduction in reporter activity and also binding to SBE sites may be a direct result of the 
observed reduction in the pool of activated R-Smads available for participation in DNA 
binding. They may also reflect EBNA1-mediated differences in the availability of 
transcriptional cofactors between the cell lines. This may be particularly relevant to Smad2- 
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Figure 3.40:  Cell cycle analysis by propidium iodide staining of Mv1Lu cells
Analysis of cell cycle in serum-starved Mv1Lu cells after transient transfection with 
increasing concentrations of pSG5-EBNA1 or the empty pSG5 control vector, and 
treated with 5ng/ml recombinant hTGFβ1 for 24 hours or left unstimulated as a control. 
DNA content was measured by propidium iodide staining and subsequent flow 
cytometric analysis. Resulting histogram files were analysed for cell cycle distribution 
using MultiCycle. Representative traces from one of three independent experiments are 
shown, and the percentages of cells in G1, S and G2-M phases are indicated.
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mediated responses, as Smad2 cannot directly bind DNA (Dennler et al., 1999), and so is 
heavily reliant upon such factors. To further investigate this hypothesis, it would be 
interesting to utilise chromatin immunoprecipitation (ChIP) techniques at these sites to 
identify the protein compositions of bound transcription factor complexes. 
 
PPM1A expression is increased in both EBNA1-expressing and rEBV-infected Ad/AH cells 
and, moreover, shows enhanced nuclear colocalisation with Smad2 and Smad3 in these cells. 
PPM1A may directly reduce R-Smad levels through increased dephosphorylation and nuclear 
export. It has been reported that inducible expression of PPM1A renders cells resistant to the 
anti-proliferative effects of TGFβ (Lin et al., 2006), and so the increased levels of PPM1A 
expression induced by EBNA1 were predicted to impart protection against the growth 
inhibitory effects of TGFβ in EBNA1-expressing and EBV-infected carcinoma cells. Also, its 
selectivity in targeting only C-terminally phosphorylated Smads, and leaving linker residues 
and TGFβ-dependent activation of Smad-independent pathways unaltered (Lin et al., 2006) 
added to the appeal that PPM1A induction was a key effector in regulating Smad2/3 
phosphorylation and transcriptional activity in EBNA1-expressing and rEBV-infected cells. 
Similarly, PPM1B displays very similar functional properties, and it was hoped that an 
exciting parallel could be drawn with the ability of the two together to inhibit NFκB activity 
through increased IKKβ dephosphorylation (Sun et al., 2009). Although knockdown of the 
two phosphatases together did increase TGFβ/Smad reporter activity in EBNA1-expressing 
cells suggesting the inhibition was in part relieved, the pattern could not be repeated in rEBV-
infected cells, hinting that another EBV-encoded protein may counteract the observed effects 
of EBNA1. 
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NEDD4-2 instead poses a promising candidate due to its ability to promote the degradation of 
both R-Smads and TβRI (Kuratomi et al., 2005). A recent report by Gao et al. describes how 
phosphorylation of specific threonine residues within the Smad linker region, Thr220 in 
Smad2 and Thr179 in Smad3, marks Smads for proteasome-mediated degradation, by priming 
an association with Nedd4-2 (Gao et al., 2009), and in agreement with this theory, the 
expression of these specific Smad2 and Smad3 phospho-isoforms were elevated in the 
presence of EBNA1. This mechanism could therefore account for the reported increase in 
Smad degradation (Wood et al., 2007) and, in limiting Smad half-life, may be important to 
constrain TGFβ signalling. The defect may therefore be the result of a reduced interaction 
between Smads and their receptors as either or both are targeted for increased degradation. 
shRNA-mediated knockdown of NEDD4-2 in EBNA1-expressing cells will be a useful tool to 
test this hypothesis. 
 
It is unlikely, due to its strict requirement in the cell nucleus, that EBNA1 may function to 
inhibit Smad activity through interacting directly with TβRI, as exemplified by HCV NS5A 
(Choi and Hwang, 2006). Other viral proteins, such as adenovirus E1A oncoprotein, the 
human papilloma virus (HPV) type 16 E7 oncoprotein, HPV type 5 oncoprotein E6 and 
KSHV viral IFN regulatory factor 1 (vIRF1) (Nishihara et al., 1999, Lee et al., 2002, 
Mendoza et al., 2006, Seo et al., 2005) are able to interact directly with the Smad proteins 
themselves to thereby abrogate TGFβ signalling; EBNA1 however, while capable of altering 
the half-life of Smad2, and despite demonstrating an ability to interact with host proteins, as is 
exemplified by its sequestration of the cellular deubiquitinating enzyme, USP7 (Holowaty et 
al., 2003), shows no notable physical interaction with the Smad2 protein (Flavell et al., 2008). 
It does however remain a possibility that EBNA1 is able to bind modifiers of Smad activity, 
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such as PPM1A or NEDD4-2, in order to influence their activity, which should be verified 
using immunoprecipitation experiments. 
 
Receptor expression levels can serve as a predictor of TGFβ-mediated biological responses 
(Rojas et al., 2009). TβRII expression is frequently down-regulated in human cancers and 
may be a direct target of EBV, as it is reportedly down-regulated in some BL cell lines 
(Inman and Allday, 2000). Furthermore, TβRII gene mutation is though to result from 
microsatellite instability on chromosome 11 in a proportion of NPC samples (Harn et al., 
2002). This loss of TβRII holds great potential as the mechanism by which resistance to anti-
proliferative TGFβ-mediated stimuli can be acquired, and is likely the key mechanism 
employed by C666-1 cells.  
 
In KSHV-infected primary effusion lymphoma (PEL) cell lines, the inhibition of TGFβ 
signalling attributed to the epigenetic down-regulation of TβRII is instigated by KSHV-
encoded LANA (Di Bartolo et al., 2008). Considering the high degree of functional similarity 
between EBNA1 and LANA (Renne et al., 2001), it seemed reasonable to assume that 
EBNA1 may have a similar effect. The lack of TβRII expression in the C666-1 cell line 
supports an EBV-induced cause (Harn et al., 2002, Wood et al., 2007). In dissecting TGFβ 
signalling in C666-1 cells, a constitutively active TβRI was found to alleviate the inherent 
repression on TGFβ activity, signalling independently of both ligand binding and activation 
by the type II receptor, while a wild-type version proved unable to overcome the defect.  
 
Successful reconstitution of TβRII gene expression in deficient human colon cancer cell lines 
has been shown to effectively restore TGFβ-mediated growth inhibition in these cells (Biswas 
 170 
et al., 2008). However, while subsequent transfection of TβRII plasmids into C666-1 cells 
was sufficient to restore TGFβ signalling activity and associated target gene expression in 
these cells, it was unable to restore TGFβ-mediated growth inhibition, suggesting that growth 
inhibitory pathways that feed into cell cycle control are corrupted in these cells. Indeed, 
transient transfection of a dominant-negative EBNA1 construct into C666-1 cells does not 
restore TβRII expression (data not shown), and attempts to permanently repair the defect and 
generate clones with stable expression of TβRII proved unsuccessful, as the cells appear to 
select against long-term maintenance of TβRII. Treatment of Akata BL cells with 5´-
azacytidine reinstates the expression of the TβRII message, subsequently restoring Smad 
phosphorylation and TGFβ-mediated responses (Chen et al., 2007), while transcription of 
TβRII in these cells can also be induced by treatment with the HDAC inhibitor, trichostatin A 
(TSA), which not only restores cell growth inhibition and apoptotic responses, but also the 
propensity to reactivate EBV into lytic cycle (Fukuda et al., 2006). With this in mind, it would 
be useful to treat C666-1 cells with TSA and 5´-azacytidine to hopefully underpin the 
mechanism for TβRII loss in C666-1 cells, and subsequently examine the effects of reverting 
the defect both on C666-1 cellular phenotype and behaviour, but also on the behaviour of 
EBV. 
 
In contrast to the C666-1 cell line, all other cell lines studied expressed detectable levels of 
TβRII, and the expression of both receptors was, for the most part, increased in the presence 
of EBNA1. Moreover, the expression of LMP1 in SCC12F cells was found to induce the 
expression of both TβRI and TβRII (Dr. Mhairi Morris, unpublished observations), and RP 
analysis of NPC tumour microarray data has previously revealed an up-regulation of TβRI 
and TβRII genes in NPC biopsies, further confirmed by IHC staining of NPC tumour sections 
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(Hu et al., manuscript in preparation). Interestingly, TβRII expression was found to be 
abrogated in cells having undergone epithelial-to-mesenchymal transition (EMT), a major 
feature of invasive cancer subject to TGFβ control (Heldin et al., 2009), hinting that loss of 
TβRII could in fact be a later event, involved in the promotion of an EMT-like phenotype to 
assist in cancer cell invasion and migration. Data in support of this comes from the finding 
that MDCK cells undergoing EMT in response to LMP1, lose TβRII expression (Laverick et 
al., manuscript in preparation). 
 
Despite the overall increases in TGFβ receptor expression, a reduction in the levels of 
expression at the cell surface were observed in EBNA1-expressing and rEBV-infected Ad/AH 
cells, which also demonstrated a decreased TβRI half-life through a mechanism presumed to 
involve increased receptor turnover. The targeting of cell surface receptors is a common 
means of interfering with downstream signal transduction cascades to promote 
carcinogenesis, and the intracellular route undertaken by the TGFβ receptors directly governs 
signalling outcomes (Di Guglielmo et al., 2003, Sadowski et al., 2009). Increased proteasome-
mediated degradation and ubiquitination of TβRII has been associated with the down-
regulation of TGFβ signalling in renal cell carcinoma (Fukasawa et al., 2010), and the ability 
of viral proteins to enhance receptor turnover is not a new concept. The EBV-encoded 
LMP2A and LMP2B proteins have been reported to accelerate the turnover rate of the 
interferon receptors, IFNAR1 and IFNGR1, thereby decreasing cellular responsiveness to 
IFNα and IFNγ (Shah et al., 2009). In EBNA1-expressing cells, the observed effects would 
reduce the relative levels of TβRI available for participation in active receptor complex 
formation, thereby reducing the ability of TβRI to engage Smad phosphorylation. It would 
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therefore be useful to further extend this work using immunoprecipitation to determine the 
abundance of active complexes induced in response to TGFβ. 
 
A further reduction in TβRI degradation is observed in the rEBV-infected Ad/AH cells, 
suggesting additional contributions from other EBV-encoded latent genes. This is 
complemented by a further increased level of cytoplasmic NEDD4-2 expression in these cells. 
Intriguingly, NEDD4-2-dependent ubiquitination of ENaC is increased by an interaction 
between ENaC and Cav-1 (Lee et al., 2009). It is possible Cav-1 and NEDD4-2 may similarly 
synergise in this setting to target TβRI, as Cav-1 has also been shown to interact with TβRI 
(Razani et al., 2001). The ability of virally-encoded proteins to localise to lipid rafts is not 
uncommon. Herpes simplex virus (HSV) uses lipid rafts to mediate viral entry, and the 
association of HSV-2-encoded UL11 protein with lipid rafts is thought to play a specific role 
in virion maturation (Koshizuka et al., 2007). While EBNA1 itself is unlikely to be associated 
with lipid raft structures, it would be interesting to determine whether perhaps either LMP1 or 
LMP2A, due to their intrinsic tendency to hijack lipid rafts (Kaykas et al., 2001, Coffin III et 
al., 2003, Dykstra et al., 2001), may further potentiate this effect. It would also be interesting 
to re-examine both TGFβ receptor cell surface expression and degradation in the presence of a 
TGFβ stimulus, although it is reported that TGFβ has no detectable effect on the cell surface 
distribution of receptor complexes (Zwaagstra et al., 2008). 
 
In further characterising receptor degradation, these findings now propose a role for EBNA1 
in increasing the transcription of the lipid raft-residing proteins Cav-1, Smad7 and Smurf2, 
promoting entrance of receptors into the lipid raft pathway, enhancing their degradation and 
thus inhibiting ligand-induced signalling initiated by the TGFβ receptor complex. Preliminary 
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evidence suggests that EBNA1 may increase the abundance of Cav-1 in both EBNA1-
expressing and rEBV-infected Ad/AH cells, showing increased peripheral staining at the 
plasma membrane in EBNA1-expressing cells. In support of this theory, recently published 
data reports on the over-expression of Cav-1 in NPC tumour samples (Du et al., 2009) and 
correlates this with increased MMP secretion and metastasis. Interestingly, in rEBV-infected 
cells, Cav-1 appears to adopt a more perinuclear localisation, the significance of which 
remains to be elucidated, yet supporting the concept that this effect may be further modified 
by other EBV-encoded proteins. Smad7 not only negatively regulates TGFβ signalling 
through active competition with R-Smads for binding to TβRI (Hayashi et al., 1997), but can 
also recruit the HECT-type E3 ubiquitin ligases WWP1/Tiul1 and NEDD4-2 so as to promote 
both TβRI and R-Smad degradation (Seo et al., 2004). TβRI can also be effectively targeted 
by Smad7, in combination with Smurf2, which has additionally been inversely correlated with 
the expression of pSmad2 in oesophageal squamous cell carcinoma (Fukuchi et al., 2002). It 
is therefore unsurprising that the expression of both Smad7 and Smurf2 is up-regulated in 
EBNA1-expressing carcinoma cell lines, in which Smads and TβRI are increasingly 
degraded. To continue this work, a sucrose gradient fractionation protocol can be used to 
determine the relative abundance of receptors in lipid-raft fractions and conclusively establish 
whether the increase in Cav-1 transcription is directly reflected in an augmentation of lipid 
raft activity. 
 
Receptor recycling has been shown to occur constitutively, regardless of receptor activation 
state (Doré Jr. et al., 2001, Di Guglielmo et al., 2003, Mitchell et al., 2004, Penheiter et al., 
2010). Consequently, as an integral but downstream component of this constitutive recycling 
process, a loss of Dab2 would not be manifest as a decline in receptor internalisation rate 
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(Penheiter et al., 2010). It would however impact upon later events in the pathway, due to its 
specific involvement in the transition from the EEA1-positive to Rab-11 positive 
compartment (Mitchell et al., 2004, Penheiter et al., 2010), disrupting the association of 
receptors with Rab11 and thereby arresting receptors in EEA1-positive endosomes, which 
would likely contribute to a substantial reduction in Smad2 phosphorylation (Penheiter et al., 
2010). Reduction in pSmad2/3C may therefore be a result of the combination of increased 
Cav-1 and decreased Dab2 expression levels, both of which are reported to suppress TGFβ-
mediated Smad2 phosphorylation (Razani et al., 2001, Penheiter et al., 2010). 
 
PCR analysis has demonstrated that EBNA1-expressing cells show elevated expression of all 
three TGFβ ligands. This has similarly been observed in LMP1-expressing cells undergoing 
an EMT (Dr. Louise Laverick, unpublished observations), while Do et al. have also 
highlighted the potential of all three isoforms to induce EMT in vitro (Do et al., 2008). A 
study in hepatocytes suggests that this increase in TGFβ production afforded by an EMT-like 
conversion can confer apoptotic resistance and thereby promote cell survival (del Castillo et 
al., 2006). It at first seems counterintuitive that the expression levels of the TGFβ isoforms are 
raised, yet the response, at least to TGFβ1, is defective. A possibility is that the TGFβ1 
response may be specifically ablated, while that to the other isoforms prevails. Indeed, it has 
been suggested that the individual TGFβ isoforms can in fact play differential roles in 
epidermal carcinogenesis (Gold et al., 2000). Whilst TGFβ1 was deemed important in the 
maintenance of a more differentiated keratinocyte phenotype, TGFβ2 prevailed in enhancing 
the invasion and migration of undifferentiated tumour cells, and TGFβ3 in promoting stroma 
formation and angiogenesis. Although there is slight variation over the effect of EBNA1 on 
TGFβ isoform expression, elevation of TGFβ2 is consistent across cell lines. Thus selective 
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TGFβ1 inactivation may allow TGFβ2-mediated effects to predominate. Taking this into 
consideration it would be useful to examine TGFβ signalling activity in response to the 
addition of exogenous TGFβ2 and TGFβ3. 
 
Evidence to support a role for EBV infection in the secretion of TGFβ is conflicting. Elevated 
measurements of serum TGFβ1 levels have been recorded in NPC patients (Xu et al., 1999), 
and later, in a second study, extended to cases of BL and chronic active EBV infection (CEI) 
(Xu et al., 2000). However, Lin et al. failed to detect a change in TGFβ1 expression level in 
EBV-infected NPC cells, despite measuring increases in mRNA expression of EGFR, TGFα, 
IL-1β, IL-6 and GM-CSF (Lin et al., 2000a), while cytokine profiling identified only elevated 
expression of IL-1α and IL-1β in primary tumours and NPC metastases compared to control 
tissues (Huang et al., 1999). Nonetheless, data presented here suggests TGFβ secretion is 
increased in EBNA1-expressing cells. This may simply be a consequence of defective 
signalling as, particularly in the presence of TβRII defects, the ability of cells to actively 
deplete extracellular TGFβ is impaired (Clarke et al., 2009). It may however be strategically 
increased so as to mediate the characteristic tumour-promoting effects of autocrine and 
paracrine TGFβ signalling. Indeed chronic exposure of mammary epithelial NMuMG cells to 
TGFβ was sufficient to convert the typical anti-proliferative and pro-apoptotic response to one 
of EMT promotion (Gal et al., 2008). 
 
One of the most striking and consistent histopathological features of undifferentiated NPC is 
the abundance of tumour-infiltrating lymphocytes (TIL) (Gourzones et al., 2011), and the 
production of cytokines (including TGFβ) by malignant cells has profound effects on the 
activity of this infiltrate. In this way, the interaction between tumour cells, TIL and the 
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surrounding microenvironment can largely influence tumour growth and metastasis 
(Agathanggelou et al., 1995, Dennler et al., 2008). EBNA1 has already been reported to 
enhance the secretion of cytokines, interleukin-8 (IL-8) and vascular endothelial growth factor 
(VEGF) (O'Neil et al., 2008), potentially as a mechanism to enhance angiogenesis in NPC 
(Yoshizaki et al., 2001) and, just as the EBNA1-mediated increase in expression of the 
CCL20 chemokine in HL tumours and cell lines serves as a chemoattractant for FoxP3
+
CD4
+
 
T cells (Tregs) (Baumforth et al., 2008), EBNA1 may increase secretion of TGFβ to serve a 
similar purpose. Analysis of the characteristic lymphoid infiltrate of NPC tumours detected a 
proportion of Treg cells (Lau et al., 2007), and TGFβ has been specifically implicated in the 
induction of FoxP3 expression and therefore their regulatory phenotype (Fantini et al., 2004, 
Teicher, 2007). Indeed this phenomenon has been observed as a consequence of increased 
TGFβ production in gastric cancer cells (Yuan et al., 2011). The enhancement of Treg cell 
prevalence in the peripheral circulation of NPC patients has been associated with suppressive 
activity against CD4
+
 and CD8
+
 effector T-cell function (Lau et al., 2007, Yip et al., 2009), a 
strategy employed by tumour cells to subvert the immune response, which may therefore be 
important for viral persistence. The ability of the increased TGFβ secreted from EBNA1-
expressing cells to facilitate the recruitment of Treg cells could be further investigated by 
measuring the migration of isolated tonsillar T cells in response to conditioned media samples 
collected from the cells. 
  
The efficiency of latent TGFβ activation is also an important consideration. Data presented 
here indicates that the active component forms a greater proportion of the total secreted TGFβ 
in EBNA1-expressing and rEBV-infected Ad/AH cells. In support of this, Xu et al. reported 
that the active TGFβ forms a greater proportion of the total in NPC patient samples when 
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compared to control sera (Xu et al., 1999). This indicates that TGFβ secretion is not only 
increased, but, in addition, is more rapidly subject to activation in the presence of EBV, 
perhaps potentially to enhance Treg recruitment. Whether EBNA1 itself may be capable of 
directly activating latent TGFβ, as observed in vitro for the neuraminidase glycoprotein of 
influenza A and B viruses (Schultz-Cherry and Hinshaw, 1996), remains to be determined.  
 
A loss of TβRII and increased TGFβ1 expression are often linked, and also positively 
correlated, in relation to disease progression (Inman and Allday, 2000, Osada et al., 2001, 
Fukai et al., 2003, Fukuda et al., 2006). However, in most of the carcinoma cell lines studied 
here, the increase in receptor expression, in combination with the measured increase in TGFβ 
ligand secretion, supports the notion that the TGFβ signalling pathway is constitutively 
activated in epithelial cells latently infected with EBV. It is feasible that the increase in 
receptor expression may be effectively counteracted by the increase in receptor degradation, 
or instead chronic receptor stimulation may result in the sequestration of receptors away from 
the active signal cascade to juxtanuclear compartments, as described by Idkowiak-Baldys et 
al. for sustained phorbol ester-stimulation of GPCRs (Idkowiak-Baldys et al., 2009), as part 
of a mechanism to attenuate the constitutive TGFβ signalling response. 
  
The precise mechanism by which TGFβ signalling is compromised in the presence of EBNA1 
remains to be elucidated. The ability of EBNA1 to directly bind to cellular promoters has 
been reported, and potential binding sites have been identified in the promoters of numerous 
cellular genes (Dresang et al., 2009, Canaan et al., 2009), but not specifically demonstrated 
for any TGFβ-associated genes. Using both conventional and variant (HaloCHIP) chromatin 
immunoprecipitation procedures, EBNA1 was shown to associate at ATF-2 and c-Jun 
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promoters (O'Neil et al., 2008, Owen et al., 2010), potentially directing the transcriptional 
induction of these genes, which has been associated with an increase in AP-1 activity. Its 
presence also at the promoter of the c-myc gene (Owen et al., 2010) may also cause up-
regulation of c-myc expression and thereby enhance resistance to TGFβ-mediated growth 
inhibition. In contrast, EBNA1’s inhibition of IKKβ phosphorylation in the canonical NFκB  
pathway, while potentially associated with its gene transactivation capabilities, is unlikely to 
be caused by EBNA1 binding to IKKβ (Valentine et al., 2010). Future work would use ChIP 
analysis to test the possibility that EBNA1 may be present at the promoters of the genes it is 
seen to transcriptionally induce in this study, i.e. PPM1A, NEDD4-2 and Cav-1, as well as a 
variety of TGFβ-related genes. Further to this, while gene expression profiling of NPC 
tumours has been used to support findings of gene up-regulation, it would be pertinent to 
conduct immunohistochemical staining of NPC tumour sections in order to suitably validate 
this. 
 
The results suggest that many of the carcinoma cell lines used in this study already harbour 
some degree of insensitivity to TGFβ-mediated effects, which was then further exacerbated 
by the presence of EBNA1 alone or by stable latent infection with rEBV. As shown here, 
Ad/AH cells were refractory to TGFβ-mediated growth arrest, yet TGFβ/Smad-luciferase 
reporter activity, Smad phosphorylation status and target gene expression were all modulated 
in EBNA1-expressing cells. It remains a possibility that these cell lines may in fact exhibit 
reduced expression levels of TβRII when compared to untransformed cell lines, and that this 
is raised slightly in the presence of EBNA1, yet still fails to reach a significant threshold in 
order to restore signalling. 
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An increasing number of genetic and epigenetic changes have been associated with the 
development of NPC (Tao and Chan, 2007) and, while the detection of the EBV genome in 
high-grade preinvasive lesions suggests that EBV infection is a relatively early event, certain 
of these chromosomal abnormalities, in particular chromosome 3p and 9p aberrations, are 
thought to precede EBV infection (Pathmanathan et al., 1995, Lo and Huang, 2002, Lo et al., 
2004). Loss of heterozygosity and promoter hypermethylation within these regions has been 
associated with the silencing of several genes including the tumour suppressor, Ras 
association domain family 1A (RASSF1A) and the CDK inhibitors, p15
INK4B
 and p16
INK4A
 
(Lo and Huang, 2002). This may account for the reported cell cycle dysregulation identified 
from microarray analysis of NPC biopsies (Zhang et al., 2009); however, the temporal 
occurrence of these defects in relation to EBV infection in the course of NPC pathogenesis 
was not determined in this study.  
 
Premalignant genetic changes associated with transformation may be responsible for the pre-
existing lack of TGFβ sensitivity in the carcinoma cell lines, and it is tantalising to speculate 
that this may predispose the epithelial cells to EBV infection, and create a suitable 
environment for the persistent maintenance of EBNA1 expression and, accordingly, stable 
latent infection. The TGFβ pathway is intricately linked to squamous epithelial differentiation 
and it has for some time now been suggested that the stable maintenance of EBV in epithelial 
cells requires an undifferentiated environment (Knox et al., 1996, Jones et al., 2003). It is 
therefore possible that changes affecting the differentiation status of the target cell may dictate 
the ability of the cell to respond to TGFβ, perhaps even playing a significant role in the switch 
of TGFβ between tumour-suppressive and tumour-promoting roles (Ikushima and Miyazono, 
2010), and may also govern the ability of EBNA1 to modulate TGFβ signalling within. 
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Interestingly, the differentiation of EBV-infected B cells into plasma cells is associated with 
the initiation of lytic cycle in vivo (Laichalk and Thorley-Lawson, 2005), while in epithelial 
cells, stable EBV infection was only achievable in those cells that had lost the competence to 
differentiate and also failed to enter virus lytic cycle (Knox et al., 1996). EBV lytic cycle is 
reportedly induced by TGFβ in EBV-positive B cells (di Renzo et al., 1994, Fahmi et al., 
2000), and therefore both features are indicative of a loss of typical responses to TGFβ. 
 
Repairing the main TGFβ defect in C666-1 cells alleviates the assumed EBNA1-mediated 
repression of Qp, and activity is subsequently increased by TGFβ stimulation, while TGFβ 
normally exerts a repressive effect on Qp-promoter activity, certainly in EBV-infected BL 
cells (Liang et al., 2000). This indicates that reversing acquired defects may be incompatible 
with stable EBNA1 expression and genome maintenance, and indeed the level of EBNA1 
transcription appears reduced following this effect. Dysregulated TGFβ signalling may 
therefore play a significant role in the successful maintenance of EBV in the C666-1 cell line. 
Once these defects have been more extensively characterised, it will be interesting to 
specifically disable TGFβ signalling in differentiated cell lines currently unpermissive to EBV 
infection, to examine the phenotypic consequences and determine whether stable infection 
can now be tolerated.  
 
It has been reported that the EBV-mediated loss of sensitivity to the anti-proliferative effects 
of TGFβ is not synonymous with a complete abolition of TGFβ signalling (Horndasch et al., 
2002). Indeed it would be somewhat detrimental to the tumour to totally eradicate TGFβ 
signalling due to its ubiquitous role in a multitude of cellular processes and also for its 
requirement in pro-tumourigenic functions. In the work conducted by Horndasch and 
 181 
colleagues, the EBV-immortalised B cells studied demonstrated resistance to the anti-
proliferative and pro-apoptotic effects of TGFβ, but no significant changes in cell surface 
TβRII expression. Heldin et al. reported similar findings in a comparison of non-neoplastic 
and neoplastic thyroid follicle cells, and were unsuccessful in assigning a definitive 
mechanism for the observed insensitivity to growth inhibition by TGFβ1 in the HTh7 cell line 
(Heldin et al., 1999). Defective TGFβ signalling in cancer can be broadly categorised into two 
groups (Massagué, 2008); complete loss of the core pathway through inactivation of central 
components, as exemplified by the loss of TβRII in the C666-1 cell line, or selective loss of 
the tumour suppressor arm only, which appears to be the case in the majority of other 
carcinoma cell lines studied. In the latter case, remaining TGFβ responses can be co-opted by 
cells for their own tumourigenic advantage. 
 
The exact mechanism by which cancer cells acquire resistance to TGFβ-mediated anti-
proliferative effects but are still able to benefit from some TGFβ responses has long been a 
puzzle, yet features identified in this work, for example down-regulation of Dab2 and over-
expression of Cav-1 seem to support this switch in TGFβ activity. Indeed whilst cell lines 
expressing high levels of Dab2 responded appropriately to TGFβ-induced growth inhibition, 
this response was not maintained in low-expressing lines, which instead demonstrated a 
modest increase in motility rate, as well as promotion of anchorage-independent growth. 
(Hannigan et al., 2010). Similarly, Cav-1 expression in NIH3T3 fibroblast cells is seen to 
down-regulate TβRII gene transcription with ensuing diminished TGFβ-induced responses 
(Lee et al., 2007), while in melanoma cell lines it was found to enhance proliferation, and to 
promote anchorage independence, migration and invasion (Felicetti et al., 2009). Both effects 
 182 
have also been ascribed to the development of EMT (Martin et al., 2010, Bailey and Liu, 
2008). 
 
In addition, Kim et al. published a study showing the ability of Cav-1 to increase both basal 
and TGFβ1-induced type I procollagen expression, despite the fact that Cav-1 overexpression 
is proven to inhibit TGFβ/Smad signalling (Kim et al., 2008) This was attributed to a Smad-
independent mechanism involving Cav-1-induced activation of the PI3K/Akt pathways. There 
has also already been some suggestion that Smad-dependent TGFβ signalling in hepatocytes 
is accomplished via association with a clathrin-associated AP-2 complex, whilst non-Smad 
signalling via Akt activation is mediated by dynamin and caveolin-1 (Meyer et al., 2011). 
Moreover, TGFβ-induced MAPK activation is thought to be dependent on TGFβ receptor 
heterocomplex localisation in lipid rafts (Zuo and Chen, 2009). A proposed hypothesis is that 
the increased Cav-1 in conjunction with loss of Dab2 expression may preferentially divert 
receptors down the lipid raft route, from which they would receive instruction to activate non-
Smad signalling pathways so as to promote invasion, metastasis and EMT-like conversions, 
while also being subjected to increased pressure from Smad7 and Smurf2 for receptor 
degradation. 
 
Although both Smad7 and Smurf2 are themselves TGFβ target genes (Nagarajan et al., 1999, 
Ohashi et al., 2005), their expression is not exclusively reliant on canonical TGFβ/Smad 
signalling. Evidence suggests that Smad7 expression can be stimulated by IFNγ, acting 
through Jak1 and STAT1, and that this in turn induces the accumulation of Smad7-Smurf2 
complexes in the cytoplasm, where they can effectively target both TGFβ receptors and 
Smads (Ulloa et al., 1999, Kavsak et al., 2000). This observation is of particular interest in 
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light of previously published data highlighting the ability of EBNA1 to enhance STAT1 
expression and activation in response to IFNγ (Wood et al., 2007). Additionally, although 
Smurf2 is transcriptionally induced by TGFβ, this stimulation of expression is thought to 
occur via a Smad-independent pathway, as inhibition of PI3K/Akt pathway suppressed TGFβ-
mediated Smurf2 induction (Ohashi et al., 2005). 
 
Data presented here supports a model in which the negative influence of EBNA1 may in fact 
be confined to the Smad-dependent signalling arm, targeted specifically to exploiting existing 
defects in carcinoma cell lines, counteracting the adverse effects of canonical signalling, and 
so favouring cell survival. At the same time, EBNA1 may help to divert the focus of the 
response and channel TGFβ to preferentially activate non-Smad signalling pathways, which 
enhance tumour-promoting functions and may even further negatively regulate classical Smad 
signalling (Moustakas and Heldin, 2005). Other studies have shown that EBV-encoded LMP1 
inhibits TGFβ signalling via constitutive ERK1/2 phosphorylation and NFκB activation 
(Fukuda et al., 2002, Prokova et al., 2002, Mori et al., 2003), whereas LMP2A appears to 
require activation of the PI3K/Akt pathway to achieve similar effects (Fukuda and 
Longnecker, 2004). Interconnection with other signalling pathways therefore appears to be a 
key mechanism employed by EBV-encoded proteins for TGFβ signal regulation, and thus the 
ability of EBNA1 to engage with Smad-independent pathways is likely to be of paramount 
importance in augmenting the TGFβ-associated tumour promoting effects. 
 
This effect appears to be in part mediated by differential expression of Smad phospho-
isoforms. Indeed a switch towards preferential expression of linker phosphorylated Smads is 
thought to parallel the conversion of TGFβ from tumour suppressor to tumour promoter. In 
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examining the relative expression levels of phospho-isoforms during sporadic human 
colorectal carcinogenesis, Yamagata and co-workers (Yamagata et al., 2005) describe a 
model, which has recently also been extended to hepatocellular carcinoma (Murata et al., 
2009), in which tumour cells are able to gain advantage through the selective inhibition of the 
TβRI-dependent pSmad3C pathway, deemed responsible for anti-proliferative tumour 
suppressor functions of TGFβ, with concomitant enhancement of the JNK-dependent 
pSmad3L, which promotes cell growth and induces a more invasive tumour phenotype 
(Matsuzaki et al., 2009, Matsuzaki and Okazaki, 2006, Sekimoto et al., 2007). This linker 
phosphorylation may even be directly important in acquiring resistance to TGFβ. Indeed a 
linker phosphorylation-resistant Smad3 mutant (EPSM) was able to restore sensitivity of Ras-
transformed epithelial cells to growth inhibition (Kretzschmar et al., 1999), and induced 
expression of p15
INK4B
 and p21
WAF1/Cip1
 in melanoma cells (Cohen-Solal et al., 2011). 
 
In all studies to date, the C666-1 cell line has demonstrated a profound lack of TGFβ 
responsiveness in terms of both R-Smad activation and complex formation, and TGFβ/Smad 
reporter activity, for which a lack of TβRII expression is held accountable (Wood et al., 
2007). However, it is shown here that linker phosphorylated Smads are still expressed by 
C666-1 cells, yet cannot be induced by TGFβ due to the absence of the ligand-binding TβRII. 
They may therefore emphasise the importance of Smad-independent signalling in carcinoma 
cell lines and be essential in mediating TGFβ-related effects in C666-1 cells. 
 
This domain specific phosphorylation of Smad2 and Smad3 may also prove to be a key 
determinant in enabling EBNA1 to confer a selective advantage to tumour cells, inducing a 
preferential shift towards the expression of linker phosphorylated Smad2 and Smad3 in order 
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to specifically up-regulate those genes which favour tumour cell invasion and promote 
oncogenic effects. Future studies would assess the contribution of various signalling pathways 
to Smad linker phosphorylation in EBNA1-expressing and EBV-infected cells, and the effects 
of these linker-phosphorylated forms on cell motility and invasion by selectively targeting 
Smad2/3 with shRNAs. 
 
Although Ad/AH, HONE-1 and AGS cell lines all show an increase in expression of at least 
some linker-phosphorylated isoforms, the pattern of Smad linker phosphorylation is not 
rigidly repeated across the panels, emphasising the cell-specific nature of TGFβ signalling in 
the three cell lines. Indeed the overall response may depend on the total combination of linker 
Ser/Thr sites phosphorylated, which will most likely be cell type- and context-dependent 
(Wrighton et al., 2006). A reduction in C-terminally phosphorylated pSmad2 has previously 
been confirmed by immunohistochemical staining of NPC tumour biopsies (Dr. Victoria 
Wood, unpublished observations). In this respect it would be useful to also examine the 
expression and localisation of linker phosphorylated Smads in a similar manner. Additional 
sites, as yet unstudied, within the Smad3 linker domain, glutamine 222 and proline 229, have 
been characterised as contributing towards Smad oligomerisation and DNA binding (Vasilaki 
et al., 2009), and so would also warrant investigation once commercial antibodies become 
available. 
 
In examining potential kinase involvement in the enhancement of Smad linker 
phosphorylation, the main kinase inhibitors seen to reduce phosphorylation were flavopiridol, 
U0126 and SP600125, which inhibit CDK, MEK-ERK/MAPK and JNK activities 
respectively. This suggests that the observed effects in EBNA1-expressing cells may be 
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mediated by enlisting CDKs, ERK-MAPK and JNK. Increased expression of the active forms 
of ERK-MAPK and JNK is observed in EBNA1-expressing cells in support of this, and, of all 
of the pathways investigated, ERK-MAPK, as well as PI3K signalling pathways were judged 
most significant in mediating LMP1-induced EMT (Laverick et al., manuscript in 
preparation).  
 
Furthermore, when studying Smad linker phosphorylation in the panel of three epithelial lines 
used in this study, some of the phosphorylated isoforms, particularly of Smad3, are no longer 
induced in response to exogenous stimulation with TGFβ. In cancer cells, linker 
phosphorylation is often constitutive, and has been recently demonstrated in melanoma cells 
(Cohen-Solal et al., 2011). Potential mechanisms for this include hyperactivation of 
associated MAPK pathways, or a down-regulation of linker phosphatases, or acquired 
resistance to their action (Sekimoto et al., 2007, Cohen-Solal et al., 2011). This is worthy of 
further investigation to determine whether EBNA1 potentiates this aberrant activation. 
 
Overall, data presented here implies that EBNA1 specifically modulates TGFβ signalling in 
carcinoma cells so as to facilitate pro-tumourigenic roles. It increases the transcription of 
several key proteins involved in the negative regulation of both TGFβ receptors and Smad 
proteins which may in part account for the previously reported attenuation of responses 
(Wood et al., 2007), while potentially manipulating Smad-independent signalling pathways 
and thereby modulating the nature of Smad phosphorylation, to ensure tumour-promoting 
effects predominate. Further analysis is required in order to pinpoint the exact mechanism for 
these observations and to further understand the contribution of these effects to NPC 
pathogenesis. 
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CHAPTER 4 
 
Modulation of BMP signalling by the EBV-encoded EBNA1 protein 
 
4.1 Introduction 
The TGFβ signalling pathway has been extensively investigated with regard to its role in 
cancer, yet the involvement of the closely-related BMP signalling pathway in tumour 
progression has only recently drawn attention. BMP signalling, as detailed in section 1.7, 
represents a branch of the TGFβ superfamily most extensively characterised for its roles in 
embryonic development, osteoblast differentiation and subsequent bone formation (Katagiri et 
al., 1994, Ducy and Karsenty, 2000, Cao and Chen, 2005, Sieber et al., 2009). Studies are 
now emerging to suggest a specific function for BMPs in tumour development and 
progression (Alarmo and Kallioniemi, 2010, Singh and Morris, 2010). Although the precise 
roles that BMPs play in this setting are still largely uncertain, an accumulating body of 
evidence suggests that the BMP signalling pathway is modulated in certain types of cancer, 
and that it can contribute to the invasive and metastatic properties of tumour cells. 
 
Over-expression of BMP2 has been documented in a variety of carcinoma-derived cell lines 
(Hatakeyama et al., 1997), and has been identified as being dysregulated in primary 
pancreatic cancer, oral squamous cell carcinoma, and in non-small-cell lung cancers (Kleeff et 
al., 1999, Jin et al., 2001, Soares et al., 2010, Langenfeld et al., 2005). Additionally, BMP6 is 
found to be over-expressed in metastatic prostate adenocarcinoma (Bentley et al., 1992), 
whilst over-expression of BMP7 has been documented in primary breast tumours (Alarmo et 
al., 2006), and both BMP4 and BMP7 are reportedly up-regulated in melanoma (Rothhammer 
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et al., 2005). Furthermore, activation of the BMP signalling pathway, typically interpreted as 
increased levels of phosphorylated Smad1/5/8, has been reported in primary colon carcinoma 
(Lorente-Trigos et al., 2010), non-small-cell lung cancer (Langenfeld et al., 2006), renal cell 
carcinoma (Markić et al., 2010), and in oestrogen-receptor positive and metastatic breast 
cancers (Helms et al., 2005, Katsuno et al., 2008). 
 
To date, the status and integrity of the BMP signalling pathway has not been investigated in 
NPC. However, recent gene expression profiling of microdissected NPC tumours has 
identified up-regulation of the TGFβ superfamily ligands, BMP2 and activin A in NPC 
tumours (Hu, PhD thesis, 2010). This study has also revealed gene expression profiles which 
indicate significant dysregulation of TGFβ/Activin/BMP signalling in authentic NPC tumours 
and in the EBV-positive NPC cell line C666-1. This at first appears counterintuitive, given the 
established TβRII defect and the consequential ablation of canonical TGFβ signalling in 
C666-1 cells, as well as the attenuation of TGFβ signalling in EBNA1-expressing and rEBV-
infected carcinoma cell lines, as reported in Chapter 3. It was therefore hypothesised that 
alternative but related members of the TGFβ superfamily and their associated effects may 
contribute to this observed gene expression signature. 
 
A high degree of concordance is found between TGFβ and activin transcriptional responses. 
This is not surprising, given that both TGFβ and activin ligands share the same receptor 
binding properties and utilise the same set of R-Smads, Smad2 and Smad3, in combination 
with the co-Smad, Smad4 for signal transduction (Ryu and Kern, 2003, Schnepp and Hua, 
2003). A previous study therefore sought to determine the status of activin signalling in the 
C666-1 cell line (Hu, PhD thesis, 2010). This study confirmed an intact activin signalling 
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pathway which, in the face of an abrogated TGFβ signalling pathway, enabled the induction 
of Smad2 phosphorylation and expression of TGFβ-responsive genes, PAI-1 and p21WAF1/Cip1, 
in response to activin A stimulation. However, the absence of significant activin A ligand 
expression in C666-1 cells cast doubt on the relative importance of the pathway to signalling 
within these cells. 
 
A more detailed analysis of the gene expression profiles of NPC tumours and the C666-1 cell 
line identified over-expression of the BMP family member BMP2, findings which suggest 
that the BMP signalling pathway may play a more prominent role or cooperate with TGFβ in 
NPC pathogenesis. The essential structure of the BMP pathway is similar to that described for 
TGFβ and activin, in that BMPs also signal via heterotetrameric receptor complexes at the 
cell surface and intracellular Smad complexes containing the common Smad mediator, 
Smad4. However, BMP signals are propagated through a different set of R-Smads, Smad 
1/5/8 (Miyazono, 1998, Piek et al., 1999, Miyazono et al., 2001), and the methods of receptor 
oligomerisation are thought to be more flexible in nature (Groppe et al., 2008, Nickel et al., 
2009). Contrary to the mode of receptor binding employed by TGFβ and activin ligands, 
BMPs possess a comparatively low affinity for their type II receptors, with a higher affinity 
instead to their type I receptors (Rosenzweig et al., 1995, Nickel et al., 2009); binding is 
further substantially increased in the presence of heteromeric type I/type II receptor 
complexes (Rosenzweig et al., 1995, Piek et al., 1999). 
 
Despite this, a degree of functional similarity is apparent between BMPs and TGFβ, 
particularly in their corresponding abilities to function in a context-dependent fashion as both 
tumour suppressors and tumour promoters (Singh and Morris, 2010). Furthermore, some 
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BMPs are also predicted to exhibit a comparable switch in behaviour to that of TGFβ in 
cancer progression. In colon cancer, cells isolated from a primary colon cancer biopsy 
underwent growth inhibition in response to BMP2, but developed resistance with sustained 
exposure, and instead acquired the ability to undergo BMP2-mediated EMT, and displayed 
enhanced cellular motility and invasion (Kang et al., 2009). 
 
In addition to the increase in BMP2 ligand expression, gene profiling has identified a general 
up-regulation of several BMP signalling pathway components in NPC tumours; namely, 
ActRI, BMPRIA, BMPRII, Smad1, Smad4 and Smad5 (Hu, 2010). This study therefore 
sought to explore the possible contribution of BMP2 to TGFβ family signalling in C666-1 
cells, and extended these observations to other carcinoma cell lines to determine whether 
EBV or, more specifically, EBNA1 might be involved in regulating BMP signalling.  
 
4.2 The status of the BMP signalling pathway in NPC tumours and C666-1 cells 
4.2.1 Gene expression profiling of the BMP signalling pathway in NPC tumour 
biopsies 
To obtain an overall impression of the status of the BMP signalling pathway in NPC tumours, 
normalised array intensities obtained from gene expression array analysis were subjected to 
further hierarchical clustering using dChip software so as to generate a heat map displaying 
differentially regulated genes associated with the BMP signalling pathway. Here, array 
intensities from authentic NPC tumours and the EBV-positive C666-1 cell line were 
compared to normal epithelium. As shown in Figure 4.1, a large number of BMP signalling 
pathway components were found to be up-regulated, suggesting an overall activation of the 
BMP signalling pathway in NPC tumours and the C666-1 cell line. Two tumour samples  
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Figure 4.1:  Gene expression profiling of BMP pathway-associated genes in NPC 
tumours
Extensive literature searches revealed a set of genes associated with the BMP signalling 
pathway. The resulting gene list was utilised to identify significantly differentially regulated 
genes, using expression array data generated in a separate study from 16 tumours and 4 
normal controls, which were visualised using dChip software for hierarchical clustering 
analysis. The expression level of each gene in an individual sample is colour coded: blue for 
downregulation, red for upregulation and white for unchanged. Normal samples are 
highlighted by the green box.
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(HK_68(8) and XY3_NPC8) however do not appear to cluster with the rest, indicating that, 
although BMP pathway activation is a common feature of a large proportion of NPC tumours, 
it is not universally observed. 
 
4.2.2 The expression of BMP pathway components in C666-1 cells 
In an earlier study where TGFβ and activin signalling responses were examined in C666-1 
cells, the telomerase-immortalised oral keratinocyte line OKF6 was used as a suitable control 
(Hu, PhD thesis, 2010), given its sensitivity to TGFβ1-mediated cell growth suppression 
(Peng et al., 2006). It was therefore also used in this study so as to provide a direct 
comparison with previously published data. 
 
The elevated expression of BMP2 in the EBV-positive cell line C666-1 had already been 
validated by QPCR (Hu, PhD thesis, 2010). To expand upon this observation, RT-PCR 
analysis was enlisted to profile key components of the BMP pathway in the EBV-positive 
C666-1 versus the OKF6 cell line, so as to identify genes whose expression may be 
specifically altered by the presence of EBV. These findings are depicted in Figure 4.2. Several 
BMP ligands were examined and, in addition to confirming the increase of BMP2 expression, 
this analysis also identified a substantial up-regulation of BMP7 at the mRNA level. 
Conversely, the expression of both BMP4 and BMP6 appeared to be transcriptionally down-
regulated in C666-1 cells. 
 
BMP ligands are reported to bind a variety of type I and type II receptors and, of those 
receptors studied, an up-regulation of ActRIIB was identified, with little change in the  
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Figure 4.2:  Expression of BMP pathway components in OKF6 and C666-1 cells
RT-PCR analysis for mRNA expression levels of BMP ligands (BMP2, 4, 6 and 7), BMP 
receptors (ActRI, ActRIIB, BMPRIA, BMPRIB and BMPRII), BMP-specific Smads
(Smad1, Smad5 and Smad8) and classical BMP target genes (Id1, Id2 and Id3) in OKF6 and 
C666-1 cells. EBNA1 was included as a control for EBV expression in the C666-1 cells and 
GAPDH was included as a positive control to confirm equal RNA input into the PCR 
reactions, while negative water controls confirmed the absence of contamination. 
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expression of BMPRIA, but down-regulation of ActRI, BMPRIB and BMPRII. These 
receptors recruit and specifically activate the BMP-specific R-Smads, Smad1, Smad5 and  
Smad8 to propagate the BMP signal. The expression of Smad1 was relatively unchanged 
between OKF6 and C666-1 cells, while Smad5 expression was decreased and Smad8 could 
not be detected in C666-1 cells. 
 
In several studies, BMP treatment has identified the Id genes, Id1, Id2 and Id3 as direct BMP 
target genes (Hollnagel et al., 1999, Korchynskyi and ten Dijke, 2002, Kang et al., 2003a, 
Kowanetz et al., 2004). Examination of their relative expression levels in OKF6 and C666-1 
cells revealed little difference between the two cell lines in terms of Id1 expression, but 
increased expression of both Id2 and Id3 in C666-1 cells compared to OKF6 cells. 
 
4.2.3 BMP pathway activation in C666-1 cells 
A representation of the degree of BMP pathway activation can be gained by examining the 
relative levels of phosphorylated Smad1/5/8. This was measured in OKF6 and C666-1 cells 
by immunoblotting of total cell lysates after treatment with BMP2, or subsequent inhibition 
with the BMP inhibitor, Noggin. A representative immunoblot, shown in Figure 4.3, 
demonstrates that the basal levels of phosphorylated Smad1/5/8 were substantially higher in 
C666-1 cells compared to OKF6 cells. Stimulation with BMP2 resulted in an appropriate 
induction of Smad1/5/8 phosphorylation in OKF6 cells, but did not further potentiate the 
constitutively raised levels observed in C666-1 cells, perhaps indicating that the BMP 
signalling pathway was saturated in this cell line. The BMP antagonist, Noggin, was effective 
in reducing the levels of Smad1/5/8 phosphorylation, which were partially restored by the 
addition of BMP2 in C666-1 cells, but not in OKF6 cells. 
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Figure 4.3:  Smad1/5/8 phosphorylation in OKF6 and C666-1 cells
Immunoblotting for protein expression levels of the phosphorylated form of 
Smad1/5/8 in serum-starved OKF6 and C666-1 cells treated with 100ng/ml 
recombinant hNoggin, for 1 hour, followed by 50ng/ml recombinant hBMP2 for 
a further 24 hours, or left unstimulated as controls. β-actin was included to 
confirm equal protein loading.
Noggin (100ng/ml)    - - +        +     - - +     +
BMP2 (50ng/ml)       - +        - +     - +      - +
OKF6 C666-1
pSmad1/5/8
EBNA1
β-actin
60kDa
70kDa
42kDa
MW
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4.2.4 BMP reporter activity in C666-1 cells 
The integrity of the BMP signalling pathway was further investigated using a BMP-specific 
reporter construct, BRE-Luc, which contains a BMP-response element (BRE) from the mouse 
Id1 promoter. The BRE-luciferase reporter construct is specifically activated by BMP, but not 
by either TGFβ or activin (Korchynskyi and ten Dijke, 2002). OKF6 and C666-1 cells were 
transiently transfected with the BRE-luc reporter, and were subsequently either stimulated 
with increasing concentrations of BMP2, or incubated with various concentrations of the 
BMP antagonist, Noggin, for 24 hours. Relative luciferase activity was determined, and is 
depicted graphically in Figure 4.4. Stimulation with BMP2 was sufficient to induce a dose-
dependent increase in the levels of BRE-Luc reporter activity in OKF6 cells, while a titration 
of BMP2 had little influence on the measured levels of BRE-Luc reporter activity in C666-1 
cells, possibly reflecting saturation of the BRE by the particularly high endogenous levels of 
activated pSmad1/5/8. In both cell lines, Noggin was effective in inhibiting the level of BRE-
Luc activity by greater than fifty percent over the concentration range used. 
 
4.2.5 The effect of exogenous Noggin on BMP responses 
Once it had been established that the levels of BMP signalling were constitutively elevated in 
C666-1 cells, the study sought to investigate whether disruption of the pathway would 
noticeably impact upon BMP gene expression. BMP2 has been implicated in the induction of 
p21
WAF1/Cip1
 and Id1 expression (Wen et al., 2004, Ogata et al., 1993, Clement et al., 2000, 
Langenfeld et al., 2006). As shown in Figure 4.5, addition of the BMP antagonist, Noggin, 
had little detectable effect on the expression level of Id1 protein in OKF6 cells, which was 
basally much higher than that detected in C666-1 cells. In contrast however, Id1 expression in 
C666-1 cells was completely abolished in response to BMP inhibition with Noggin. The  
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Figure 4.4:  The effect of BMP2 and Noggin on BRE-luc reporter activity in OKF6 and 
C666-1 cells
Dual luciferase reporter assays showing BRE-Luc activity in OKF6 and C666-1 cells 
stimulated with increasing concentrations of either recombinant hBMP2 (A) or recombinant 
hNoggin (B) for 24 hours or left unstimulated as a control. Histograms are shown to depict the 
relative luminescence after normalising to Renilla luciferase values and expressing as a ratio 
of activity relative to the control vector pGL3-basic. Data from three independent experiments 
is presented as the mean fold differences in activity + SE, relative to that observed in 
unstimulated cells which is given an arbitrary value of 1. 
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Figure 4.5:  The effect of BMP pathway inhibition on the expression of BMP 
target genes, Id1 and p21, in OKF6 and C666-1 cells
Immunoblotting for protein levels of Id1 and p21 in serum-starved OKF6 and 
C666-1 cells treated with 100ng/ml recombinant hNoggin for 24 hours, or left 
unstimulated as controls. Immunoblotting for EBNA1 is included to confirm 
EBV status and blots were re-probed for β-actin to confirm equal protein loading.
Noggin (100ng/ml)      - +          - +
OKF6 C666-1
Id1
EBNA1
β-actin
p21
15kDa
21kDa
70kDa
42kDa
MW
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expression of p21
WAF1/Cip1
 however was relatively unaffected by interfering with BMP 
signalling in both cell lines studied. 
 
4.2.6 The effect of BMP pathway stimulation and inhibition over a 24-hour time period 
To extend this investigation, time-courses of BMP2 and Noggin treatment were undertaken 
over a 24-hour period. OKF6 and C666-1 cells were treated with either 50ng/ml BMP2 or 
100ng/ml Noggin, and protein samples were collected at 0, 1, 2, 4, 6, 8 and 24 hour time-
points, before subsequent analysis by immunoblotting for a variety of both BMP- and TGFβ-
associated Smad proteins and BMP/TGFβ targets. Representative immunoblots are shown in 
Figure 4.6 and 4.7. Phosphorylation of Smad 1/5/8 were induced by exogenous BMP2 
stimulation in OKF6 cells and maintained for the most part before declining slightly after 24 
hours. The levels of pSmad1/5/8 in C666-1 cells were significantly elevated prior to 
stimulation and remained consistently high over the 24-hour time-course. 
 
As a result of the defective TGFβ signalling pathway in C666-1 cells, phosphorylation of the 
TGFβ-associated R-Smads, Smad2 and Smad3, was not induced to detectable levels by TGFβ 
stimulation. To determine whether BMP2 might be able to cross-activate the TGFβ pathway, 
and thereby negate the TβRII receptor defect, the phosphorylation of Smad2 was also 
analysed in response to BMP2 stimulation. It was found however that Smad2 phosphorylation 
was largely unaffected by BMP2 stimulation in OKF6 cells, and remained absent in C666-1 
cells. In accordance, the classical TGFβ target gene, PAI-1, showed little change in 
expression in response to BMP2 stimulation in OKF6 cells and remained undetected in C666-
1 cells. Id1 and p21
WAF1/Cip1
, while well-established as targets of TGFβ (Kang et al., 2003a, 
Datto et al., 1995, Levy and Hill, 2005), and key players in the TGFβ-induced cytostatic  
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Figure 4.6:  Expression of BMP- and TGFβ-associated proteins over a time-course 
of BMP2 treatment
Immunoblotting for protein levels of the phosphorylated form of Smad1/5/8, the serine 
465/467 phosphorylated forms of Smad2, PAI-1, p21 and Id1 in serum-starved OKF6 
and C666-1 cells treated with 50ng/ml recombinant hBMP2 and harvested at 0, 1, 2, 4, 
6, 8 and 24 hours post-treatment. Blots were re-probed for β-actin to confirm equal 
protein loading. A second immunoblot for Id1, exposed for the longer time of 5 
minutes, is also shown.
Time (hrs)  0      1     2      4    6  8  24   0     1     2     4    6     8     24
OKF6 C666-1
pSmad2 
S465/467
p21
PAI-1
pSmad1/5/8
EBNA1
β-actin
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response (Siegel and Massagué, 2003, Massagué and Gomis, 2006), can also respond to BMP 
signalling. In OKF6 cells, p21
WAF1/Cip1
 expression was induced by BMP2, peaking one hour 
after stimulation, and gradually decreasing over the remainder of the time-course. Expression 
was only marginally induced in C666-1 cells, with the greatest response observed at around 4 
hours and, by 24 hours had returned to basal levels. Id1 followed a similar pattern in OKF6 
cells, with the highest level of induction 1 to 2 hours after stimulation, before gradually 
returning to basal levels. Id1 expression was only detected in C666-1 cells once the exposure 
time of the blot was increased, and was relatively unchanged in response to BMP2 exposure. 
 
In studying the effect of Noggin treatment on cells (Figure 4.7), the levels of basal Smad1/5/8 
phosphorylation were much lower in OKF6 cells, and were rapidly, and almost completely 
inhibited after only one hour of Noggin treatment. In C666-1 cells, the levels of 
phosphorylated Smad1/5/8 were also efficiently reduced by the addition of Noggin, although 
this effect required more time. Noggin treatment effectively reduced the expression of the 
p21
WAF1/Cip1
 and Id1 target genes in OKF6 cells, but not until later time-points. Unexpectedly, 
in C666-1 cells, the addition of Noggin produced an increase in p21
WAF1/Cip1
 expression at the 
4, 6 and 8-hour time-points. Increased exposure of the Id1 immunoblot revealed an effective 
abrogation of Id1 expression with increased exposure to Noggin.  
 
4.2.7 The effect of Noggin treatment on expression of the inhibitory I-Smads 
The inhibitory Smads (I-Smads), Smad6 and Smad7, are reported target genes of both TGFβ 
and BMP signalling (Afrakhte et al., 1998, Takase et al., 1998, von Gersdorff et al., 2000, 
Ishida et al., 2000, Pogoda and Meyer, 2002, Benchabane and Wrana, 2003), and demonstrate 
an ability to form negative feedback loops which directly impact upon the signalling  
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Figure 4.7:  Expression of BMP- and TGFβ-associated proteins over a time-course of 
Noggin treatment
Immunoblotting for protein levels of the phosphorylated form of Smad1/5/8, p21 and Id1 in 
serum-starved OKF6 and C666-1 cells treated with 100ng/ml recombinant hNoggin and 
harvested at 0, 1, 2, 4, 6, 8 and 24 hours post-treatment. Blots were re-probed for β-actin to 
confirm equal protein loading. A second immunoblot for Id1, exposed for the longer time of 
5 minutes, is also shown.
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OKF6 C666-1
pSmad1/5/8
p21
Id1
β-actin
EBNA1
60kDa
21kDa
15kDa
15kDa
70kDa
42kDa
(1min)
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pathways. In this way, they function to directly antagonise both TGFβ and BMP signalling 
(Hayashi et al., 1997, Imamura et al., 1997, Nakao et al., 1997, Hata et al., 1998, Nakayama et 
al., 1998, Souchelnytskyi et al., 1998, Ishisaki et al., 1999, Denissova et al., 2000, Miyazono 
et al., 2005). A time-course of Noggin treatment, shown in Figure 4.8, indicated that the BMP 
signalling pathway was not particularly influential in determining the levels of Smad6 and 
Smad7 expression in either OKF6 or C666-1 cells. However, the study did reveal that, while 
expression of Smad6 was much higher in the OKF6 cells compared to C666-1 cells, the 
opposite result was seen for Smad7 expression. 
 
4.2.8 The effect of BMP pathway stimulation and inhibition on cell cycle progression 
BMP2 has demonstrated an ability to induce cell cycle arrest in several human B cell lines 
(Ishisaki et al., 1999, Yamato et al., 2000) and to inhibit the growth of androgen-sensitive 
LNCaP prostate cancer cells, MCF-7 and MDA-MB-231 human breast cancer cells and 
human MKN74 gastric cancer cells (Ide et al., 1997, Ghosh-Choudhury et al., 2000a, Ghosh-
Choudhury et al., 2000b, Wen et al., 2004), Similarly, both BMP2 and BMP7 have been 
reported to induce growth suppression in human colon cancer cells (Beck et al., 2006), while 
the growth inhibitory effect of BMP7 has additionally been reported on anaplastic thyroid 
carcinoma cells and androgen-insensitive PC-3 and DU-145 prostate cancer cells (Franzén 
and Heldin, 2001, Miyazaki et al., 2004). 
 
Given the ability of BMP2 signalling to govern the expression of genes contributing to a 
growth arrest response, the effect of both stimulating and inhibiting the BMP pathway on cell 
cycle progression was investigated. OKF6 and C666-1 cells were grown in 0.5% serum for 16 
hours prior to stimulation with either 50ng/ml BMP2 or 100ng/ml Noggin, or left  
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Figure 4.8:  Expression of inhibitory Smads over a time-course of Noggin 
treatment
Immunoblotting for levels of Smad6 and Smad7 protein expression in serum-
starved OKF6 and C666-1 cells treated with 100ng/ml recombinant hNoggin and 
harvested at 0, 1, 2, 4, 6, 8 and 24 hours post-treatment. Blots were re-probed for 
β-actin to confirm equal protein loading.
Time (hrs)   0     1    2   4   6   8    24    0    1  2   4  6   8  24
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unstimulated as a control. After 24, 48, 72 and 96 hours, cells were harvested and stained with 
propidium iodide, then analysed by flow cytometry. Data was subsequently analysed using 
MultiCycle, and representative histograms are shown in Figure 4.9. The analysis revealed no 
significant differences in cell cycle distribution between cell lines in the absence of 
stimulation. Addition of either BMP2 or Noggin did not markedly shift the distribution 
pattern, suggesting that BMP signalling within these cell lines does not influence cell cycle 
progression. 
 
4.3 The status of the BMP signalling pathway in EBNA1-expressing carcinoma cell 
lines 
4.3.1 BMP2 levels in Ad/AH, HONE-1 and AGS carcinoma cell lines 
Having identified increased levels of BMP2 expression and constitutive activation of the 
BMP signalling pathway in the C666-1 cell line, it was important to determine whether a 
similar phenomenon was observed in the Ad/AH, HONE-1 and AGS carcinoma cell lines 
and, specifically, whether a role for EBNA1 could be demonstrated in this effect. Therefore, it 
was initially considered vital to examine the basal expression levels of BMP2 in these cell 
lines. 
 
To this end, RNA was extracted from Ad/AH, HONE-1 and AGS cells expressing either a 
neomycin resistance cassette or EBNA1, or infected with rEBV. Following cDNA synthesis, 
RT-PCR was performed using oligonucleotides specific to BMP2. It is apparent from Figure 
4.10A that BMP2 transcription was increased in EBNA1-expressing cells across all three cell 
lines. This increase was supported in rEBV-infected Ad/AH and AGS cells, but could not be 
shown for rEBV-infected HONE-1 cells. These same differences were confirmed and  
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Figure 4.10:  The expression of BMP2 in Ad/AH, HONE-1 and AGS carcinoma cell lines
A) RT-PCR analysis of levels of BMP2 mRNA expression in Ad/AH, HONE-1 and AGS cells 
expressing either a control neomycin resistance cassette or EBNA1, or stably infected with 
rEBV. GAPDH was included as a positive control to confirm equal RNA input into the PCR 
reactions, while negative water controls confirmed the absence of contamination. QPCR analysis 
for BMP2 mRNA levels is also shown, in which GAPDH was included as an internal baseline 
control. Histograms are shown displaying the mean fold change differences SE (n=3) relative 
to Neo control cells (** denotes a P-value <0.01 and * denotes a P-value <0.05).
B) Immunoblotting for BMP2 protein levels in Ad/AH, HONE-1 and AGS cells expressing either a 
neomycin resistance cassette, or EBNA1, or stably infected with rEBV, with β-actin included to 
confirm equal protein loading. 
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quantified by QPCR, which served to demonstrate an approximate 1.5-fold increase in 
expression attributable to the presence of EBNA1 in Ad/AH and HONE-1 cell lines, with 
more pronounced increases in the AGS-EBNA1 cell line, in relation to their respective Neo 
control counterparts. 
 
Protein lysates were subsequently generated and immunoblotting performed to determine the 
relative levels of BMP2 protein. Figure 4.10B shows that the levels of BMP2 protein were 
increased in EBNA1-expressing and rEBV-infected cell lines, where corresponding increases 
in BMP2 transcripts were observed. 
 
4.3.2 Gene expression profiling of the BMP signalling pathway in Ad/AH cell lines 
To ascertain whether EBNA1 had any effect on BMP signalling, an overall view of 
differentially regulated BMP pathway-associated genes was obtained through hierarchical 
clustering analysis of existing Affymetrix gene expression array data obtained from Ad/AH 
cells stably expressing EBNA1 versus the parental Ad/AH cell line (Valentine et al., 2010). 
The resultant heat map of differentially regulated genes generated using dChip software is 
shown in Figure 4.11. A large number of up-regulated genes (red) implies a specific role for 
EBNA1 in the activation of the BMP signalling pathway. 
 
4.3.3 Profiling of BMP pathway components in Ad/AH, HONE-1 and AGS cell lines 
RT-PCR analyses of BMP ligands, receptors, Smads and target genes were conducted in 
Ad/AH, HONE-1 and AGS cells expressing either a neomycin resistance cassette, EBNA1, or 
stably infected with rEBV. As can be deduced from Figure 4.12, the majority of pathway 
components are expressed in all cell lines with the exception of the AGS cell panel which, 
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Figure 4.11:  Gene expression profiling of BMP pathway-associated genes in Ad/AH 
cell lines
Extensive literature searches revealed a set of genes associated with the BMP signalling 
pathway. The resultant gene list was utilised to identify significantly differentially 
regulated genes, using expression array data generated in a separate study from Ad/AH 
cells stably expressing EBNA1 and parental Ad/AH cells, which were visualised using 
dChip software for hierarchical clustering analysis. The expression level of each gene in 
an individual sample is colour coded: blue for down-regulation, red for up-regulation and 
white for unchanged.
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Figure 4.12:  Expression of BMP pathway components in Ad/AH, HONE-1 and AGS carcinoma 
cell lines
RT-PCR analysis for mRNA expression levels of BMP ligands (BMP2, 4, 6 and 7), BMP receptors 
(ActR1, ActRIIB, BMPRIA, BMPRIB and BMPRII), BMP-specific Smads (Smad1, Smad5 and Smad8) 
and classical BMP target genes (Id1, Id2 and Id3) in Ad/AH (A), HONE-1 (B) and AGS (C) cells 
expressing either a control neomycin resistance cassette or EBNA1, or stably infected with rEBV. RT-
PCR reactions were also performed to confirm EBNA1 status and the housekeeping gene GAPDH was 
included as a positive control to confirm equal RNA input into the PCR reactions, while negative water 
controls confirmed the absence of contamination.
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 regardless of the presence of EBNA1, lacked detectable expression of BMP6, BMPRIB and 
Smad8 transcripts. A closer agreement of expression patterns was discovered for Ad/AH and 
HONE-1 cell panels, with a reduction in BMP4 expression and increase in BMP6 expression 
in rEBV-infected lines, and also an increase in BMP6 expression in the EBNA1-expressing 
Ad/AH cells. In addition, increased BMPRIA expression was observed in EBNA1-expressing 
Ad/AH and HONE-1 cells, and also rEBV-infected Ad/AH cells, while a down-regulation of 
Smad8 was found in both EBNA1-expressing and rEBV-infected Ad/AH and HONE-1 cells. 
Of particular note, BMPRII was consistently down-regulated in the presence of EBNA1 and 
rEBV across all three cell lines.  
 
In examining the Id genes as examples of classical BMP target genes, it was found that 
expression of Id1 was consistently up-regulated in the EBNA1-expressing clones of all three 
cell lines, as well as the rEBV-infected Ad/AH and AGS cells. Increased expression of Id2 
however was observed in HONE-1 EBNA1-expressing and rEBV-infected cells only, while 
Id3, although up-regulated in Ad/AH EBNA1-expressing and rEBV-infected cells, appeared 
to be down-regulated across the HONE-1 panel and showed little change in expression across 
the AGS panel. 
 
4.3.4 BMP pathway activation in Ad/AH, HONE-1 and AGS cells 
The expression levels of phosphorylated Smad1/5/8 in Ad/AH, HONE-1 and AGS Neo 
control, EBNA1 and rEBV-infected cells were then determined by immunoblotting. As can be 
seen in Figure 4.13, the basal levels of phosphorylated Smad1/5/8 were elevated in the 
EBNA1-expressing cells across all three cell lines, and this was particularly well supported in 
the rEBV-infected Ad/AH cell line. Again, unlike their Neo control counterparts, and as  
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A)
B)
C)
Figure 4.13:  Smad1/5/8 phosphorylation in Ad/AH, HONE-1 and AGS carcinoma cell 
lines
Immunoblotting for protein expression levels of the phosphorylated form of Smad1/5/8 in 
serum-starved Ad/AH (A), HONE-1 (B) and AGS (C) cells expressing either a control 
neomycin resistance cassette or EBNA1, or stably infected with rEBV, and treated with 
100ng/ml recombinant hNoggin for 1 hour, then subsequently with 50ng/ml recombinant 
hBMP2 for a further 24 hours. Blots were re-probed for β-actin to confirm equal protein 
loading.
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demonstrated in C666-1 cells, the response of EBNA1-expressing cells was not further 
induced by BMP2 stimulation, again possibly because the response may already be saturated. 
For the majority of cell lines, treatment with Noggin effectively suppressed the levels of 
Smad1/5/8 phosphorylation which, in the Ad/AH EBNA1-expressing and rEBV-infected cell 
lines, were regained following exogenous BMP2 stimulation. However, Noggin treatment had 
little effect on the levels of Smad1/5/8 phosphorylation in the HONE-1 and AGS EBNA1-
expressing cells.  
 
4.3.5 BMP reporter activity in Ad/AH, HONE-1 and AGS cells 
BMP signalling activity in the Ad/AH, HONE-1 and AGS cell panels was further investigated 
by transient transfection of the BRE-Luc reporter construct. Cells were subsequently 
stimulated with 50ng/ml BMP2 or treated with 100ng/ml Noggin for 24 hours, and their 
relative luciferase activity was determined. Results are represented graphically in Figure 4.14. 
 
In the Ad/AH cell panel, the basal levels of BRE-Luc reporter activity were elevated in both 
EBNA1-expressing and rEBV-infected cells compared to Neo control cells. This was further  
significantly induced to greater than two-fold in response to BMP2 stimulation, and was 
reduced below basal levels in the presence of Noggin. In contrast, in HONE-1 cells, there 
appeared to be a general decrease in the levels of BMP2-induced reporter activity in EBNA1-
expressing and rEBV-infected cells. Furthermore, a significant decrease in BRE-Luc reporter 
activity was observed both basally and under stimulation in AGS EBNA1-expressing and 
rEBV-infected cells compared to their Neo control counterparts. 
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A)
C)
B)
Figure 4.14:  The effect of BMP2 and Noggin on BRE-luc reporter activity in Ad/AH, 
HONE-1 and AGS cells
Dual luciferase reporter assays showing BRE-Luc activity in Ad/AH (A), HONE-1 (B) and AGS 
(C) cells expressing either a control neomycin resistance cassette or EBNA1, or stably infected 
with rEBV, treated with either 50ng/ml recombinant hBMP2 or 100ng/ml recombinant hNoggin
for 24 hours or left untreated as a control. Histograms are shown to depict the relative 
luminescence after normalising to Renilla luciferase values and expressing as a ratio of activity 
relative to the control vector pGL3-basic. Data from five independent experiments is presented as 
the mean fold differences in activity + SE, relative to that observed in unstimulated Neo control 
cells which is given an arbitrary value of 1 (** denotes a P-value <0.01 and * denotes a P-value 
<0.05). 
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4.4 Potential functional consequences of BMP signalling pathway activation 
4.4.1 The effect of BMP pathway inhibition on cell migration 
BMP2 has been specifically associated with the migratory and invasive capacity of liver 
cancer SMMC7221 cells (Wu et al., 2011), while BMP2, and slightly less potently, BMP4 
and BMP7, have been shown to stimulate the migration and invasion of prostate cancer cells 
in vitro (Feeley et al., 2005, Feeley et al., 2006a). In the latter study, the BMP antagonist, 
Noggin, was used effectively to inhibit cellular migration of both BMP2- and BMP4-
stimulated cells. 
 
The effect of BMP pathway inhibition on the migration of Ad/AH, HONE-1 and AGS cell 
panels was similarly measured by transwell migration assay. Representative fields from one 
of five experiments are shown in Figure 4.15. As previously shown in section 3.3.3, compared 
to Neo control cells, both EBNA1-expressing cells and their rEBV-infected counterparts 
displayed increased rates of migration on fibronectin over a 24-hour period. In the AGS and 
HONE-1 panels, treatment of Neo control cells with Noggin increased migration, whereas cell 
migration was partially inhibited by Noggin treatment in EBNA1-expressing cells. This 
pattern did not however appear to be repeated in the rEBV-infected cell lines. In the Ad/AH 
cells however, Noggin was effective in causing partial inhibition of the migration of both 
EBNA1-expressing and rEBV-infected cells, with a comparative negligible effect in the Neo 
control cells (Figure 4.15B). 
 
To investigate this further, C666-1 cell migration was also studied under conditions where 
TGFβ and BMP signalling were inhibited. Representative fields from one of five experiments 
are shown in Figure 4.16. Whereas SB431542 had little or no effect on the migration of  
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Figure 4.15:  The effect of inhibition of BMP signalling on the migration of Ad/AH, HONE-1 and 
AGS carcinoma cell lines
Serum-starved Ad/AH (A), HONE-1 (B) and AGS (C) cells expressing either a control neomycin 
resistance cassette or EBNA1, or stably infected with rEBV were seeded into the upper wells of 
transwell migration chambers in serum-free medium with and without 100ng/ml Noggin, and allowed to 
migrate for 24 hours. The number of migrated cells in five representative fields were counted and 
histograms were created showing the mean number of cells migrated ( SD) (** denotes a P-value <0.01 
and * denotes a P-value<0.05).
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Figure 4.16:  The effect of inhibition of TGFβ and BMP signalling on the migration of C666-1 cells
Serum-starved C666-1 cells were seeded into the upper wells of transwell migration chambers in serum-
free medium with and without either 10μM or 100μM SB431542, or 100ng/ml or 1μg/ml Noggin, and 
allowed to migrate for 24 hours toward 10% FCS. The number of migrated cells in five representative 
fields were counted and histograms were created showing the mean number of cells migrated ( SD) (** 
denotes a P-value <0.01).
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C666-1 cells, treatment with Noggin slightly enhanced cell migration, which was significantly 
potentiated by a ten-fold increase in Noggin concentration. 
 
4.4.2 Potential crosstalk between TGFβ and BMP signalling pathways 
Much debate exists over the possibility and potential mechanism by which alternative TGFβ 
family ligands may be capable of promiscuous activation of related signalling pathways 
through differential receptor utilisation and subsequent activation of the appropriate Smad 
effectors. The premise for such a hypothesis among TGFβ superfamily members was 
illustrated at an early stage by the proven ability of BMPs to signal through receptors 
classically regarded as activin receptors (Yamashita et al., 1995, Macías-Silva et al., 1998, 
Nagaso et al., 1999). 
 
Firstly the possibility that BMP2 may also exert some influence over TGFβ signalling was 
investigated. The expression of the serine 465/467 phosphorylated form of the TGFβ 
pathway-specific R-Smad, Smad2, was examined in the Ad/AH, HONE-1 and AGS cell 
panels, and also the OKF6 and C666-1 cells, by immunoblotting in the presence and absence 
of 50ng/ml BMP2. As shown in Figure 4.17, stimulation of cells with BMP2 for 24 hours had 
negligible effects on levels of serine 465/467 phosphorylated forms of Smad2 in all cell lines 
studied. 
 
TGFβ, on the otherhand, has already been shown to cross-activate BMP-Smads, Smad1 and 
Smad5 in C2C12 cells, HaCaT human keratinocytes, mammary epithelial and breast cancer 
cells (Wrighton et al., 2009, Daly et al., 2008, Liu et al., 1998, Liu et al., 2009). In some 
instances, this is predicted to be mediated via mixed type I receptor complexes comprising  
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Figure 4.17:  The effect of BMP2 on the phosphorylation of Smad2
Immunoblotting for protein expression levels of the serine 465/467 phosphorylated
form of Smad2 in serum-starved OKF6 and C666-1 cells (A), and Ad/AH (B), HONE-
1 (C) and AGS (D) cells expressing either a control neomycin resistance cassette or 
EBNA1, or stably infected with rEBV, stimulated with 50ng/ml recombinant hBMP2 
for 24 hours. Immunoblotting for EBNA1 expression was included for confirmation of 
cell line status and blots were re-probed for β-actin to confirm equal protein loading.
OKF6 C666-1
BMP2 (50ng/ml)         - +           - + 
EBNA1
pSmad2 
Ser465/467
β-actin
60kDa
70kDa
42kDa
MW
 
 228 
C)
D)
AGS
rEBV
AGS
EBNA1
AGS
Neo
BMP2 (50ng/ml)     - +         - +         - +
EBNA1
pSmad2 
Ser465/467
β-actin
60kDa
70kDa
42kDa
HONE-1
rEBV
HONE-1
EBNA1
HONE-1
Neo
BMP2 (50ng/ml)     - +         - +         - +
EBNA1
pSmad2 
Ser465/467
β-actin
60kDa
70kDa
42kDa
MW
 
 229 
TβRI, ActRIA and/or BMPRIA (Daly et al., 2008), while in others it is thought to occur 
completely independently of BMP type I receptors (Wrighton et al., 2009). 
 
It was therefore questioned whether TGFβ could instead signal via the BMP pathway in 
carcinoma cells. In C666-1 cells, it was hypothesised that, in the absence of a functional 
TGFβ pathway, due to loss of TβRII expression, C666-1 cells might possess the ability to 
divert TGFβ signalling into a more focussed BMP response. Representative immunoblots 
shown in Figure 4.18 demonstrate that treatment of Ad/AH, HONE-1 and AGS cells with 
TGFβ promoted an increase in the levels of phosphorylated Smad1/5/8. As shown previously, 
the basal levels of pSmad1/5/8 were higher in EBNA1-expressing and rEBV-infected cell 
lines, including C666-1, and this was further augmented by TGFβ treatment. A noticeable 
TGFβ-induced increase could not be detected in the C666-1 cells, presumably due to the lack 
of responsiveness of C666-1 cells to TGFβ. 
 
These observations were extended in the C666-1 cell line to examine the effects of Noggin 
pre-treatment so that a potential induction of Smad1/5/8 phosphorylation might be more 
easily observed. As shown in Figure 4.19, treatment with Noggin significantly depleted 
pSmad1/5/8 levels, which could be partially restored by stimulation with TGFβ in OKF6 cells 
only, but not in C666-1 cells. Similarly, a time-course of treatment with a neutralising 
antibody to TGFβ (clone 1D11) was carried out, and its effects on the activation of the BMP-
specific Smads were studied by immunoblotting. As shown in Figure 4.20, neutralisation of 
TGFβ bioactivity did not markedly impact upon levels of Smad1/5/8 phosphorylation, 
indicating that TGFβ is not a significant contributor to the high levels of activated Smad1/5/8 
in C666-1 cells. 
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Figure 4.18:  The effect of TGFβ on the phosphorylation of Smad1/5/8
Immunoblotting for protein levels of the phosphorylated form of Smad1/5/8 in serum-
starved OKF6 and C666-1 cells (A), and Ad/AH (B), HONE-1 (C) and AGS (D) cells 
expressing either a control neomycin resistance cassette or EBNA1, or stably infected 
with rEBV, stimulated with 5ng/ml recombinant hTGFβ1 for 24 hours. Immunblotting
for EBNA1 was included for confirmation of cell line status and blots were re-probed 
for β-actin to confirm equal protein loading.
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Figure 4.19:  The effect of TGFβ stimulation on Smad1/5/8 
phosphorylation following BMP pathway inhibition in C666-1 cells
Immunoblotting for protein levels of the phosphorylated form of 
Smad1/5/8 in serum-starved OKF6 and C666-1 cells treated with 
100ng/ml recombinant hNoggin for 1 hour, before stimulation with 
5ng/ml recombinant hTGFβ1 for a further 24 hours. EBNA1 
expression status was confirmed and blots were re-probed for β-actin to 
confirm equal protein loading.
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Figure 4.20:  The effect of TGFβ pathway inhibition on Smad1/5/8 
phosphorylation in C666-1 cells
Immunoblotting for protein levels of the phosphorylated form of Smad1/5/8 
in C666-1 cells treated with 10μg/ml monoclonal anti-TGFβ antibody (clone 
1D11), and harvested at 0, 1, 2, 4, 6, 8 and 24 hour post-treatment. β-actin
was included to confirm equal protein loading.
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4.4.3 Bone metastasis 
Given the prominent role of BMPs in bone formation, it is feasible that the enhanced BMP 
signalling pathway activity may specifically contribute to bone metastasis in NPC. Bone 
metastasis has been reported as a complication of the more advanced stages of NPC, where it 
is generally associated with poor prognosis (Micheau et al., 1987). Although bone metastases 
in NPC have not been extensively characterised, bone is a common site of metastasis in 
prostate, lung and breast cancers (Mundy, 2002), where its occurrence has gained 
considerably more attention. Indeed BMPs have been specifically linked to accelerated bone 
metastasis formation in all three cancer types (Feeley et al., 2005, Dai et al., 2008, Feeley et 
al., 2006b, Alarmo et al., 2008, Katsuno et al., 2008). 
 
A study by Kang and co-workers identified a specific set of genes found to be significantly 
differentially regulated in human breast cancer cell lines that demonstrate a defined 
propensity for metastasis to bone (Kang et al., 2003b). This gene set was deemed important in 
cooperatively promoting bone metastasis. To determine whether similar gene expression 
signatures could be induced by EBNA1, and also existed in NPC tumours, the same gene list 
was used to identify genes that were commonly differentially regulated, using gene expression 
data obtained from separate studies (Hu, PhD thesis, 2010, Valentine et al., 2010). Although it 
is important to appreciate that these genes are specific to breast cancer and therefore precise 
matches are not expected due to dissimilar cell origin, they were useful in providing a general 
guideline and suggesting potential genes with common involvement in bone metastasis.  
 
Data was subjected to hierarchical clustering analysis using dChip software and findings were 
visualised as heat maps. As illustrated in Figure 4.21, several genes identified as being  
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A)
Figure 4.21:  Gene expression profiling of bone metastasis-associated genes in Ad/AH cell 
lines
Gene expression signatures specifically associated with bone metastasis in breast cancer (Kang 
et al., 2003) were utilised to identify commonly differentially regulated genes found to be either 
under-expressed (A) or over-expressed (B) in Ad/AH cells stably expressing EBNA1 compared 
to parental Ad/AH cells. Expression array data generated in a separate study was subjected to 
further hierarchical clustering analysis, the results of which were visualised as a heat map using 
dChip software. The expression level of each gene in an individual sample is colour coded: blue 
for down-regulation, red for up-regulation and white for unchanged.
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under-expressed in the breast cancer bone metastasis signature were also down-regulated in 
EBNA1-expressing Ad/AH cells compared to control cells, and a number of over-expressed 
genes associated with bone metastasis were similarly up-regulated. In contrast, less 
concordance was observed between the breast cancer bone metastasis gene set and gene 
expression signatures of the NPC tumours (Figure 4.22), although normal samples did behave 
similarly, and NPC tumours clustered together, although into two separate subgroups for the 
over-expressed genes. 
 
4.5 Discussion and Future Work 
Findings presented in this chapter identify a novel function for the EBV-encoded EBNA1 
protein, namely its ability to stimulate expression of the TGFβ family member, BMP2. The 
generality of this effect was substantiated, as expression of EBNA1 in a variety of epithelial 
cell lines was sufficient to stimulate the expression of both BMP2 mRNA and protein, 
suggesting that these effects are probably linked to transcriptional up-regulation of BMP2. 
These findings serve to complement existing data describing elevated levels of BMP2 in 
authentic NPC tumours and the EBV-positive NPC cell line, C666-1 (Hu, PhD thesis, 2010). 
Profiling of the BMP signalling pathway in these carcinoma cell lines confirmed the integrity 
of the signalling pathway, indicating the capability of cells to respond to BMP signals, while 
measurement of Smad1/5/8 phosphorylation and detectable activation of the BRE-Luc 
reporter confirmed the functional integrity of the BMP signalling response. The elevated 
levels of phosphorylated Smad1/5/8 in the presence of EBNA1 and also EBV infection in all 
cell lines studied support a role for EBV, and more specifically for EBNA1, in modulating the 
BMP signalling pathway, through autocrine induction of BMP ligands. 
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A)
Figure 4.22:  Gene expression profiling of bone metastasis-associated genes in NPC 
tumours
Gene expression signatures specifically associated with bone metastasis in breast cancer 
(Kang et al., 2003) were utilised to identify commonly differentially regulated genes found to 
be either under-expressed (A) or over-expressed (B) in 4 normal samples and 15 NPC tumours 
plus the C666-1 EBV-positive NPC cell line. Expression array data generated in a separate 
study was subjected to further hierarchical clustering analysis, the results of which were 
visualised as a heat map using dChip software. The expression level of each gene in an 
individual sample is colour coded: blue for down-regulation, red for up-regulation and white 
for unchanged. Normal samples are highlighted by green boxes.
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The initial RT-PCR analyses revealed a number of changes in the transcription of genes 
associated with the BMP signalling pathway. The relevance of these observations is presently 
unclear, and it is important to note that further validation at the protein level is required before 
firm conclusions can be drawn. The RT-PCR analysis did suggest that the expression of 
different BMP receptors was frequently modified by the expression of EBNA1 or infection 
with EBV, although the observed patterns were not always consistent. 
 
It is generally accepted that BMP ligand specificity of a receptor complex is mainly dictated 
by the type I receptor (Alarmo and Kallioniemi, 2010). In the cell lines studied, expression of 
BMPRIA was found to be increased in Ad/AH and HONE-1 cells expressing EBNA1, an 
effect which, in the context of squamous cell carcinoma, has been attributed a specific role in 
the malignant transformation of the oral epithelium (Jin et al., 2001, Soares et al., 2010). 
Additionally, prominent expression of BMPRIB in malignant glioma, breast cancer and renal 
cell carcinoma has been correlated with tumour grade (Yamada et al., 1996, Helms et al., 
2005, Markić et al., 2010), though in the results presented here, a failure to detect BMPRIB in 
all AGS-derived cell lines, as well as an observed down-regulation of BMPRIB in C666-1 
cells are not in support of this observation. In contrast however, EZH2-dependent epigenetic 
silencing of BMPRIB has been detected in a subset of glioblastoma tumour-initiating cells, 
where it is proposed to impair BMP-mediated astroglial differentiation and instead favour 
tumourigenicity (Lee et al., 2008). Interestingly, up-regulation of EZH2 has already been 
observed in a number of NPC tumour samples (Hu et al., manuscript in preparation), while 
increased levels of expression of EZH2 have also been noted in EBV-positive NPC and GC 
cell lines (R. Port, unpublished observations); However, its potential contribution to 
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epigenetic effects has yet to be determined, as does the significance of EBNA1 to this 
observation. 
  
The expression profile of BMPRIB is reportedly more restricted across cell types in contrast 
to the wider expression of BMPRIA (Kawabata et al., 1998, Miyazono et al., 2010), which 
may account for its absence in the AGS cell lines. In addition, several studies suggest 
BMPRIA and BMPRIB mediate discrete functions. Indeed, they are found to regulate distinct 
processes during chick limb development (Zou et al., 1997), transmit divergent signals in 
specifying the commitment and differentiation of osteoblasts and adipocytes from bone-
derived mesenchymal progenitor cells (Chen et al., 1998) and, furthermore, differentially 
modulate prostate cancer growth in response to BMP, with BMPRIA conveying growth 
stimulation and BMPRIB eliciting growth suppressive effects (Ide et al., 1997). If a similar 
phenomenon were to be observed in the carcinoma cell lines used in this study, the increase in 
BMPRIA expression and/or down-regulation of BMPRIB would be in keeping with the 
promotion of tumour cell growth.  
 
One particularly striking result was the observed down-regulation of BMPRII in all cell lines 
studied. Loss-of-function mutations in BMPRII have been implicated in the development of 
primary pulmonary hypertension (Yu et al., 2005), while the loss of BMPRII expression 
appears to be a frequent event in cancer progression, as has been observed, particularly in 
metastatic variants, in renal cell carcinoma, prostate cancer and bladder cancer (Kim et al., 
2003, Markić et al., 2010, Kim et al., 2004a, Kim et al., 2004b). In support of this, expression 
of a dominant-negative BMPRII potentiated tumour cell proliferation and lung metastases in a 
mouse model of mammary carcinoma formation (Owens et al., 2011). In contrast however, a 
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requirement for BMPRII has been demonstrated for the enhanced proliferation of breast 
cancer cells in response to BMP2 (Pouliot et al., 2003) suggesting that its loss is only 
beneficial to certain tumour cell types. The evidence gathered here however suggests that 
rEBV-infected epithelial cells may fall into this category. 
 
Although the precise mechanism for this loss of BMPRII is undetermined at this stage, it is 
known to occur at the transcriptional level in EBNA1-expressing cell lines. Treatment with 
the demethylating agent 5-aza-2´-deoxycytidine was able to restore BMPRII expression in the 
human bladder cancer cell line TSU-Pr1, hinting at the involvement of epigenetic mechanisms 
in BMPRII silencing (Kim et al., 2004); this has yet to be determined in these carcinoma 
lines. In the context of viral infection and BMP signalling, KSHV infection, and in particular 
the expression of the K5 E3 ubiquitin ligase gene, has been associated with a reduction of cell 
surface BMPRII in the development of pulmonary arterial hypertension (PAH), through a 
mechanism involving increased ubiquitination and lysosomal degradation of the BMPRII 
receptor (Durrington et al., 2010). Fortuitously, an increase in receptor degradation is unlikely 
to impact on Smad1/5/8 phosphorylation, which occurs at the cell surface and precedes 
endosomal sorting and degradation (Hartung et al., 2006). It may therefore also be 
informative to study potential ubiquitin ligases that may target BMPRII. 
 
Poorly differentiated prostate cancers are commonly found to exhibit a loss of expression of at 
least one BMP receptor (Kim et al., 2000), potentially as a mechanism of evading the growth-
inhibitory effect of naturally high levels of BMPs in the bone microenvironment. This 
strategy may provide tumour cells with a mechanism for ablating certain growth-inhibitory 
signalling responses whilst retaining other more favourable effects. Moreover, a loss of 
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expression of the BMPRII receptor would unlikely have such a profound impact as, for 
example, a loss of TβRII on TGFβ signalling, as BMPs can also signal through the activin 
receptors ActRIIA and ActRIIB. Indeed, deletion of Bmpr2 in pulmonary artery smooth 
muscle cells in an ex vivo system did not abolish BMP signalling (Yu et al., 2005), with cells 
instead transmitting signals via ActRIIA. This observation is particularly pertinent to C666-1 
cells which, although lacking BMPRII, show up-regulation of ActRIIB which may adequately 
compensate in the transmission of BMP signals. Type II receptors do however differ in their 
ability to interact with type I receptors and the resulting receptor complexes formed therefore 
vary in signalling capacity. The exact nature of the effects of this shift in receptor usage is 
therefore worthy of further investigation. 
 
Furthermore, the loss of BMPRII in the cell lines studied did not seem to adversely affect 
Smad1/5/8 activation, suggesting that BMP signalling is not completely attenuated. This adds 
credence to the hypothesis that the high levels of pSmad1/5/8 observed in EBNA1-expressing 
cells may occur as a result of signalling through alternative receptor combinations, which may 
shift the nature of the BMP signalling response. In the pulmonary artery smooth muscle cell 
model, siRNA-mediated knockdown of Bmpr2 abrogated, but did not completely abolish 
BMP2 and BMP4 signalling, and concomitantly augmented signalling by BMP6 and BMP7 
(Yu et al., 2005). This is likely a result of the varying affinities exhibited by different BMP 
ligands for the various receptor combinations. BMP2 was found to bind more efficiently to 
BMPRII in combination with ActRI or BMPRIB compared to BMPRIA, while BMP7 binding 
to BMPRII was more potent with ActRI rather than BMPRIA or BMPRIB (Liu et al., 1995). 
Similarly, BMP7 can bind ActRI, BMPRIA and BMPRIB in the presence of the type II 
activin receptors, ActRII and ActRIIB (ten Dijke et al., 1994, Yamashita et al., 1995), while 
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BMP4, while efficiently binds BMPRIA and BMPRIB, does not share the demonstrated 
ability of BMP7 to signal through the activin receptor, ActRIA. Intriguingly, in the induction 
of osteoblast differentiation in C2C12 cells, BMP4 activates Smads 1, 5 and 8, whereas 
BMP6 and BMP7 target only Smad1 and 5 (Aoki et al., 2001), probably as a result of 
preferential binding to different type I receptors, and likely generate distinctive signalling 
outputs. The observed response is in fact likely to be determined by the overall complement 
of BMP ligands and receptor complexes present in different cell types. There also exists the 
additional possibility in some cell lines that the increase in Smad1/5/8 phosphorylation may 
be mediated instead by TGFβ, as will be discussed later. 
 
Smad8 is reported to be epigenetically silenced in multiple types of cancer including breast 
and colon cancers (Cheng et al., 2004). It was therefore unsurprising that it was not expressed 
at detectable levels in either C666-1 or AGS cells. The significance of this remains to be 
elucidated, however the additional down-regulation of Smad8 in EBNA1-expressing and 
rEBV-infected Ad/AH and HONE-1 cells suggest that it may be commonly targeted. An 
interesting study by Pardali and colleagues concluded that, of all five R-Smads, Smad8 
displayed the best efficiency in both promoter activation and endogenous gene induction of 
p21
WAF1/Cip1
 (Pardali et al., 2005). Down-regulation of Smad8 may potentially be part of a 
selective mechanism to protect against the induction of growth arrest. 
 
The observed increase of the BMP target Id1 in EBNA1-expressing Ad/AH, HONE-1 and 
AGS cells is encouraging given the increased expression of Id1 in NPC tumour samples 
(Wang et al., 2002). The reported ability of the EBNA1 homologue of KSHV, LANA, to 
contribute to Id1 expression in Kaposi’s sarcoma tumour cells suggests that LANA may also 
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engage the BMP signalling pathway (Tang et al., 2003). However, the low levels of protein 
expression in C666-1 cells in comparison with the OKF6 cells indicate that Id1 is not 
consistently up-regulated in response to stable latent infection with EBV. 
 
In monitoring the levels of Smad1/5/8 phosphorylation, it was discovered that, in some cell 
lines where the levels were particularly high, stimulation with BMP2 failed to elevate this 
further. This implies that the cells have, at this stage, attained a level of resistance to the 
effects of BMP2, which is not uncommon in the acquisition of tumourigenic features. The 
high levels of Smad1/5/8 phosphorylation may therefore be attributable to the actions of other 
BMPs. Alternatively, this may be indicative of the attainment of a saturation threshold within 
these cells, or a constitutive activation, possibly attributable at least in part to the observed 
increases in BMP2 ligand expression. 
 
In EBNA1-expressing and rEBV-infected Ad/AH cells, inhibition of Smad1/5/8 
phosphorylation by Noggin treatment could be effectively reversed to initial levels by the 
subsequent exogenous addition of BMP2, indicating that BMP2 is the predominant 
contributor to the phosphorylated Smad1/5/8 in these cells. However, in the rEBV-infected 
HONE-1 and AGS cell lines stimulation with BMP2 was not sufficient to restore levels, and 
could only achieve a partial restoration in C666-1 cells. In these cell lines it is possible that 
other BMP subtypes may play a more influential role. Indeed, a study comparing 
osteoinductive and non-osteoinductive strains of osteosarcoma cells concluded that the 
potential for osteoinductivity was likely conferred by the specific complement of BMP 
subtypes present, their threshold levels and interactions with each other (Raval et al., 1996). 
RT-PCR detected increases in the expression of BMP7 in C666-1 cells, and also of BMP6 in 
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some EBNA1-expressing and rEBV-infected lines, which are likely to produce differential 
effects. In addition, certain BMPs have demonstrated the ability to form heterodimers, 
generally reported to exhibit more potent activity in comparison with homodimers, both in 
terms of biological activity and also in the secretion rate of active BMPs (Sampath et al., 
1990, Aono et al., 1995, Hazama et al., 1995, Nishimatsu and Thomsen, 1998, Piek et al., 
1999, Valera et al., 2010). A more comprehensive profiling of BMP ligand expression and 
their potential for heterodimerisation in the presence of EBNA1 is required to gain further 
insights into possible cooperative effects. 
 
If, as discussed earlier, constitutive activation of the BMP signalling pathway does occur 
within the cell lines, further stimulation with BMP2 may fail to elicit noticeable effects on 
target gene expression. Indeed, in C666-1 cells, expression of the BMP target gene, Id1, was 
unaltered over the course of the treatment with BMP2 over a 24-hour period. However, a loss 
of expression over time in response to Noggin treatment reinforces the idea that BMP 
signalling contributes to Id1 expression in this cell line. 
 
Conversely, it appears that the expression levels of the I-Smads, Smad6 and Smad7 are 
unlikely governed by BMP signalling. However, it is most interesting to observe the higher 
levels of Smad6 in OKF6 cells, but of Smad7 in C666-1 cells, given that Smad7 is generally 
more potent than Smad6 in repressing TGFβ and activin signalling (Hanyu et al., 2001, Itoh et 
al., 1998), while Smad6 preferentially inhibits the BMP pathway (Itoh et al., 1998, Miyazono 
et al., 2005). This may be indicative of a relative suppression of BMP signalling in OKF6 
cells and further compounded inhibition of TGFβ signalling in C666-1 cells. 
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Despite the ability of BMP signalling to modulate genes such as p21
WAF1/Cip1
 and Id genes in 
the OKF6 and C666-1 cell lines, no demonstrable effects were observed on cell cycle 
distribution in either cell line. However, this is in agreement with the inability of BMP2 to 
stimulate proliferation of OSCC cells (Gao et al., 2010), and also studies in which it was 
concluded that the BMP2-dependent stimulation of Id expression was not sufficient to direct 
cells into proliferation or apoptosis (Clement et al., 2000), while high level induction of 
p21
WAF1/Cip1
 expression in various epithelial cells could only very weakly suppress epithelial 
cell proliferation due to concomitant induction of Id2 (Pardali et al., 2005). It is highly 
possible that the effects of BMPs in the epithelial cell lines may parallel those observed with 
TGFβ, uncoupling and acquiring resistance to potentially tumour suppressive effects while 
allowing pro-tumourigenic response to predominate. 
 
An example of one such response is the enhanced cellular migration in the presence of 
EBNA1 and EBV, as assessed by transwell migration assay. The results also suggest that 
increased BMP signalling within EBNA1-expressing and rEBV-infected carcinoma cell lines 
contributed at least to a partial extent to this increase in cell migration, as it was susceptible to 
reduction by treatment with Noggin. The opposite effect however was seen in C666-1 cells. 
An interesting study by Hsu and co-workers describes a correlation between melanoma 
tumour progression and the over-expression of BMP7 (Hsu et al., 2008). Forced expression of 
Noggin in melanoma cells was found to protect cells from BMP7-induced growth inhibitory 
effects, conferring the cells with a growth advantage. It is possible that, in a similar fashion, 
the addition of increasing concentrations of Noggin to C666-1 cells further promotes the 
acquisition of resistance to the potentially growth suppressive effects of BMP7 in favour of 
enhanced proliferation and migration. These observations are particularly relevant in light of 
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the observed increase in BMP7 mRNA expression detected in C666-1 cells. It will therefore 
be useful to specifically examine the effects of BMP7 stimulation on the cell cycle profile of 
C666-1 cells, as well as on their migration ability in transwell migration assays. Interestingly, 
the Ad/AH, HONE-1 and AGS EBNA1-expressing and rEBV-infected cells, whose migration 
is inhibited by Noggin, do not demonstrate this same increase in BMP7 expression. It will 
however be necessary to examine the migration of these other carcinoma cells lines using 
higher concentrations of Noggin. 
 
The BMP antagonist, Noggin, is a cysteine-knot containing protein, which acts effectively as 
a BMP ligand trap, sequestering the BMP ligand in an inactive complex, thereby inhibiting its 
engagement with the cell-surface receptors (Groppe et al., 2002). However, Noggin was not 
always efficient in inhibiting Smad1/5/8 phosphorylation in certain cell lines. There are 
several possible explanations for this; a higher concentration of Noggin may be required to 
effectively quench BMP activity in cell lines in which levels of pSmad1/5/8 are particularly 
high. Alternatively, the observed Smad1/5/8 phosphorylation may be mediated by BMPs not 
targeted by Noggin. As determined by in vitro experiments, Noggin binds BMP2 and BMP4 
with very high affinity, BMP7 with lower affinity, and has variable effects also on BMP5, 
BMP13 and BMP14 (Zimmerman et al., 1996, Krause et al., 2011). It may be informative to 
instead use the newer small-molecule inhibitors, dorsomorphin and its optimised derivative, 
LDN-193189, which instead target the kinase domain of type I receptors and therefore have a 
more global effect (Yu et al., 2008, Cuny et al., 2008, Boergermann et al., 2010). 
Additionally, the ineptitude of Noggin in reducing Smad1/5/8 phosphorylation in certain 
scenarios could also be explained if a significant contribution to the measured levels of 
pSmad1/5/8 was instead a result of TGFβ-induced phosphorylation. 
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Of particular interest was the finding that, while Noggin proved ineffectual in decreasing 
pSmad1/5/8 levels in HONE-1 and AGS EBNA1-expressing cells, it retained the ability to 
diminish BRE-Luc reporter activity in the same cell lines. In marked contrast to the increase 
in levels of Smad1/5/8 phosphorylation in these cells compared to their Neo control 
counterparts, the luciferase reporter activity was instead reduced. A possible explanation for 
this is that the pSmad1/5/8 signal is composed predominantly of the TGFβ-induced form, 
which has a demonstrated ability to increase the activity of the TGFβ-responsive promoter 
p3TP-lux (Liu et al., 1998, Wrighton et al., 2009), but fails to induce transcriptional activity 
from the BRE-Luc reporter (Liu et al., 2009, Wrighton et al., 2009). Moreover, Daly et al. 
suggest TGFβ stimulation can actually induce formation of mixed R-Smad complexes, again 
unable to activate BMP-responsive elements (Daly et al., 2008). Further to this, the formation 
of such complexes is thought to require higher concentrations of TGFβ (Daly et al., 2008, 
Wrighton et al., 2009), which has fortuitously been reported in Chapter 3. These points 
considered, it would be useful in future studies to examine the effects of TGFβ receptor 
inhibitors on Smad1/5/8 phosphorylation in the carcinoma cell lines, in addition to conducting 
a more detailed analysis of the Smad complexes found within the cells. 
 
The ability of TGFβ to induce Smad1/5 phosphorylation is an interesting concept. In 
endothelial cells, while activation of canonical TGFβ signalling via TβRI had an inhibitory 
effect on cellular proliferation and migration, TGFβ-mediated Smad1/5 phosphorylation via 
the ALK1 receptor stimulates endothelial cell proliferation and migration (Goumans et al., 
2002, Wrighton et al., 2009). In fact, ALK1 has been shown to function as a direct lateral 
antagonist of TGFβ/TβRI signalling (Goumans et al., 2003). Whether a similar setting is 
recapitulated in epithelial cells is not yet known, although it would likely be mediated by a 
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different type I receptor, as ALK1 is generally considered to be an endothelial-specific TGFβ 
type I receptor (Piek et al., 1999). 
 
Nevertheless, this ability to stimulate Smad1/5 phosphorylation may provide an additional 
method, supplementary to the BMP-mediated effects, through which the tumour-promoting 
facets of TGFβ behaviour are enhanced in the absence of a functional Smad2/3 pathway. It 
may therefore be directly relevant to the extensively reported switch in TGFβ behaviour 
during tumour progression. Intriguingly, the homozygous missense TGFBR2 mutation, 
R537P, which rendered HNSCC A253 cells refractory to TGFβ-mediated growth arrest, was 
found to result in the constitutive activation of Smad1/5 of the BMP pathway, and a highly 
motile and invasive cell type (Bharathy et al., 2008). Despite a loss of Smad2/3 activation, 
high intrinsic TβRII kinase activity was observed. The mutation of TβRII may therefore 
favour interaction with an alternative type I receptor with consequent selective 
hyperactivation of the Smad1/5 pathway. With this in mind, it would be interesting to screen 
for the occurrence of such mutations in NPC tumours, but also to determine the levels of 
TβRII kinase activity as well as the preferred binding partners of the receptor in the panels of 
carcinoma cells.  
 
TGFβ-induced Smad1/5 phosphorylation in all reported cases requires TβRII (Daly et al., 
2008, Wrighton et al., 2009). Therefore, although still totally feasible in the Ad/AH, HONE-1 
and AGS carcinoma cell lines, it is unlikely to be a significant mechanism in C666-1 cells. 
Indeed the pan-TGFβ neutralising antibody, clone 1D11, had little effect on pSmad1/5/8 
levels in C666-1 cells over the time-course of treatment. On a similar note, it would be 
interesting to examine the subsequent effects of restoring responsiveness to TGFβ signalling 
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by transient transfection of a TβRII expression plasmid, as has been described earlier in 
Chapter 3, on the BMP signalling pathway.  
 
BMPs are among a number of factors believed to be secreted by metastatic tumour cells and 
to act locally in the bone microenvironment to stimulate proliferation and differentiation of 
osteoblasts (Bentley et al., 1992, Mundy, 2002). Furthermore, increased serum BMP2 levels 
have been reported in gastric cancer and non-small-cell lung cancer (Park et al., 2008, Park et 
al., 2010, Choi et al., 2011), where they demonstrate a strong positive correlation with both 
tumour grade and metastatic burden. Despite the consistent observations of increased 
endogenous BMP2 expression in the presence of either EBNA1 expression or EBV infection, 
an associated increase in BMP2 secretion could not be demonstrated by ELISA (data not 
shown). It may however be useful to verify this using an analogous model to the mink lung 
epithelial cell assay for TGFβ secretion described in Chapter 3. Such assays have already 
been generated by stable transfection of a variety of cell lines with the BRE-Luc reporter 
(Logeart-Avramoglou et al., 2006, Zilberberg et al., 2007), and are generally considered more 
sensitive. 
 
The patterns of gene expression observed in breast cancer cell lines displaying a predilection 
for metastasis to bone did not match particularly well with the NPC tumour biopsy samples. 
However, this could partly be a result of sample selection, as tumours within this particular 
set were derived from primary tumour biopsies and not metastatic disease. Additionally, as 
the authors of the original paper discuss, those genes that demonstrate a general association 
with metastasis, irrespective of the target site, were not included, and therefore the expression 
of these metastasis-related genes in NPC tumours was not determined. It is possible that BMP 
 252 
pathway-associated genes may fall within this category. Despite this, it is encouraging that 
EBNA1 is seen to induce a similar increase or decrease in expression of genes considered 
over-expressed or under-expressed respectively in the bone metastasis signature. 
 
Bone has been identified as a preferential site for NPC metastasis and, in a study dating back 
to 1987, it was suggested that the undifferentiated form of NPC had the highest incidence of 
bone metastases compared to other subtypes (Micheau et al., 1987). Furthermore, the 
epithelial cell line, NPC-BM1, established from the bone marrow biopsy of a female 
Taiwanese patient with NPC was histopathogically characterised as non-keratinising, poorly 
differentiated subtype (Liao et al., 1998). Given the significant association of EBV with the 
undifferentiated NPC subtype, these studies support a hypothesis for the role of EBV in 
potentiating metastasis to bone. In order to pursue this further, it would be prudent to 
characterise the NPC-BM1 cell line specifically in terms of the BMP pathway. This could be 
extended to examine the metastatic ability of NPC-BM1 cells in vivo under BMP pathway 
inhibition. However it would be necessary to obtain pairs of autologous metastatic and 
primary tumours in order to conclusively investigate this observation. 
 
Secretome analysis of NPC-BM1 cells and NPC tissue transcriptome analysis detected 
cystatin A release from NPC cells in vitro and statistically elevated levels of cathepsin B and 
MnSOD, each with prospective roles in tumour metastasis (Chang et al., 2010). Probing of 
microarray data generated from EBNA1-expressing Ad/AH cells for cystatin A, cathepsin B 
and MnSOD predicted up-regulation of each of the genes by fold-changes of 2.61, 1.82 and 
2.19, respectively. 
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BMP2 is able to induce classical osteoblast differentiation markers, ALP, osteocalcin and 
Osf2/Cbfa1 gene transcription and positively regulates bone formation in vivo (Spinella-
Jaegle et al., 2001, Vaes et al., 2002, Lee et al., 2000). Runx2, the product of the Osf2/Cbfa1 
gene, is a transcription factor with a well-characterised role in the induction of osteoblast 
marker genes (Yang et al., 2003), and whose aberrant expression has been noted in both 
prostate and breast cancer cells, which frequently metastasise to bone (Baniwal et al., 2010, 
Leong et al., 2010). Significantly, osteocalcin (BGLAP) was found to be up-regulated 2.5-
fold on the Ad/AH EBNA1 microarray, while Osf2/Cbfa1 was up-regulated approximately 3-
fold. These findings, although requiring further validation, create fascinating avenues for 
further investigation. The potential that EBNA1 may be able to induce genes associated with 
osteoblast differentiation and/or bone metastases either directly, or indirectly through an 
enhancement of BMP2 signalling, may allude to a specific role for EBNA1 in promoting the 
formation of bone metastases. Further investigation could involve the use of existing cell 
models, such as the breast cancer cell line, MDA-MB-231, with a proven ability to 
metastasise to bone, to determine whether either the additional expression of EBNA1 or 
infection with EBV could accelerate metastatic development. Ultimately, an in vivo model is 
required in which to accurately measure the osteoinductive activity of both C666-1 and 
EBNA1-expressing carcinoma cells.  
 
While at present the interaction of viral proteins with the BMP signalling pathway has not 
been widely researched in cancer, one study has reported the ability of the hepatitis B virus-
encoded oncoprotein pX to activate BMP2-induced transcription in vivo, providing a potential 
contributory factor to hepatitis B virus-induced liver fibrosis (Lee et al., 2001). These data 
therefore represent the novel discovery that a virally-encoded protein may specifically 
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activate BMP signalling as a means by which to foster cellular migration to distant sites so as 
to establish a metastatic focus. This hypothesis is further enhanced by the intriguing 
possibility that this phenomenon may be specifically enhanced by the tumour-promoting 
aspect of TGFβ signalling. 
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CHAPTER 5 
 
Generation and validation of a panel of EBNA1 constructs in a lentiviral 
expression system. 
  
5.1 Introduction 
The role of the EBV-encoded EBNA1 protein in the modulation of cellular gene transcription 
in epithelial cell lines has been further extended in Chapters 3 and 4, yet the accountable 
mechanism could not be definitively determined. While its critical functions in the 
maintenance, replication and transcription of the EBV genome have been ascribed to specific 
domains of the EBNA1 protein (Wu et al., 2002), as described in more detail in section 
1.5.1.3, research implicating particular regions of the protein in cellular gene transactivation is 
very limited. Therefore, in order to pursue this further, a panel of EBNA1 domain mutants 
was generated in the hope of elucidating a suitable mechanism. A contemporary lentiviral 
cloning strategy was employed in order to provide more stable, long-term expression beyond 
that offered by existing retroviral-based systems. The deletion mutants were obtained by PCR 
amplification of a series of EBNA1-derived sequences contained within pc3oriP vectors (Wu 
et al., 2002). In addition to deletions of specific individual domains, the sequences each 
encompass a deletion of the gly-ala repeat region, located between residues 90-325, mainly to 
ensure suitability for PCR-directed cloning, as this region is highly repetitive and GC rich. 
This region is generally considered dispensable for the major replication, segregation and 
viral gene transactivation functions of EBNA1 (Yates et al., 1985, Ceccarelli and Frappier, 
2000), so in theory exclusion of this region should not dramatically impact upon the 
behaviour of the derived mutants. The initial panel of mutants was created by Miss Sonia 
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Maia (University of Birmingham, UK) in the Multisite Gateway
®
 Lentiviral Expression 
System (Invitrogen), under the control of the human metallothionein (hMTIIa) promoter, 
which is positively regulated by the addition of zinc to the growth medium. This panel was 
used to generate stable cell lines, which are validated herein. To further this work, and to 
corroborate the suggestion that a gly-ala-deleted EBNA1 can substitute as a pseudo wild-type, 
a complete wild-type version was generated for comparison. Dominant-negative derivatives 
of the EBNA1 protein were also created and validated, before subsequent cloning into the 
same lentiviral expression system. 
 
The Multisite Gateway
®
 Lentiviral Expression System uses replication-incompetent HIV-
derived lentiviral vectors within a 2nd generation packaging system to generate stable cell 
lines by viral transduction and subsequent drug selection. An overall schematic of the cloning 
procedure is depicted in Figure 5.1, and is described in more detail in the following sections. 
While previously used retroviruses were capable only of infecting replicating cells (Miller et 
al., 1990, Lewis and Emerman, 1994), these lentiviruses additionally possess the ability to 
infect and thereby facilitate highly efficient in vitro delivery of target genes to non-dividing, 
terminally differentiated cells (Naldini et al., 1996, Buchschacher and Wong-Staal, 2000). 
This method therefore carries the attractive potential for use in the transduction of primary 
keratinocytes, and a prospective use in examining the contribution of EBNA1 in the earliest 
stages of cell transformation, with subsequent monitoring of its action and requirement 
throughout the transformation process. 
 
 257 
Figure 5.1:  Schematic representation of the cloning procedure for generation of EBNA1 
lentiviral constructs 
 
The desired EBNA1 gene fragments were generated either by restriction endonuclease 
digestion or PCR amplification and subsequently ligated into the pCR
®
8/GW/TOPO
®
 vector 
at the site indicated. pCR
®
8/GW/TOPO
®
 vectors were combined in a homologous 
recombination reaction with a second entry vector containing the promoter of choice, 
pENTR
™
5´-TOPO
®
-hMTIIa, so as to insert the hMTIIa promoter and EBNA1 sequences into 
the destination vector, pLenti6/R4R2/V5-DEST. The resulting lentiviral vectors were 
validated by diagnostic restriction digests and by transient transfection to determine correct 
expression. These were then used to produce lentivirus, ready for viral transduction of the cell 
line of interest. Plasmid maps were obtained from the Invitrogen website. 
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5.2 Validation of EBNA1 mutant lentiviral constructs 
5.2.1 Transient transfection of EBNA1 mutant lentiviruses 
Ad/AH cells were transiently transfected with either pc3oriP or pLenti6/R4R2/V5-DEST 
EBNA1 mutant plasmids. 24 hours post-transfection, cells transfected with lentiviral vectors 
were additionally stimulated with 50μM ZnSO4 for 16 hours, or left unstimulated as a control. 
Protein samples were harvested and lysates subjected to immunoblotting analysis using K67, 
a rabbit polyclonal antibody specific for EBNA1. Lysates from Ad/AH Neo control, EBNA1 
and rEBV-infected cells were also included for EBNA1 protein molecular weight comparison. 
Figure 5.2 shows that EBNA1 protein was successfully expressed from each of the vectors, 
with appropriate differences in molecular weight corresponding with the size of the deletion. 
 
5.2.2 Validation of stable EBNA1 mutant Ad/AH cell lines 
Ad/AH cells stably expressing each of the panel of EBNA1 mutant lentiviruses were seeded 
into 10cm dishes at a density of 1x10
6
 and were incubated for 48 hours before stimulation 
with 50μM ZnSO4 for 16 hours. RNA samples were extracted and subsequent RT-PCR 
analysis, shown in Figure 5.3A, indicates that EBNA1 transcripts were absent in the cells 
carrying a control lentiviral vector expressing the hMTIIa promoter only, but were expressed 
in all of the mutant EBNA1 cell lines. EBNA1-expressing cell lines also all demonstrated 
responsiveness to zinc induction at this level, with greater levels of EBNA1 expression seen 
following the addition of ZnSO4. 
 
Cells were additionally seeded at a density of 2x10
4
 onto 12-well Teflon-coated slides, and 
subsequently grown for 24 hours, before stimulation with 50μM ZnSO4 for 16 hours. 
Immunofluorescence staining was performed using R4, a rabbit polyclonal antibody specific  
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Figure 5.2:  Validation of EBNA1 expression from pc3oriP and pLenti6/R4R2/V5-DEST 
constructs
Immunoblotting for EBNA1 protein expression in Ad/AH cells transiently transfected with 
either pc3oriP (O) or pLenti6/R4R2/V5-DEST (L) vectors containing the panel of EBNA1 
mutant sequences. After 24 hours, cells transfected with the lentiviral vectors were stimulated 
with 50μM ZnSO4 for 16 hours or left unstimulated as a control. β-actin was included to 
confirm equal protein loading. Lysates taken from Ad/AH Neo control, EBNA1 and rEBV-
infected cells were included for comparison of the relative molecular weights of mutant 
proteins to wild-type EBNA1.
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(
A)
Figure 5.3:  Validation of EBNA1 expression in stable Ad/AH cell lines
A) RT-PCR analysis of EBNA1 mRNA expression in Ad/AH cells stably expressing 
pLenti6/R4R2/V5-DEST lentiviral constructs containing EBNA1 mutant 
sequences under the control of an hMTIIa promoter, and either stimulated with 
50μM ZnSO4 for 16 hours, or left unstimulated. GAPDH was included as a 
positive control.
B) Immunofluorescence staining for EBNA1 protein expression was performed in the 
same cell lines, either stimulated with 50μM ZnSO4 for 16 hours, or left 
unstimulated. Representative images are shown.
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for EBNA1, and protein expression was examined by fluorescence microscopy. 
Representative images shown in Figure 5.3B indicate that EBNA1 protein was successfully 
expressed and was susceptible to further induction by zinc stimulation in the majority of cell 
lines, with the exception of a noticeable loss of signal in the Ad/AH EBNA1 Δ8-67 mutant 
cell line, suggesting this deletion may markedly affect protein stability, as expression was 
detected at the mRNA level (Figure 5.3A), and at the protein level following transient 
transfection (Figure 5.2). The lack of staining in Ad/AH Neo and hMTIIa controls confirmed 
antibody specificity. 
 
5.3 Generation of recombinant pCR
®
8/GW/TOPO
®
 transfer plasmid containing 
wild-type EBNA1 
5.3.1 Isolation of the wild-type EBNA1 sequence by restriction endonuclease digestion 
The complete wild-type EBNA1 sequence is inclusive of the gly-ala repeat region between 
residues 90-325, and is therefore, as already stated, not a favourable template for PCR-based 
cloning strategies. DNA encoding wild-type EBNA1 was therefore excised by EcoRI and 
BglII restriction endonuclease digestion from a pSG5-EBNA1 vector containing the Sau3A-
PvuII subfragment of the EBV BamHI-K fragment (Sample et al., 1992). The EBNA1 
fragment was then isolated using the QIAEX II Agarose Gel Extraction kit (Qiagen), and 
subjected to a BsaHI restriction digestion to remove a polyadenylation site in the sequence, 
and so prevent premature transcription termination. Successful isolation of the desired 
EBNA1 fragments was verified by agarose gel electrophoresis of the restriction fragments, as 
shown in Figure 5.4. To create a template suitable for use within the TOPO
®
 Cloning 
procedure, the restriction fragment was end-filled using T4 DNA polymerase and terminal 3´ 
deoxyadenosine nucleotides added with Taq DNA polymerase. 
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Uncut
EcoRI
only
BsaHI
6722bp
2288bp
358bp
Figure 5.4:  Excision of wild-type EBNA1 fragment by restriction 
endonuclease digestion
A) Restriction digestion of pSG5-EBNA1 using EcoRI and BglII restriction 
endonucleases to excise the Sau3A-PvuII subfragment of the EBV 
BamHI-K fragment (2646bp) from the pSG5 vector (4076bp).
B) Restriction digestion of the Sau3A-PvuII subfragment using BsaHI
restriction endonuclease to excise the required wild-type EBNA1 
fragment (2288bp) and remove sequence containing a polyadenylation
site (358bp). Restriction digestion of  pSG5-EBNA1 (6722bp) using 
EcoRI and uncut pSG5-EBNA1 plasmid are shown for size comparison.
EcoRI
+ BglII
4076bp
2646bp
A)
B)
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5.3.2 PCR of dominant-negative EBNA1 sequences 
A dominant-negative EBNA1 construct was derived in a similar manner to the existing panel 
of mutants from the pc3oriP-EBNA1 Δgly-ala plasmid using oligonucleotide primers (see 
Table 2.12.2) targeting sequences within the EBNA1 cDNA such that all sequence upstream 
of the nuclear localisation signal, situated between amino acids 379 and 386 (Ambinder et al., 
1991), would be deleted, effectively removing domains responsible for the transcriptional 
activation, segregation and replication functions of EBNA1. In this way, the DNA binding 
and dimerisation motifs, located between C-terminal residues 459 and 607 (Ceccarelli and 
Frappier, 2000), are retained, so fulfilling the defined criteria of efficient dominant-negative 
EBNA1 inhibitors, as outlined by Kirchmaier and Sugden (Kirchmaier and Sugden, 1997). 
Additionally, the same set of primers was used in a reaction with the pc3oriP-EBNA1 Δ395-
450 construct to create a second dominant-negative construct carrying the additional domain 
deletion, due to the reported interaction of this region with the human deubiquitinating 
enzyme, USP7 (Holowaty et al., 2003). As predictions outlined in Chapter 3 suggest that the 
mechanism through which EBNA1 is able to modulate TGFβ signalling may in part be related 
to its ability to influence ubiquitination, it was considered necessary to also eliminate this 
region.  
 
PCR amplification was performed on 0.01ng DNA in a reaction using the Expand High 
Fidelity PCR System (Roche). The optimum annealing temperature was determined prior to 
the final cloning PCR by PCR amplification over a temperature gradient. Gel-loading buffer 
was added to the PCR reactions, before analysis by agarose gel electrophoresis. As can be 
confirmed in Figure 5.5, fragments of the correct sizes were successfully amplified in the 
PCR reactions. 
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dnEBNA1
dnEBNA1
Δ395-450 H2O
789bp
622bp
Figure 5.5:  PCR amplification of dominant negative EBNA1 gene fragments
Amplification of the dominant negative EBNA1 gene fragments (dnEBNA1 = 789bp, 
dnEBNA1 Δ395-450  = 622bp) was performed by PCR on 0.01ng pc3oriP-EBNA1 
Δgly/ala and pc3oriP-EBNA1 Δ395-450 templates, using High fidelity DNA 
polymerase.
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5.3.3 Generation of pCR
®
8/GW/TOPO
®
 entry vectors 
The excised wild-type EBNA1 coding sequence and Taq polymerase-amplified dominant-
negative EBNA1 PCR products were ligated into the linearised pCR
®
8/GW/TOPO
®
 vector, as 
detailed in section 2.12.5. pCR
®
8/GW/TOPO
®
 vectors containing the EBNA1 sequences were 
then used to transform One Shot
®
 TOP10 E.coli cells under spectinomycin selection. 10pg of 
pUC19 DNA was transformed in a similar manner, but under ampicillin selection, as a 
positive control for transformation efficiency, while a non-transformed bacterial culture was 
used as a negative control. 
 
Between ten and twenty colonies were picked for analysis and grown overnight in 3ml LB 
nutrient broth containing 100μg/ml spectinomycin in an orbital shaker at 37°C, and DNA 
isolated from overnight bacterial cell cultures using the Qiagen QIAprep Spin Miniprep Kit 
(Qiagen), as detailed in section 2.12.7.1. DNA concentrations were measured using a Nano-
drop spectrophotometer and samples were stored at -20°C. 
 
5.3.3.1  Diagnostic restriction endonuclease digests 
In order to ensure that the pCR
®
8/GW/TOPO
®
 vectors contained the desired EBNA1 
fragments in the correct orientation, a series of diagnostic restriction digests were performed. 
EcoRI was used for both the wild-type and dominant-negative sequence-containing constructs 
to identify which samples contained the inserted fragment of the correct size. A double 
restriction digest reaction with NcoI and EcoRV revealed the fragment orientation of wild-
type sequences, while SacII and XbaI were used to determine the orientation of dominant-
negative sequences. 
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Gel images of the resolved products of wild-type EBNA1 restriction digests are shown in 
Figure 5.6. The EcoRI cut of a positive clone should effectively separate the desired 2.29kb 
wild-type EBNA1 fragment from the pCR
®
8/GW/TOPO
®
 vector (2.82kb). It is apparent from 
Figure 5.6A that, of the twenty clones analysed, only samples 2, 5, 12, 14 and 18 were 
digested correctly, indicating that, although some colonies grew and plasmid DNA could be 
successfully extracted, the ligation reaction had not been successful. Those samples selected 
from the initial EcoRI digest were then subjected to a second restriction digest using NcoI and 
EcoRV. While a single cut with NcoI confirmed the linearization of the vector, retrieval of 
3.15kb and 1.95kb fragments indicated the correct orientation of the EBNA1 sequence, as can 
be seen for samples 12 and 18 in Figure 5.6B. 
 
Similarly, for the dominant-negative EBNA1 sequences, successful insertion of the PCR-
amplified products is exemplified by the detection of 789bp and 622bp fragments in addition 
to the pCR
®
8/GW/TOPO
®
 vector, for dominant-negative and the 395-450 deleted dominant-
negative EBNA1 respectively. Ten colonies were analysed for each and, as can be ascertained 
from Figure 5.7A, all samples appeared to contain the correct EBNA1 sequence, with the 
exceptions of sample 8 for the standard dominant-negative, and sample 5 for the dominant-
negative with 395-450 deletion. 
 
Subsequent SacII and XbaI double restriction digests are shown in Figure 5.7B. Again, 
digestion with SacII confirmed linearization of the vector, while the double digest identified 
samples 2, 4 and 7 for dominant-negative EBNA1 and samples 4, 5, 6 and 10 for dominant-
negative EBNA1 Δ395-450, as containing the correct fragments in the right orientation. 
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EBNA1
pCR®8
2.29kb
1    2 3     4 5  6 7  8  9   10  11 12   13  14  15 16 17  18  19   20
* * * * *
NcoI
only
NcoI + 
EcoRV
NcoI
only
NcoI
only
NcoI
only
NcoI
only
NcoI + 
EcoRV
NcoI + 
EcoRV
NcoI + 
EcoRV
NcoI + 
EcoRV
2 12 14 185
5.1kb
3.15kb
1.95kb
* *
A)
B)
Figure 5.6:  Diagnostic restriction digests of pCR®8/GW/TOPO® vector containing wild-type 
EBNA1
A series of diagnostic digestions were performed to validate insertion of the wild-type EBNA1 
(wtEBNA1) gene fragment into the pCR®8/GW/TOPO® vector.
A) EcoRI restriction digests were performed on the pCR®8/GW/TOPO®-wtEBNA1 plasmid to 
confirm the insertion of the gene fragment of interest. The asterisk (*) marks those samples 
containing a fragment of the correct size.
B) NcoI and EcoRV double restriction endonuclease digests were performed on the 
pCR®8/GW/TOPO®-wtEBNA1 vector to validate the correct orientation of the inserted wild-
type EBNA1 gene fragment. The asterisk (*) marks those samples containing the EBNA1 
sequence in the correct orientation.
A plasmid map of pCR®8/GW/TOPO® ,  highlighting its key features and generated using ApE
Plasmid Editor software, is shown, adapted from the map found at:
http://tools.invitrogen.com/content/sfs/vectors/pcr8gwtopo_map.pdf
689 EcoRI (2)
TOPO recognition site 1 678...682
671 EcoRI (2)
GW1 priming site 607...631
attL1 569...668
Spn promoter 930...1063
SpnR 1064...2074
pUC ori 2141...2814
pCR8 GW TOPO.ape
2817 bp
TOPO recognition site 2 683...687
attL2 696...795
GW2 priming site 733...757
806 EcoRV (1)
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A)
1          2      3       4    5      6      7          8   9     10
2817bp
789bp
dnEBNA1
* * * * * * * * *
1       2          3        4      5         6       7         8        9       10
2817bp
622bp
dnEBNA1 Δ395-450
* * * * * * * * *
Figure 5.7:  Diagnostic restriction digests of pCR®8/GW/TOPO® vector containing 
dominant negative EBNA1 sequences
A series of diagnostic digestions were performed to validate insertion of the dominant-negative 
EBNA1 (dnEBNA1) gene fragments into the pCR®8/GW/TOPO® vector (2817bp).
A) EcoRI restriction digests were performed on the pCR®8/GW/TOPO®-dnEBNA1 and 
dnEBNA1 Δ395-450 plasmids to confirm the insertion of the gene fragments of interest. 
The asterisk (*) marks those samples containing a fragment of the correct size.
B) SacII and XbaI double restriction endonuclease digests were performed on the 
pCR®8/GW/TOPO®-dnEBNA1 and dnEBNA1 Δ395-450 vectors to validate the correct 
orientation of the inserted dominant negative EBNA1 gene fragments. The asterisk (*) 
marks those samples containing the EBNA1 sequences in the correct orientation.
A plasmid map of pCR®8/GW/TOPO® ,  highlighting its key features and generated using ApE
Plasmid Editor software, is shown, adapted from the map found at:
http://tools.invitrogen.com/content/sfs/vectors/pcr8gwtopo_map.pdf
attL2 696...795
689 EcoRI (2)
TOPO recognition site 2 683...687
TOPO recognition site 1 678...682
671 EcoRI (2)
GW1 priming site 607...631
attL1 569...668
GW2 priming site 733...757
924 XbaI (1)
Spn promoter 930...1063
pUC ori 2141...2814
pCR8 GW TOPO.ape
2817 bp
SpnR 1064...2074
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5.3.3.2  DNA Sequencing 
Potentially positive transformants were selected from the restriction digest screening process 
and their sequences determined to ensure precise cloning. Chosen samples were sequenced 
using the ABI Prism 310 (Applied Biosystems) sequencing protocol (see section 2.12.8). 
Results were then analysed using Chromas software and the sequences were checked against a 
consensus EBV genome sequence using the online alignment tool BLAST (bl2seq) (NCBI). 
Segments of the sequencing traces and their respective proportional identities with the EBV 
genome sequence are shown in Figure 5.8. 
 
5.4 Multisite Gateway
®
 LR Recombination 
The recombinant lentiviral expression vectors containing the EBNA1 mutant sequences were 
designed so that EBNA1 expression could be driven under the influence of the zinc-inducible 
human metallothionein (hMTIIa) promoter. The same configuration was therefore required 
for the wild-type and dominant-negative EBNA1 constructs. The hMTIIa promoter had been 
previously cloned into the pENTR
™
5´-TOPO
®
 vector by Miss Sonia Maia using the 
pENTR
™
5´-TOPO
®
 TA cloning kit (Invitrogen). This entry clone was added in combination 
with a second entry vector, pCR
®
8/GW/TOPO
®
-EBNA1, in a homologous recombination 
reaction with pLenti6/R4R2/V5-DEST, as detailed in section 2.12.9.1, which juxtaposed the 
hMTIIa promoter and desired EBNA1 sequences within the same lentiviral vector. 
 
Reactions were used to transform the ONE SHOT
®
 Stabl3
™
 strain of E.coli competent cells 
under ampicillin selection, and resulting bacterial colonies were selected to derive overnight 
cultures, which were mini-prepped as outlined in section 2.12.7.1. Remaining cultures were 
stored at 4°C for Maxi-Prep of cultures found to contain successfully recombined plasmids. 
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Figure 5.8:  Sequencing reaction outputs
Sequencing outputs were visualised using Chromas and segments of example traces for 
wild-type EBNA1 (A), dominant-negative EBNA1 (B) and dominant-negative EBNA1
Δ395-450 (C) are shown. Each peak represents a discrete signal from each base of the 
analysed sequence (red = thymine, green = adenine, blue = cytosine and black = guanine).
Gene sequences were exported from Chromas in FASTA format and aligned against the 
EBV genome sequence using BLAST. A sample of the BLAST output is shown for each. 
Small errors in sequence were analysed and resolved by equating mismatches in the 
alignment with overlapping peaks on the Chromas traces.
A)
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B)
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5.4.1 Diagnostic restriction digests 
The recombinant pLenti6/R4R2/V5-DEST vectors containing the wild-type and dominant-
negative EBNA1 sequences were validated by separate EcoRI and EcoRV restriction digests, 
designed to isolate, for EcoRI, the pLenti6/R4R2/V5-DEST vector, EBNA1 sequence and 
hMTIIa promoter separately, and for EcoRV, the pLenti6/R4R2/V5-DEST vector with the 
promoter and EBNA1 sequence as a single fragment. Restriction digest reaction products 
were resolved by agarose gel electrophoresis and gel images are shown in Figures 5.9 and 
5.10. For the wild-type EBNA1 (Figure 5.9), it is evident following restriction digestion that 
all ten colonies contained lentiviral vectors into which both desired sequences had been 
successfully recombined. 
 
For the standard dominant-negative EBNA1, EcoRI digests, shown in Figure 5.10A, indicate 
the convincing presence of hMTIIa and EBNA1 sequence in samples 1, 4, 5, 6, 8 and 10, with 
low levels of detection in the remaining samples. This pattern is appropriately reflected in the 
result with EcoRV (Figure 5.10B). The restriction digests of pLenti6/R4R2/V5-DEST-
dnEBNA1 Δ395-450 again indicate the presence of the desired sequences in all samples, 
although with only low levels of detection in samples 2, 6 and 7 (Figures 5.10C and 5.10D). 
 
5.4.2 Maxi-prep of plasmid DNA 
Cultures corresponding to samples that yielded correctly sized fragments after digestion were 
used to inoculate 500ml LB nutrient broth containing 100μg/ml ampicillin. Bacterial cultures 
were left to grow overnight in an orbital shaker at 37°C. Using Invitrogen PureLink HiPure 
Plasmid Filter Maxiprep kit, DNA was extracted and purified according to the manufacturer’s 
instructions, and as detailed in section 2.12.7.2. The DNA concentration of each plasmid was  
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Figure 5.9:  Diagnostic restriction digests of pLenti6/R4R2/V5-DEST vector containing 
the hMTIIa promoter and wild-type EBNA1
EcoRI and EcoRV restriction endonuclease digestion to validate the insertion of the hMTIIa
promoter and wild-type EBNA1 (wtEBNA1) gene fragment into the pLenti6/R4R2/V5-DEST 
vector.
(A plasmid map of pLenti6/R4R2/V5-DEST can be found at: 
http://toolszh.invitrogen.com/contents/sfs/vectors/plenti6_r4r2_v5dest_map.pdf)
 
 279 
1          2         3         4         5         6         7         8         9        10
pLenti6/R4R2/
V5-DEST
8070bp
hMTIIa + dnEBNA1
1671bp
A)
B)
Figure 5.10:  Diagnostic restriction digests of pLenti6/R4R2/V5-DEST vector containing 
the hMTIIa promoter and dominant negative EBNA1 sequences
A series of diagnostic digestions were performed to validate insertion of the hMTIIa promoter 
and dominant negative EBNA1 (dnEBNA1) gene fragments into the pLenti6/R4R2/V5-DEST 
vector.
A) EcoRI restriction digestion was performed to individually isolate the hMTIIa promoter 
and standard dnEBNA1 gene fragment from the pLenti6/R4R2/V5-DEST vector.
B) EcoRV restriction digests were performed to determine whether the juxtaposed hMTIIa
promoter and dnEBNA1 gene fragments could be isolated from the pLenti6/R4R2/V5-
DEST vector.
C) As above, EcoRI restriction digests were performed on clones obtained from 
transformation with pLenti6/R4R2/V5-DEST-dnEBNA1 Δ395-450.
D) As above, EcoRV restriction digests were performed on clones obtained from 
transformation with pLenti6/R4R2/V5-DEST-dnEBNA1 Δ395-450.
(A plasmid map of pLenti6/R4R2/V5-DEST can be found at: 
http://toolszh.invitrogen.com/contents/sfs/vectors/plenti6_r4r2_v5dest_map.pdf)
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measured using a Nano-drop spectrophotometer, and samples were aliquoted and stored at -
20°C for further use. 
 
5.5 Validation of recombinant lentiviral vectors 
5.5.1 Transient transfection of lentiviral constructs into Ad/AH cells 
Ad/AH cells were transiently transfected with 2μg pLenti6/R4R2/V5-DEST-wtEBNA1 and 
incubated for 24 hours post-transfection, before stimulating with 50μM ZnSO4 for a further 
16 hours, or leaving unstimulated as a control. Both RNA and protein were harvested and 
subsequently used in RT-PCR and immunoblotting procedures to detect expression of the 
EBNA1 mRNA and protein respectively. Extracts from Ad/AH Neo control and Ad/AH 
EBNA1 cells were included as references for EBNA1 size and molecular weight, and 
representative images are shown in Figure 5.11. It is evident that EBNA1 transcripts can be 
successfully derived from the pLenti6/R4R2/V5-DEST vector (Figure 5.11A), and that the 
resulting protein is of the correct molecular weight for the wild-type protein (Figure 5.11B).  
 
In order to determine the relative expression levels of EBNA1 from the lentiviral construct in 
comparison to an existing equivalent construct, both pSG5- and pLenti6/R4R2/V5-DEST-
wtEBNA1 plasmids were transfected in increasing concentrations into Ad/AH cells. Protein 
lysates were analysed by immunoblotting for EBNA1 using the K67 rabbit polyclonal 
antibody, and a representative immunoblot is shown in Figure 5.12. For both EBNA1 vectors, 
the level of EBNA1 protein detected rose in accordance with the increase in transfected 
protein. However, it is very apparent that the levels of EBNA1 expression were much lower 
for the pLenti6/R4R2/V5-DEST vector, compared to the pSG5 vector, at each corresponding 
concentration. 
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A)
B)
Figure 5.11:  Validation of EBNA1 expression from pLenti6/R4R2/V5-DEST-hMTIIa-
wtEBNA1 upon transient transfection into Ad/AH cells
A) RT-PCR analysis for EBNA1 mRNA expression in Ad/AH cells transiently transfected with 
the recombinant wtEBNA1 lentiviral plasmid and either stimulated with 50μM ZnSO4 for 16 
hours, or left unstimulated. GAPDH was included as a positive control to confirm equal RNA 
input into the PCR reactions, while samples generated from Ad/AH Neo control and Ad/AH 
EBNA1 lysates served as controls for EBNA1 expression.
B) Immunoblotting for EBNA1 protein expression in Ad/AH cells transiently transfected with 
the recombinant wtEBNA1 lentiviral plasmid and either stimulated with 50μM ZnSO4 for 16 
hours, or left unstimulated. Protein lysates obtained from Ad/AH Neo control, EBNA1 and 
rEBV-infected cells were included as controls for EBNA1 expression, while β-actin served as 
a loading control.
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Figure 5.12:  Determination of relative levels of EBNA1 expression following 
transient titration of pSG5-EBNA1 and pLenti6/R4R2/V5-DEST-hMTIIa-
wtEBNA1 plasmids into Ad/AH cells
Immunoblotting for EBNA1 protein expression in Ad/AH cells transiently 
transfected with increasing concentrations of either a pSG5-EBNA1 plasmid or the 
recombinant wtEBNA1 lentiviral plasmid (pLenti6-wtEBNA1), with β-actin
included as a loading control.
EBNA1
β-actin
pLenti6-wtEBNA1 (μg)    - - - - - 0   0.5     1     1.5      2
pSG5-EBNA1 (μg)   0      0.5     1      1.5     2                  - - - - -
70kDa
42kDa
MW
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Dominant-negative EBNA1 lentiviral constructs were then validated in a similar manner, 
subsequent to verification of the wild-type version, and so are shown alongside the wild-type 
lentivirus for comparison. As demonstrated in Figure 5.13A, EBNA1 transcripts were 
successfully detected from both vectors carrying dominant-negative sequences, and these 
were efficiently translated into EBNA1 protein of appropriately reduced molecular weight 
according to their respective deletions, as shown in Figure 5.13B. The level of expression of 
the Δ395-450 version did however appear to be significantly reduced. 
 
5.6 Generation of stable cell lines 
5.6.1 Lentivirus production 
The human kidney epithelial packaging cell line 293FT was used to produce whole virus from 
the recombinant lentiviral plasmids. Cells were seeded into 10cm dishes at a density of 1x10
6
 
and grown to 80-90% confluency, before transient co-transfection with 4μg 
pLenti6/R4R2/V5-DEST expression vector, and 4μg of each of the packaging plasmids, 
pMD2.G and psPAX2 (Addgene). Transfected cells were incubated overnight, then refed with 
DMEM supplemented with 10% heat-inactivated FCS. Cells were then grown for 
approximately 48 hours, after which viral supernatants were harvested and filtered through 
0.45μm filters. Virus-containing supernatants were then aliquoted into 1ml fractions and 
stored at -80°C. 
 
5.6.2 Lentiviral transduction of Ad/AH target cells 
Ad/AH cells were seeded into 6-well plates at density of 2.5x10
5
 cells per well and grown at 
37°C until approximately 60% confluent. 1ml supernatants containing wild-type, dominant-
negative and dominant-negative Δ395-450 EBNA1 lentiviruses, as well as a GFP control  
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A)
Figure 5.13:  Validation of EBNA1 expression from pLenti6/R4R2/V5-DEST-
hMTIIa-dnEBNA1 and pLenti6/R4R2/V5-DEST-hMTIIa-dnEBNA1 Δ395-450 
upon transient transfection into Ad/AH cells
A) RT-PCR analysis for EBNA1 mRNA expression in Ad/AH cells transiently 
transfected with either the recombinant dnEBNA1 lentiviral plasmids or the 
hMTIIa promoter control vector, and either stimulated with 50μM ZnSO4 for 16 
hours, or left unstimulated. GAPDH was included as a positive control to confirm 
equal RNA input into the PCR reactions, while samples generated from Ad/AH 
Neo control and Ad/AH EBNA1 lysates served as controls for EBNA1 
expression.
B) Immunoblotting for EBNA1 protein expression in Ad/AH cells transiently 
transfected with either the recombinant dnEBNA1 lentiviral plasmids or the 
hMTIIa promoter control vector, and either stimulated with 50μM ZnSO4 for 16 
hours, or left unstimulated. Protein lysates obtained from Ad/AH Neo control, 
EBNA1 and rEBV-infected cells are included as controls for EBNA1 expression, 
while β-actin served as a loading control.
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virus, were mixed with Polybrene
®
 (Millipore) at a final concentration of 6μg/ml, then applied 
to cells in each well. Cells were incubated overnight at 37°C and then refed the following day 
with fresh normal growth medium. After 72 hours, successful lentiviral transduction was 
assessed by GFP visualisation in those cells transduced with control virus. A blasticidin 
resistance cassette within the pLenti6/R4R2/V5-DEST plasmid was exploited for drug 
selection of positively transduced cells.  
 
5.6.3 Immunofluorescent staining of stable lentivirally transduced Ad/AH cells 
Ad/AH cells stably expressing the wild-type and dominant-negative lentiviruses were seeded 
at a density of 2x10
4
 onto each well of a 12-well Teflon-coated slide and grown for 24 hours 
before stimulating with 50μM ZnSO4 for a further 16 hours. Immunofluorescence staining 
was then performed using R4, a rabbit polyclonal antibody specific for EBNA1. 
Representative fluorescence microscopy images are shown in Figure 5.14. It is evident that 
the lentiviral constructs exhibited a degree of inherent leakiness, resulting in levels of EBNA1 
expression roughly comparable with levels observed in Ad/AH EBNA1 cells, which can then 
be further induced by the addition of zinc. 
 
5.7 Deletion of different EBNA1 protein domains differentially affects TGFβ/Smad 
luciferase reporter activity 
In order to validate the functionality of the expression plasmids, the panel of 
pLenti6/R4R2/V5-DEST EBNA1 mutants, along with the wild-type EBNA1 vector, were 
transiently transfected into Ad/AH cells in addition to the TGFβ-responsive p(CAGA)12-Luc 
reporter, demonstrated in Chapter 3 to be inhibited by functional EBNA1 expression. The 
relative luciferase activity is depicted graphically in Figure 5.15. Transfection of wild-type  
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Ad/AH-wtEBNA1 Ad/AH-dnEBNA1
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Figure 5.14:  Validation of recombinant EBNA1 protein expression in stable 
Ad/AH cell lines by immunofluorescence staining
Immunofluorescence staining for EBNA1 protein expression in Ad/AH cells stably 
expressing the pLenti6/R4R2/V5-DEST plasmid carrying the wtEBNA1, dnEBNA1 
and dnEBNA1 Δ395-450 sequences. Representative images are shown.
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Figure 5.15:  The effect of transient expression of EBNA1 mutant proteins on TGFβ
reporter activity
Dual luciferase reporter assay showing p(CAGA)12-Luc activity in Ad/AH cells transiently 
transfected with one of the panel of pLenti6/R4R2/V5-DEST-EBNA1 mutants or the wild-
type EBNA1. A histogram is shown to depict the relative luminescence after normalising to 
Renilla luciferase values and expressing as a ratio of activity relative to the control vector 
pGL3-basic. Data from four independent experiments is presented as the mean fold 
differences in activity + SE, relative to that observed in the Ad/AH pLenti6/R4R2/V5-
DEST-hMTIIa control cells which is given an arbitrary value of 1 (** denotes a P-value 
<0.01 and * denotes a P-value <0.05). 
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EBNA1 effectively and significantly recapitulated the expected decrease in luciferase reporter 
activity in relation to the control vector carrying the hMTIIa promoter only. While deletion of 
the gly-ala repeat region, and also additional deletions of the 8-67, 61-83 and 395-450 regions 
did not dramatically impact upon the levels demonstrated with the wild-type construct, 
deletions of residues 41-376 and also 325-376 were sufficient to restore levels of TGFβ 
reporter activity and even to elevate them slightly above control levels.  
 
5.8 Discussion and Future Work 
Wild-type, dominant-negative and domain mutant EBNA1 sequences have been successfully 
cloned into a readily-inducible lentiviral expression system. Viral transduction and 
subsequent blasticidin drug selection has enabled the generation of stable cell lines in the 
Ad/AH epithelial cell background. The advantage of maintaining these cell lines as polyclonal 
populations, in comparison to the existing EBNA1-expressing cell lines derived from a single 
clone, is that they eliminate the risk that observations may be skewed by clonal variation.  
 
While continuation of this work was limited by time constraints, validation of the stable cell 
lines suggests that, at this stage, direct comparisons between the lines may not be possible due 
to differences in EBNA1 protein expression levels. Expression of both EBNA1 mRNA and 
protein was confirmed and shown to be successfully responsive to zinc induction for the 
majority of mutants, with the exception of the mutant deleted for the 8-67 region. While the 
EBNA1 transcript could be detected at the mRNA level, expression of the EBNA1 protein 
was detected only with transient transfection of the vector, indicating that this particular 
deletion may interfere with the long-term maintenance of the protein within the cells. Others 
have reported similar findings using the same protein sequence contained within a pc3oriP 
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vector (Wu et al., 2002) and also a version fused to HaloTag protein for use in ChIP 
experiments (Owen, PhD thesis, 2010). It is therefore possible that deletion of the 8-67 
region, in combination with the gly-ala repeat deletion, may create a particularly unstable 
conformation. 
 
Generation of the wild-type EBNA1 sequence allowed comparison with the gly-ala-deleted 
mutant. Indeed preliminary evidence suggests that the two constructs mediate a similar 
reduction in TGFβ reporter activity; however more extensive functional investigation is 
required. The dominant-negative EBNA1 proteins will be useful in proving that any observed 
effects achieved with the remaining EBNA1 lentiviruses were solely attributable to the 
actions of EBNA1, rather than a simple stress response to the applied protein dose. In future 
studies they would also provide useful tools to compete out EBNA1 activity in EBV-infected 
cells and so determine whether continued EBNA1 function is required to maintain the 
phenotype of EBV-infected cells. Furthermore, it has been reported that adenovirus-mediated 
transduction of a dominant-negative EBNA1 protein was able to negatively influence viral 
episome maintenance within EBV-infected cells, independent of cell lineage and viral latency, 
and therefore potentially impede tumour cell growth (Nasimuzzaman et al., 2005), 
highlighting a prospective method of eliminating EBV from infected cells. Ultimately, such a 
protein capable of outcompeting regular EBNA1 function could be of great significance from 
a therapeutic angle. 
 
As determined by immunoblotting, the Δ395-450 dominant-negative variant appears to 
exhibit a much reduced level of EBNA1 expression when compared to both wild-type and 
standard dominant-negative versions. In previous reports, deletion of the 395-450 region had 
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no noticeable effect on the turnover and cell-surface MHC class I presentation of EBNA1 
(Holowaty et al., 2003), but the effect of its deletion in combination with the gross mutation 
of upstream sequence was not studied. In the stable cell line generated using this particular 
recombinant lentiviral vector however, the level of EBNA1 expression detected by 
immunofluorescence is comparable with the other derivatives, suggesting the issue lies with 
the immunoblot procedure and the associated difficulties in simultaneously detecting proteins 
of disparate molecular weights. 
 
In agreement with an earlier observation, the lentiviral vectors do appear to drive a lower 
level of transgene expression when compared with previously used retroviral versions (Vigna 
and Naldini, 2000). The hMTIIa promoter has been shown to exhibit an inherent leakiness, 
permitting low levels of EBNA1 expression in the absence of zinc stimulation. This is a 
particularly favourable trait as these levels are much closer to physiological levels than the 
inevitable overexpression of EBNA1 when driven from CMV (as in the pc3oriP vectors) or 
SV40 promoters (as shown with pSG5-EBNA1).  
 
In the context of this thesis, the panel of EBNA1 mutants will be an invaluable toolset in 
determining the regions of the EBNA1 protein involved in its modulation of TGFβ 
superfamily signalling. From this it is hoped that a specific mechanism can be delineated. 
Already, these lentiviral constructs have been utilised transiently to demonstrate that deletion 
of EBNA1 domains required for transactivation of EBV-encoded genes abrogates EBNA1’s 
ability to inhibit NFκB activity (Valentine et al., 2010). Preliminary luciferase reporter assay 
data obtained here is in agreement with this, with deletion of the 325-376 region, implicated 
in both the segregation and viral gene transactivation functions (Shire et al., 1999, Ceccarelli 
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and Frappier, 2000, Wu et al., 2000, Wu et al., 2002) increasing the inhibited TGFβ reporter 
activity above control levels and the gross mutant, Δ41-376, with the additional deletion of 
the 61-83 region, also with a reported role in transcriptional activation (Wu et al., 2002), 
showing a similar effect.  
 
Due to the broader tropism of the lentiviral vector, the panel can now be tested in its ability to 
target a much wider range of target cells, particularly those differentiation-competent lines 
currently considered unpermissive to stable EBNA1 expression (Jones et al., 2003), in the 
hope of ultimately achieving infection of primary nasopharyngeal epithelial cells. Subsequent 
detailed phenotypic analysis would additionally facilitate examination of the role of EBNA1 
in the early stages of tumourigenesis, which is at present not possible using current cell 
models based on cell lines that are initially immortalised prior to viral transduction. 
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CHAPTER 6 
 
General Discussion and Future Work 
 
As the only EBV-encoded protein consistently expressed in all forms of viral latency and, by 
definition, all EBV-associated malignancies, the function of EBNA1 in EBV-infected cells 
has been intensely scrutinised. Aside from its essential roles in genome maintenance and 
segregation, there is now an increasing appreciation that EBNA1 possesses supplementary 
roles in the dysregulation of key cellular signalling pathways, largely associated with its 
ability to modulate cellular gene transcription and interact with important host cell proteins. 
Inadvertent activation of these pathways may, under certain circumstances, contribute to the 
pathogenesis of EBV-associated tumours. Within this thesis, existing observations have been 
extended to further define the effects of EBNA1 in the modulation of TGFβ signalling, while 
an EBNA1-mediated activation of the closely-related BMP pathway has been discovered. 
 
TGFβ classically evokes an anti-proliferative response in epithelial cells, via a Smad2/3-
mediated pathway that ultimately regulates the transcription of key cell cycle regulatory 
proteins. Data presented in Chapter 3 suggests that in cells stably expressing EBNA1, or 
stably infected with a recombinant EBV, canonical TGFβ signalling is dysregulated, either 
through a complete abrogation of pathway signalling through defects in TβRII, as observed in 
C666-1 cells, or alternatively, via specific modulation of Smad transcriptional activity, 
through alterations in Smad phosphorylation status. 
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Interestingly, profiling of TGFβ signalling pathway components in the carcinoma cell lines 
conducted in an earlier study, revealed that the TGFβ signalling pathway is largely intact in 
these cells lines (Wood et al., 2007). Indeed, in Chapter 3 it is confirmed that C-terminal 
Smad phosphorylation is still induced in response to TGFβ in these lines, albeit to a lesser 
extent than in control cells. Furthermore, in C666-1 cells, the restoration of TβRII expression 
dramatically induced TGFβ/Smad reporter activity and stimulated Smad2/3 phosphorylation, 
findings which indicate that the essential components of this signalling pathway are intact in 
these cells. However, as exemplified in the Ad/AH cell line, both EBNA1-expressing and 
rEBV-infected cells, and their control counterparts, were refractory to TGFβ-mediated growth 
arrest, suggesting this defect cannot be directly attributed to the expression of EBNA1 or 
EBV infection. Although the defects involved are currently unknown, they may reflect 
changes in key tumour suppressor genes that function downstream in the TGFβ signalling 
pathway and may likely occur through mutation or epigenetic inactivation. Possible 
candidates include RASSF1A and the CDK inhibitors, p16
INK4A
 and p15
INK4B
, whose 
dysregulation have been reported in NPC tumours, and whose inactivation are predicted to 
occur prior to EBV infection and subsequent progression to NPC (Lo and Huang, 2002). 
Interestingly, high frequencies of methylation of both p16
INK4A
 and RASSF1A have also been 
documented in EBV-positive GC (Kang et al., 2002), findings which suggest that inactivation 
of these tumour suppressor proteins may be an essential component in EBV-driven 
tumourigenesis. The lack of a TGFβ-mediated growth arrest response may therefore be due to 
a lack or disruption of expression of key components required for its completion. Indeed, the 
inability of TβRII to restore a growth arrest response in C666-1 cells adds credence to the 
importance of such epigenetic changes. 
 
 296 
This is supported further by the recent identification of MDS1-EVI1, mapping to 3q26, as a 
susceptibility locus for NPC development (Bei et al., 2010), and the reported amplification of 
Evi1 in NPC cell lines (Guo et al., 2002). The ability of Evi1 to antagonise the growth 
inhibitory effects of TGFβ by suppressing Smad3 transcriptional activity (Kurokawa et al., 
1998) may have important consequences in the modification of TGFβ signalling and may 
constitute a key determinant in NPC pathogenesis. 
 
The profound inhibition of TGFβ reporter activity and reduction in TGFβ-mediated 
phosphorylation of Smad2 and Smad3 by EBNA1, seems counterintuitive in terms of the 
virus’s propensity to replicate in epithelial tissue, and the well-documented ability of TGFβ1 
to trigger lytic reactivation in EBV-infected B cells (di Renzo et al., 1994, Fahmi et al., 2000). 
While viral replication in epithelial cells is an integral part of the natural life cycle of EBV, 
EBV-associated epithelial tumours are instead characterised by the maintenance of a latent 
EBV infection. These findings suggest that expression of EBNA1 may, under normal 
circumstances, positively regulate viral replication through autocrine induction of TGFβ1, 
while inappropriate infection of pre-malignant cells carrying TGFβ signalling defects may 
complement pre-existing changes in the TGFβ signalling network to facilitate stable latent 
infection. 
 
The mechanism of TGFβ1-mediated EBV reactivation appears to enlist the concerted actions 
of both canonical, implicating Smad3 and multiple SBE sites (Liang et al., 2002, Oussaief et 
al., 2009, Iempridee et al., 2011) and non-canonical TGFβ signalling elements, implicating 
ERK/MAPK, PI3K/Akt and NFκB pathways (Fahmi et al., 2000, Oussaief et al., 2009, 
Oussaief et al., 2011), resulting in the activation of BZLF1 transcription and a corresponding 
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increase in the production of Zta (ZEBRA). Reports of BZLF1 RNA transcripts and Zta 
protein expression, and also antibodies to Zta in many NPC tumour lesions (Cochet et al., 
1993, Martel-Renoir et al., 1995) suggest canonical TGFβ signalling must still function in 
NPC tumour cells, and imply the likely occurrence of sporadic abortive lytic cycle in NPC 
cells. In this regard, studies in a SCID mouse model suggest that lytic infection may play a 
key role in EBV-associated disease progression (Hong et al., 2005), dependent on the 
expression of immediate early and early lytic viral genes, but not full viral lytic replication.  
 
The absence of TβRII expression in C666-1 cells would presumably render them incapable of 
inducing BZLF1 and subsequent lytic cycle. A similar phenomenon is observed in Akata BL 
cells which lack sensitivity to TGFβ1-mediated EBV reactivation until TβRII expression is 
induced by treatment with the HDAC inhibitor TSA (Fukuda et al., 2006). However, in a 
recent report, activation of the BMP signalling pathway, as is observed in C666-1 cells, has 
been shown to facilitate EBV reactivation in latency I BL cells (Yin et al., 2010). However, in 
newly infected primary B cells, BMP-mediated viral reactivation is effectively inhibited 
through the sustained induction of the cellular microRNA, miR-155 (Lu et al., 2008), and 
indeed up-regulation of miR-155 has also been documented in NPC cell lines and tumour 
samples (Chen et al., 2009, Du et al., 2011). In this context it may therefore serve to prevent 
BMP-mediated EBV reactivation and maintain viral latency. It is therefore not surprising that 
the BZLF1 protein product could not be detected by Western blotting of C666-1 cell lysates, 
and only rare cells were stained by IHC (Cheung et al., 1999). The C666-1 cell line may 
therefore be representative of only a rare subset of tumours in which EBV residence is 
stringently latent. It may therefore be important to determine whether miR-155 is similarly 
induced in C666-1 cells and other EBV-infected epithelial cell lines, while further attempts 
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should be made to establish a C666-1 derivative cell line stably expressing TβRII to enable 
more detailed analysis. 
 
During epithelial cell infection in vitro, the virus preferentially targets differentiated primary 
epithelial cells (Feederle et al., 2007), presumably as these are more compliant with viral 
reactivation and propagation. Viral access into undifferentiated cells is therefore considered a 
rare event, probably restricted to rare pathological conditions where expression of an as yet 
unidentified epithelial EBV receptor is expressed under conditions of chronic inflammation or 
wound healing (Tsang et al., 2010). The abortion of complete viral productive cycle in NPC 
implies that this process is in someway defective in tumour cells, and is likely dictated by the 
permissivity of the host cell. Given their largely undifferentiated phenotype, it is feasible that 
the ability of NPC tumour cells to respond to pro-differentiation stimuli may be specifically 
abrogated, either by epigenetic changes and/or insensitivity to TGFβ. Viral replication may 
rely on cellular factors specifically associated with the differentiated phenotype which, by 
definition, would not be expressed in undifferentiated cells. Indeed studies have shown that 
“initiated” progenitor cells within keratinocyte populations have acquired resistance to the 
terminal differentiation signals of both TGFβ and the phorbol ester, TPA and, as a result, 
display a selective growth advantage in the formation of squamous cell carcinomas 
(Parkinson et al., 1983, Parkinson et al., 1984, Parkinson, 1985, Parkinson and Balmain, 
1990). Furthermore, less differentiated immature hepatocytes have been found to demonstrate 
resistance to TGFβ1-induced apoptosis (Sánchez et al., 1999), again conferring a survival 
advantage to these undifferentiated cells. The absence of such factors may also be responsible 
for disparate effects of EBNA1 in carcinoma cell lines compared to the differentiation-
competent OKF6 and Mv1Lu cells. An important experiment required to extend this work 
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would be to inactivate components of the canonical TGFβ signalling pathway in non-
permissive, i.e. TGFβ-responsive, cell lines, and assess their susceptibility to EBV infection. 
The identification of a mechanism that may alleviate defects in carcinoma cells thereby 
permitting complete productive cycle and resultant cell death may facilitate the development 
of treatments for EBV-positive epithelial malignancies, such as NPC and EBV-aGC. 
 
An additional feature of lytic cycle reactivation is the ability of Zta to increase TGFβ1 mRNA 
levels as well as the amount of secreted active TGFβ1 (Cayrol and Flemington, 1995). The 
increased production of TGFβ1 by EBNA1-expressing and EBV-infected epithelial cells may 
therefore represent an attempt of the virus to stimulate EBV reactivation via autocrine 
methods, and so may be a side-effect of increased Zta expression in the absence of complete 
productive lytic cycle. This may have an early role in facilitating horizontal transmission of 
the virus in epithelium and increasing the total number of latently infected cells, which may 
inadvertently favour disease development. Indeed Tsang et al. (Tsang et al., 2010) reported 
exogenous TGFβ1 can promote EBV infection of pre-malignant nasopharyngeal epithelial 
cells. The additional possibility however still remains, as discussed in Chapter 3, that the 
observed increase in TGFβ1 expression and secretion may constitute a strategy by EBV, 
through EBNA1, to diminish immune surveillance through effects on infiltrating T cells. Such 
a strategy may also inadvertently enhance pro-tumourigenic effects in EBV-infected epithelial 
cells that have acquired defects in the TGFβ signalling pathway. 
 
With this is mind, the observed repression of TGFβ-mediated signalling seems unlikely to be 
a direct inhibitory effect on Smad activity, as is observed for other viral proteins, including 
adenovirus E1A, HBV pX, HTLV-1 Tax, HPV-5 E6 and HPV-16 E7, HCV core and non-
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structural protein 3 (NS3) and KSHV vIRF1 (Nishihara et al., 1999, Lee et al., 2001, Lee et 
al., 2002a, Mendoza et al., 2006, Lee et al., 2002b, Cheng et al., 2004, Seo et al., 2005). This 
is corroborated by the observed inability of EBNA1 to interact with Smad2 protein in vitro 
(Flavell et al., 2008). The reduction in binding at SBE transcriptional sites in the presence of 
EBNA1 highlights a need to examine the relative compositions of active Smad complexes, as 
EBNA1 may instead alter the transcription and subsequent availability of cofactors or, as 
reported for adenovirus E1A in its interaction with the transcriptional co-activators p300/CBP 
(Nishihara et al., 1999), may directly interfere with their recruitment to target gene promoter 
sites as a means of modulating the response. 
 
The observed decrease in TGFβ activity may therefore constitute an indirect consequence of 
increased negative regulation rather than a direct inhibitory effect, and indeed, this is 
supported by evidence presented in Chapter 3. The initial hypothesis implicating the increased 
expression of closely-related PPM1A and PPM1B phosphatases proved inconclusive, as their 
knockdown by shRNA methods could only partially restore Smad phosphorylation levels in 
EBNA1-expressing cells, and these effects could not be repeated in rEBV-infected cells. 
More convincing evidence however was provided in studies of the ubiquitin ligase, NEDD4-
2, in increasing Smad protein turnover, particularly in light of the observation that the Smad 
linker residues specifically targeted by NEDD4-2 are increasingly phosphorylated in the 
presence of EBNA1. Moreover, the reported increases in Smad7 suggest greater antagonism 
of R-Smad function in these cells. Furthermore, the high level of Smad7 expression in C666-1 
compared to OKF6 cells suggests EBV infection may indeed be responsible for this method 
of TGFβ signalling inhibition. 
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Although EBNA1 may uncouple the Smad-dependent arm of the TGFβ signalling pathway, it 
does not appear to inhibit non-canonical signalling. It can now be speculated that the pro-
tumourigenic aspects of TGFβ are further potentiated by the cross-talk with other signalling 
pathways, which are activated by EBNA1. In particular, ERK-MAPK and JNK pathways 
have been identified as potentially significant candidates. These signalling pathways are 
particularly important in the differential phosphorylation of Smad2 and Smad3 proteins in 
their linker regions, which specifically promote these effects, but can also serve to impede 
classical transcriptional responses mediated by C-terminally phosphorylated Smads. These 
linker-phosphorylated Smads may be directly involved in the observed increases in cell 
migration of EBNA1-expressing cells. It will therefore be important to assess the relative 
abundance of these linker phosphorylated Smad isoforms in NPC tumour biopsies to 
substantiate this hypothesis, and to further dissect the respective contributions of connecting 
signalling pathways. In addition, transgenic mice with targeted expression of EBNA1 to either 
the epidermis or gastric compartments are currently being generated which may be used to 
determine whether these effects are replicated in vivo, and to assess their relevance to the 
pathogenesis of NPC and EBV-positive GC. 
 
In contrast, as measured by pSmad1/5/8 phosphorylation, the BMP signalling pathway 
appears to be constitutively activated in EBNA1-expressing and rEBV-infected cells, which 
may be a direct result of the ability of EBNA1 to enhance BMP2 expression at the 
transcriptional level; however, elucidation of the ability of EBNA1 to associate with the 
promoters of BMP-related genes would be required to verify this. Several reports have 
implicated retinoids, Sp1 transcription factors and the protein kinase C pathway in the 
transcriptional regulation of BMP2 gene expression (Heller et al., 1999, Abrams et al., 2004, 
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Xu and Rogers, 2007, Helvering et al., 2000), but perhaps of most interest is the reported up-
regulation of BMP2 by FGF2, and the mediation of this effect by Runx2 (Choi et al., 2005). 
The Ad/AH microarray data suggests that both FGF2 and Runx2 are up-regulated in EBNA1-
expressing cells, by fold changes of 1.69- and 2.97-fold, respectively, and so may contribute 
significantly to the observed up-regulation of BMP2. 
 
The characteristic induction of Id proteins suggests an overall inhibitory influence of BMPs 
on cell differentiation. Although unfavourable in terms of promoting viral reactivation, this 
effect may be important in supporting the undifferentiated phenotype of the host cell. 
Evidence presented here further suggests this increased BMP activity may serve to increase 
the migratory capacity of EBNA1-expressing cells and, additionally, may play a role in 
promoting metastasis, particularly to bone. Again, the transgenic mouse models will be useful 
in providing an in vivo setting in which to enable clarification of these points. 
 
The mechanism by which this preferential activation of BMP signalling is achieved is at yet 
undetermined, and certainly warrants further investigation. The BMP signalling pathway is 
undoubtedly, as has also been shown for the TGFβ signalling pathway, further complicated by 
cross-talk with further interconnecting signalling pathways. The potential contribution of such 
cross-talk in the modification of the overall signalling response remains to be investigated. 
Indeed, a more comprehensive investigation of the dynamics of BMP signalling in the 
presence of EBNA1 is essential to provide further mechanistic insight. 
 
Another possibility is that the larger number of both ligands and receptors that participate in 
the BMP signalling pathway activity, and therefore greater variety of signalling combination 
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possibilities may effectively mask any abrogations. Although down-regulation of certain 
receptors is reported in the presence of EBNA1, the expression of other receptors of the same 
type is maintained, so may functionally compensate. Furthermore, the relative expression 
levels of the different isoforms of both TGFβ and BMP ligands present in the cells will 
inevitably influence the nature of the overall response. While total ablation of either pathway 
in an attempt to reduce tumourigenic activity would not be practical, given their ubiquitous 
roles in cellular homeostasis, if the predominant effect were to be attributed to a single 
isoform, selective inhibition using neutralising antibodies and/or shRNA techniques may be 
of clinical importance. 
 
The extent of cooperation between the pathways in eliciting the observed effects in epithelial 
cells is not precisely clear. In this study, BMP2 was unable to induce Smad2 phosphorylation 
in any of the carcinoma cell lines examined, while studies in C666-1 cells further suggested 
that TGFβ-mediated Smad transcriptional responses cannot be mediated by BMP2. However, 
the observed ability of TGFβ to induce pSmad1/5/8 phosphorylation in the presence of 
EBNA1 may be of great significance in modulating the tumourigenic effects of TGFβ, and 
identifies a need to more extensively monitor the function of each pathway when the other is 
specifically inhibited. 
 
In osteoblasts, BMP2 treatment has been shown to decrease TGFβ ligand binding to TβRII, 
yet without affecting steady state mRNA or total protein TβRII levels, and with resultant 
dampening of TGFβ-mediated effects (Centrella et al., 1995, Chang et al., 2002). This is 
achieved through a reduction of cell surface TβRII, with relocation to more intracellular and 
perinuclear regions. It is interesting to speculate that the observed reduction in cell surface 
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expression of TGFβ receptors in EBNA1-expressing cells may in fact be a result of the higher 
expression levels of BMP2. This reinforces the importance of monitoring the cellular 
localisation of TGFβ receptors in EBNA1-expressing cells, as well as their ligand binding 
activity, if this work were to be further developed. 
 
Finally, the generation of wild-type and mutant versions of EBNA1 in self-inactivating 
lentivirus vectors will provide valuable tools for the extension of this work. With the potential 
to achieve successful infection of primary nasopharyngeal epithelial cells they may prove 
important in determining where the changes identified herein occur in relation to EBV 
infection and the specific roles they play in dictating the maintenance of a latent infection. It 
is hoped that it may be established whether BMP signalling and the changes to the TGFβ 
signalling pathway play a role in malignant transformation or whether their effects are 
confined to the later stages of cancer.  
 
In summary, data presented within this thesis has extended our knowledge on the function of 
EBNA1 in the modulation of cellular signalling pathways, specifically in directing TGFβ 
superfamily signalling in inactivating their tumour suppressive influences and potentiating 
oncogenic effects, while the development of lentiviral technologies has provided an effective 
model for subsequent investigation of these observations. In due course, the elucidation of 
specific mechanisms employed by EBNA1 in manipulating these key cellular signalling 
pathways may enable the development of specific treatments to counteract its effects in EBV-
associated malignancies such as NPC and EBV-positive GC. 
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